



L19 ANSWER 1 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2007:572432 CAPLUS Full-text  
 DN 147:189388  
 TI Divergent Synthesis of Multifunctional Molecular Probes To Elucidate the  
 Enzyme Specificity of Dipeptidic  $\gamma$ -Secretase Inhibitors  
 AU Fuwa, Haruhiko; Takahashi, Yasuko; Konno, Yu; Watanabe, Naoto; Miyashita,  
 Hiroyuki; Sasaki, Makoto; Natsugari, Hideaki; Kan, Toshiyuki; Fukuyama,  
 Tohru; Tomita, Taisuke; Iwatsubo, Takeshi  
 CS Lab. Biostructural Chem., Grad. Sch. Life Sci., Tohoku Univ., 1-1  
 Tsutsumidori-Amamiya, Aoba-ku, Sendai, 981-8555, Japan  
 SO ACS Chemical Biology (2007), 2(6), 408-418  
 CODEN: ACBCCT; ISSN: 1554-8929  
 PB American Chemical Society  
 DT Journal  
 LA English  
 GI




I



II

AB Divergent synthesis of multifunctional mol. probes based on caprolactam-  
 derived dipeptidic  $\gamma$ -secretase inhibitors (GSIs), Compound E (CE; I) and  
 LY411575 analog (DBZ; II), was efficiently accomplished by means of Cu(I)-  
 catalyzed azide/alkyne cycloaddn. reaction. Coupled to photoactivatable and  
 biotin moieties, these dipeptide derivs. were examined in photoaffinity  
 labeling expts., which provided direct evidence that the mol. targets of I and  
 II are the N-terminal fragment of presenilin-1 within the  $\gamma$ -secretase complex.  
 Moreover, these photoprobes directly targeted signal peptide peptidase. These  
 data suggest that the divergent synthesis of mol. probes has been successfully  
 applied to characterize the interaction of GSIs with their mol. targets and  
 define the structural requirements for inhibitor binding to intramembrane-  
 cleaving proteases.  
 IT 168162-29-6P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of caprolactam-based dipeptides via Cu(I)-catalyzed  
 azide/alkyne cycloaddn., and their uses as mol. probes for determining  
 $\gamma$ -secretase specificity for dipeptide inhibitors and for  
 development of anti-Alzheimer's agents)  
 RN 168162-29-6 CAPLUS


CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-,  
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L19 ANSWER 2 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2007:253120 CAPLUS Full-text  
 DN 146:371914  
 TI 1,4-Benzodiazepines as Inhibitors of Respiratory Syncytial Virus. The Identification of a Clinical Candidate  
 AU Henderson, Elisa A.; Alber, Dagmar G.; Baxter, Robert C.; Bithell, Sian K.; Budworth, Joanna; Carter, Malcolm C.; Chubb, Ann; Cockerill, G. Stuart; Dowdell, Verity C. L.; Fraser, Ian J.; Harris, Robert A.; Keegan, Sally J.; Kelsey, Richard D.; Lumley, James A.; Stables, Jeremy N.; Weerasekera, Natasha; Wilson, Lara J.; Powell, Kenneth L.  
 CS Arrow Therapeutics, Britannia House, London, SE1 1DA, UK  
 SO Journal of Medicinal Chemistry (2007), 50(7), 1685-1692  
 CODEN: JMCMAR; ISSN: 0022-2623  
 PB American Chemical Society  
 DT Journal  
 LA English  
 OS CASREACT 146:371914  
 AB Respiratory syncytial virus (RSV) is the cause of one-fifth of all lower respiratory tract infections worldwide and is increasingly being recognized as representing a serious threat to patient groups with poorly functioning or immature immune systems. Racemic 1,4-benzodiazepines show potent anti-RSV activity in vitro. Anti-RSV evaluation of 3-position R- and S-benzodiazepine enantiomers and subsequent optimization of this series resulted in selection of a clin. candidate. Antiviral activity was found to reside mainly in the S-enantiomer, and the R-enantiomers were consistently less active against RSV. Analogs of 1,4-(S)-benzodiazepine were synthesized as part of the lead optimization program at Arrow and tested in the XTT assay. From this exercise, (S)-1-(2-fluorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]-diazepin-3-yl)-urea, 17b (RSV-604) was identified as a clin. candidate, exhibiting potent anti-RSV activity in the XTT assay, which was confirmed in secondary assays. Compound 17b also possessed a good pharmacokinetic profile and has now progressed into the clinic.  
 IT 676128-16-8P 676128-63-5P 676128-66-8P  
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (benzodiazepines as inhibitors of respiratory syncytial virus)  
 RN 676128-16-8 CAPLUS  
 CN Benzamide, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-methoxy-4-nitro- (CA INDEX NAME)

Absolute stereochemistry.



RN 676128-63-5 CAPLUS  
 CN Urea, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-N'-(2-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 676128-66-8 CAPLUS

CN Benzamide, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-methoxy-4-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.




IT 676128-01-1P 676128-15-7P 676128-62-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(benzodiazepines as inhibitors of respiratory syncytial virus)

RN 676128-01-1 CAPLUS


CN Cyclohexanecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 676128-15-7 CAPLUS


CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy-4-nitro- (CA INDEX NAME)





RN 676128-62-4 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(2-fluorophenyl)- (CA INDEX NAME)



IT 116842-76-3P 676127-93-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(benzodiazepines as inhibitors of respiratory syncytial virus)

RN 116842-76-3 CAPLUS

CN Benzenepropanamide,  $\alpha$ -amino-N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 676127-93-8 CAPLUS


CN Benzenepropanamide, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]- $\alpha$ -[(phenylamino)thioxomethyl]amino]-, ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 3 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2006:408573 CAPLUS Full-text  
 DN 145:230559  
 TI Synthesis and analgesic and antiinflammatory properties of new benzodiazepine derivatives  
 AU Najafi, N.; Pirali, M.; Dowlatabadi, R.; Bagheri, M.; Rastkari, N.; Abdollahi, M.  
 CS Department of Pharmacology and Toxicology, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran  
 SO Pharmaceutical Chemistry Journal (2005), 39(12), 641-643  
 CODEN: PCJOAU; ISSN: 0091-150X  
 PB Springer  
 DT Journal  
 LA English  
 OS CASREACT 145:230559  
 AB Several new N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-carboxamides have been synthesized and characterized with respect to acute toxicity (LD50), analgesic and antiinflammatory properties (formalin-and carrageenan-induced foot edema models), and interaction with morphine-induced antinociception in mice. The new compds. were prepared by acyl coupling of 2-aminobenzophenones with  $\alpha$ -(benzotriazol-1-yl)-N- acylglycines followed by displacement of the benzotriazole ring with ammonia and cyclization of the resulting monoacyl amins. The LD50 of the synthesized compds. exceeds 1000 mg/kg. Three compds. produced significant analgesic action in doses 100-150  $\mu$ g/kg in the early (painful) phase of the formalin test and potentiated the morphine-induced antinociception in this test. The synthesized drugs neither showed antinociception in the second (inflammatory) phase of the formalin test nor decreased the carrageenan-induced foot edema growth. Thus, the synthesized compds. produce analgesic action but do not possess antiinflammatory properties. The analgesic activity is probably due to the interaction with  $\mu$ -and  $\delta$ -opioid receptors.  
 IT 150964-48-0P 368870-46-6P 368870-47-7P  
 368870-49-9P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (Synthesis and analgesic and antiinflammatory properties of new benzodiazepine derivs.)  
 RN 150964-48-0 CAPLUS  
 CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI)  
 (CA INDEX NAME)




RN 368870-46-6 CAPLUS  
 CN 2-Thiophenecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 368870-47-7 CAPLUS

CN 2-Furancarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 368870-49-9 CAPLUS

CN 2-Thiophenecarboxamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 4 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2006:208362 CAPLUS Full-text  
 DN 144:444888  
 TI 1,4-Benzodiazepines as Inhibitors of Respiratory Syncytial Virus  
 AU Carter, Malcolm C.; Alber, Dagmar G.; Baxter, Robert C.; Bithell, Sian K.;  
 Budworth, Jo; Chubb, Ann; Cockerill, G. Stuart; Dowdell, Verity C. L.;  
 Henderson, Elisa A.; Keegan, Sally J.; Kelsey, Richard D.; Lockyer,  
 Michael J.; Stables, Jeremy N.; Wilson, Lara J.; Powell, Kenneth L.  
 CS Arrow Therapeutics Ltd, London, SE1 1DA, UK  
 SO Journal of Medicinal Chemistry (2006), 49(7), 2311-2319  
 CODEN: JMCMAR; ISSN: 0022-2623  
 PB American Chemical Society  
 DT Journal  
 LA English  
 OS CASREACT 144:444888  
 AB Respiratory syncytial virus (RSV) is the cause of one-fifth of all lower  
 respiratory tract infections worldwide and is increasingly being recognized as  
 a serious threat to patient groups with poorly functioning immune systems.  
 Our approach to finding a novel inhibitor of this virus was to screen a 20  
 000-member diverse library in a whole cell XTT assay. Parallel assays were  
 carried out in the absence of virus in order to quantify any associated cell  
 toxicity. This identified 100 compds. with IC50's less than 50 µM. A-33903  
 (18), a 1,4-benzodiazepine analog, was chosen as the starting point for lead  
 optimization. This mol. was moderately active and demonstrated good  
 pharmacokinetic properties. The most potent compds. identified from this work  
 were A-58568 (47), A-58569 (44), and A-62066 (46), where modifications to the  
 aromatic substitution enhanced potency, and A-58175 (42), where the amide  
 linker was modified.  
 IT 70890-53-8P 368870-47-7P 676127-98-3P  
 676128-04-4P 676128-10-2P 676128-15-7P  
 676128-62-4P 676128-89-5P 676129-02-5P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (1,4-Benzodiazepines as Inhibitors of Respiratory Syncytial Virus)  
 RN 70890-53-8 CAPLUS  
 CN Acetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI)  
 (CA INDEX NAME)




RN 368870-47-7 CAPLUS  
 CN 2-Furancarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676127-98-3 CAPLUS

CN Propanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methyl- (9CI) (CA INDEX NAME)




RN 676128-04-4 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 676128-10-2 CAPLUS

CN 1-Piperazinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-methyl- (9CI) (CA INDEX NAME)




RN 676128-15-7 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy-4-nitro- (CA INDEX NAME)




RN 676128-62-4 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(2-fluorophenyl)- (CA INDEX NAME)




RN 676128-89-5 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-fluoro-2-methoxy- (9CI) (CA INDEX NAME)



RN 676129-02-5 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-ethoxy- (9CI) (CA INDEX NAME)



IT 150964-48-0 368870-46-6 676127-95-0


676127-99-4 676128-01-1 676128-02-2  
676128-03-3 676128-05-5 676128-07-7  
676128-08-8 676128-09-9 676128-43-1  
676128-65-7 676128-85-1 676129-00-3  
676129-03-6 676129-05-8 676129-07-0  
676129-09-2 676129-34-3 676129-43-4  
676129-48-9 676129-52-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)

(1,4-Benzodiazepines as Inhibitors of Respiratory Syncytial Virus)


RN 150964-48-0 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI)  
(CA INDEX NAME)




RN 368870-46-6 CAPLUS

CN 2-Thiophenecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676127-95-0 CAPLUS

CN Urea, N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 676127-99-4 CAPLUS

CN Propanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 676128-01-1 CAPLUS

CN Cyclohexanecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 676128-02-2 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-methoxy- (9CI) (CA INDEX NAME)



RN 676128-03-3 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-methoxy- (9CI) (CA INDEX NAME)




RN 676128-05-5 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-




(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 676128-07-7 CAPLUS

CN 4-Morpholinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-08-8 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-nitro- (9CI) (CA INDEX NAME)




RN 676128-09-9 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-nitro- (9CI) (CA INDEX NAME)




RN 676128-43-1 CAPLUS

CN Benzamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 676128-65-7 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 676128-85-1 CAPLUS

CN Benzamide, 4-chloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 676129-00-3 CAPLUS

CN Benzamide, N-[2,3-dihydro-2-oxo-5-[3-(trifluoromethyl)phenyl]-1H-1,4-benzodiazepin-3-yl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 676129-03-6 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,4-dimethoxy- (9CI) (CA INDEX NAME)




RN 676129-05-8 CAPLUS

CN Benzamide, N-[2,3-dihydro-5-(3-methoxyphenyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 676129-07-0 CAPLUS

CN Benzamide, N-(2,3-dihydro-8-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 676129-09-2 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 676129-34-3 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-propoxy- (9CI) (CA INDEX NAME)




RN 676129-43-4 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy-N-methyl-4-nitro- (9CI) (CA INDEX NAME)




RN 676129-48-9 CAPLUS


CN 2-Furancarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4,5-dimethyl- (9CI) (CA INDEX NAME)




RN 676129-52-5 CAPLUS  
 CN 2-Furancarboxamide, N-[5-(3-chlorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)




IT 108895-98-3P 155452-87-2P 676128-34-0P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (1,4-Benzodiazepines as Inhibitors of Respiratory Syncytial Virus)  
 RN 108895-98-3 CAPLUS  
 CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 155452-87-2 CAPLUS  
 CN Carbamic acid, (7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 676128-34-0 CAPLUS  
 CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-3-[[ (2-methoxyphenyl)methyl]amino]-5-phenyl- (9CI) (CA INDEX NAME)




RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 5 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2005:1042227 CAPLUS Full-text  
 DN 143:326401  
 TI Process for preparing benzodiazepines  
 IN Dowdell, Verity; Kelsey, Richard David; Carter, Malcolm; Henderson, Elisa Ann  
 PA Arrow Therapeutics Limited, UK  
 SO PCT Int. Appl., 83 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 3


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005090319	A1	20050929	WO 2005-GB1050	20050321
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	GB 2004-6280	A	20040319		
	GB 2004-6282	A	20040319		
	GB 2004-23462	A	20041021		
OS	CASREACT 143:326401; MARPAT 143:326401				
GI					



I



II



III

AB A process for the preparation of benzodiazepines (R/S)-I [wherein R1 = alkyl or (hetero)aryl; R3 = halo, OH, alkyl; n = 0-3; X = -NH-, -N(alkyl)-, -CO-; R4 = H, CONH(alkyl); etc., or pharmaceutically acceptable salts thereof], which are active against respiratory syncytial virus (RSV), is disclosed. Some intermediates are claimed. As an example, acylation of 2-aminoacetophenone with bromoacetyl bromide (95%) followed by cyclocondensation with NH3 in refluxing methanol (95%) and subsequent N-protection with PMB-Cl (87%) gave

benzodiazepine II (R = H). This compound underwent oximation with isoamyl nitrite in the presence of KOBu-t in toluene to afford oxime II (R = =NOH) (76%), which was reduced with H<sub>2</sub>-Ru/C to amine II (R = NH<sub>2</sub>) (81%). Crystallization induced dynamic resolution of the above racemate amine with (-)-Boc-Phe-OH (1 equivalent) and 3,5-dichlorosalicylaldehyde (0.04 equivalent) in toluene under stirring at rt provided (S)-II (R = NH<sub>2</sub>) (71% yield, 99.8% e.e.). Following condensation with 2-fluorophenylisocyanate and deprotection with AlCl<sub>3</sub> in anisole led to urea III (91% for two steps).

IT 4173-63-1P, N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)acetamide 70890-53-8P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)acetamide 103373-17-7P, 2-Chloro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 103373-21-3P, 3,4-Dichloro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 108895-98-3P, (2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamic acid benzyl ester 116842-74-1P, Pyrazine-2-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 119506-69-3P, 1-(3-Methoxyphenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 150964-48-0P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 168162-29-6P, (2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamic acid tert-butyl ester 206115-23-3P, 1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(m-tolyl)urea 368870-46-6P, Thiophene-2-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 368870-47-7P, Furan-2-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 368870-49-9P, Thiophene-2-carboxylic acid N-(7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 368870-50-2P, Furan-2-carboxylic acid N-(7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676127-95-0P, 1,1-Diethyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676127-96-1P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)propionamide 676127-97-2P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)butyramide 676127-98-3P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)isobutyramide 676127-99-4P, 2,2-Dimethyl-N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)propionamide 676128-00-0P, Cyclopentanecarboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-01-1P, Cyclohexanecarboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-02-2P, 3-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-03-3P, 4-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-04-4P, 2-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-05-5P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-trifluoromethylbenzamide 676128-06-6P, Piperidine-1-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-07-7P, Morpholine-4-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-08-8P, 4-Nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-09-9P, 3-Nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-10-2P, 4-Methylpiperazine-1-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-11-3P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-trifluoromethylbenzamide 676128-12-4P, 4-Bromo-N-(2-oxo-5-phenyl-

2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-13-5P  
, 2-Methyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-14-6P, 2-Nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-15-7P,  
2-Methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-16-8P, (S)-2-Methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-17-9P, Benzo[b]thiophene-3-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-18-0P, 2,3-Dihydrobenzofuran-5-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-19-1P, Isoxazole-5-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-20-4P, Benzo[b]thiophene-2-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-21-5P, Thiophene-3-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-22-6P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)isonicotinamide 676128-23-7P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)nicotinamide 676128-24-8P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)methanesulfonamide 676128-25-9P, Propane-1-sulfonic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-26-0P, Butane-1-sulfonic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-27-1P, 2-Bromo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzenesulfonamide 676128-28-2P, 3-Bromo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzenesulfonamide 676128-29-3P, 4-Bromo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzenesulfonamide 676128-30-6P, 2-Fluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzenesulfonamide 676128-31-7P, 3-(2-Nitrobenzylamino)-5-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one 676128-32-8P, 3-(3-Nitrobenzylamino)-5-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one 676128-33-9P, 3-(4-Nitrobenzylamino)-5-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one 676128-34-0P, 3-(2-Methoxybenzylamino)-5-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one 676128-35-1P, 3-(3-Methoxybenzylamino)-5-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one 676128-36-2P, 5-Phenyl-3-(2-trifluoromethylbenzylamino)-1,3-dihydrobenzo[e][1,4]diazepin-2-one 676128-37-3P, 5-Phenyl-3-(3-trifluoromethylbenzylamino)-1,3-dihydrobenzo[e][1,4]diazepin-2-one 676128-38-4P, 5-Phenyl-3-(4-trifluoromethylbenzylamino)-1,3-dihydrobenzo[e][1,4]diazepin-2-one 676128-39-5P, 3-[(Furan-2-ylmethyl)amino]-5-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one 676128-40-8P, N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)isobutyramide 676128-41-9P, N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)methanesulfonamide 676128-42-0P, Cyclohexanecarboxylic acid N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-43-1P, N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-methoxybenzamide 676128-44-2P, N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-4-methoxybenzamide 676128-45-3P, N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-nitrobenzamide 676128-46-4P, 2-(2-Methoxyphenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)acetamide 676128-47-5P, 2-(3-Methoxyphenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)acetamide 676128-48-6P, 2-(4-Methoxyphenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)acetamide



676128-49-7P, 2-(4-Nitrophenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)acetamide 676128-50-0P,  
2-(3-Nitrophenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)acetamide 676128-51-1P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-(2-trifluoromethylphenyl)acetamide 676128-52-2P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-(3-trifluoromethylphenyl)acetamide 676128-53-3P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-(4-trifluoromethylphenyl)acetamide 676128-54-4P, 1-(2-Methoxyphenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676128-55-5P, 1-(2-Nitrophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676128-57-7P, 1-(2-Chlorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676128-59-9P, 1-(4-Chlorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676128-61-3P, 1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(p-tolyl)urea 676128-62-4P, 1-(2-Fluorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676128-63-5P 676128-64-6P, 1-(4-Fluorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676128-65-7P, 4-Methylsulfonyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-67-9P, 5-Acetyl-2-ethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-69-1P, 6-Fluoro-4H-benzo[1,3]dioxin-8-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-72-6P, 2,4,5-Trifluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-74-8P, 2-Hydroxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-76-0P, 1H-Indole-7-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-78-2P, 3-Methoxynaphthalene-2-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-80-6P, N-[7-Chloro-5-(2-fluorophenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-4-methoxybenzamide 676128-81-7P, 1-(2-Fluorobenzyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676128-82-8P, 1-(4-Methoxybenzyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676128-83-9P, 1-(3-Methylbenzyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676128-84-0P, 1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(4-trifluoromethylphenyl)urea 676128-85-1P, 4-Chloro-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-86-2P, 4-Methoxy-3-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-87-3P, 3-Methoxy-2-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-88-4P, 5-Chloro-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-89-5P, 5-Fluoro-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-90-8P, 5-Methoxy-2-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-91-9P, 3-Methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-92-0P, 3-(2-Methoxyphenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)propionamide 676128-93-1P, 3-(3-Methoxyphenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)propionamide 676128-94-2P, 3-(4-Methoxyphenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)propionamide 676128-95-3P, N-[5-(3-Chlorophenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-2-methoxybenzamide 676128-99-7P, 4-Methoxy-N-[2-oxo-5-(4-trifluoromethylphenyl)-2,3-

dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676129-00-3P,  
2-Methoxy-N-(2-oxo-5-(3-trifluoromethylphenyl)-2,3-dihydro-1H-  
benzo[e][1,4]diazepin-3-yl]benzamide 676129-01-4P,  
4-Methoxy-N-(2-oxo-5-(3-trifluoromethylphenyl)-2,3-dihydro-1H-  
benzo[e][1,4]diazepin-3-yl]benzamide 676129-02-5P,  
2-Ethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-  
yl)benzamide 676129-03-6P, 2,4-Dimethoxy-N-(2-oxo-5-phenyl-2,3-  
dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-04-7P,  
2-Bromo-5-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-  
yl)benzamide 676129-05-8P, 2-Methoxy-N-[5-(3-methoxyphenyl)-2-  
oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide  
676129-07-0P, 2-Methoxy-N-(8-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-  
benzo[e][1,4]diazepin-3-yl)benzamide 676129-08-1P,  
2-Chloro-4-methylsulfonyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-  
benzo[e][1,4]diazepin-3-yl)benzamide 676129-09-2P,  
2-Dimethylamino-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-  
yl)benzamide 676129-10-5P, 1-(3,5-Dimethylphenyl)-3-(2-oxo-5-  
phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-11-6P  
, 1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(4-  
trifluoromethoxyphenyl)urea 676129-12-7P, 1-(4-Bromo-2-  
trifluoromethylphenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-  
benzo[e][1,4]diazepin-3-yl)urea 676129-13-8P,  
1-(4-Bromobenzyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-  
yl)urea 676129-14-9P, 1-(2,3-Dichlorophenyl)-3-(2-oxo-5-phenyl-  
2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-15-0P,  
1-(2,6-Dimethylphenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-  
benzo[e][1,4]diazepin-3-yl)urea 676129-16-1P,  
1-(2-Chloro-6-methylphenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-  
benzo[e][1,4]diazepin-3-yl)urea 676129-17-2P,  
1-(4-Nitrophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-  
yl)urea 676129-18-3P, 1-(2-Methylsulfonylphenyl)-3-(2-oxo-5-  
phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-19-4P  
, 1-(2,6-Dichlorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-  
benzo[e][1,4]diazepin-3-yl)urea 676129-20-7P,  
5-tert-Butyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-  
benzo[e][1,4]diazepin-3-yl)benzamide 676129-21-8P,  
2,5-Dimethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-  
yl)benzamide 676129-22-9P, 1-(2,6-Difluorophenyl)-3-(2-oxo-5-  
phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-23-0P  
, 1-(3-Fluorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-  
benzo[e][1,4]diazepin-3-yl)urea 676129-25-2P,  
1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(3-  
trifluoromethylphenyl)urea 676129-27-4P, 1-(3-Chlorophenyl)-3-(2-  
oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea  
676129-29-6P, 2-Methoxy-4-methylsulfonyl-N-(2-oxo-5-phenyl-2,3-  
dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-30-9P,  
4-Methylsulfonyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-  
yl)benzamide 676129-31-0P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-  
benzo[e][1,4]diazepin-3-yl)terephthalamide methyl ester  
676129-32-1P, 2-Fluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-  
benzo[e][1,4]diazepin-3-yl)benzamide 676129-33-2P,  
2,6-Difluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-  
yl)benzamide 676129-34-3P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-  
benzo[e][1,4]diazepin-3-yl)-2-propoxybenzamide 676129-35-4P,  
2-Iodo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-  
yl)benzamide 676129-36-5P, 3-Methoxy-N-(2-oxo-5-phenyl-2,3-  
dihydro-1H-benzo[e][1,4]diazepin-3-yl)terephthalamide methyl ester  
676129-37-6P, 4-Amino-5-chloro-2-methoxy-N-(2-oxo-5-phenyl-2,3-  
dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-38-7P,  
2-Methylsulfonyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-


yl)benzamide 676129-39-8P, 2-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-5-sulfamoylbenzamide 676129-40-1P, 2-Hydroxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-phenylpropionamide 676129-41-2P, 3-Hydroxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-phenylpropionamide 676129-42-3P, 3-(2-Fluorophenyl)-1-methyl-1-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-43-4P, 2-Methoxy-N-methyl-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-44-5P, 1-tert-Butyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-45-6P, 1-Cyclohexyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-46-7P, 1-Ethyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-47-8P, 1-Butyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-48-9P, 4,5-Dimethylfuran-2-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676129-49-0P, Piperidine-1-carboxylic acid N-(7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676129-57-0P, 5-Methylfuran-2-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676129-63-8P, Cyclohexanecarboxylic acid N-(8-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676129-64-9P, Thiophene-2-carboxylic acid N-(8-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676129-65-0P, 1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(thiophen-2-yl)urea 676129-66-1P, 1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(thiophen-3-yl)urea 676129-67-2P, Pyridine-2-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676129-68-3P, 1H-Pyrazole-4-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676129-69-4P, 6-Dimethylamino-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)nicotinamide 676129-70-7P, 2-Ethoxynaphthalene-1-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676129-71-8P, 9-Oxo-9H-fluorene-1-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676129-72-9P, 2-Oxo-2,3-dihydrobenzimidazole-1-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676129-75-2P, (2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamic acid methyl ester 676129-76-3P, (2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamic acid ethyl ester 676129-77-4P, (2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamic acid isobutyl ester 676129-78-5P, 2-Oxo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-(thiophen-2-yl)acetamide 676129-79-6P, 6-(Morpholin-4-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)nicotinamide

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(asym. synthesis of 3-aminobenzodiazepines via oximation of benzodiazepines with isoamyl nitrite followed by Ru/C-catalyzed hydrogenation and crystallization induced dynamic resolution)


RN 4173-63-1 CAPLUS

CN Acetamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (8CI, 9CI) (CA INDEX NAME)




RN 70890-53-8 CAPLUS

CN Acetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI)  
(CA INDEX NAME)




RN 103373-17-7 CAPLUS

CN Benzamide, 2-chloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 103373-21-3 CAPLUS

CN Benzamide, 3,4-dichloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 108895-98-3 CAPLUS

CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 116842-74-1 CAPLUS

CN 2-Pyrazinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 119506-69-3 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 150964-48-0 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 168162-29-6 CAPLUS

CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 206115-23-3 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 368870-46-6 CAPLUS

CN 2-Thiophenecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 368870-47-7 CAPLUS

CN 2-Furancarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 368870-49-9 CAPLUS

CN 2-Thiophenecarboxamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 368870-50-2 CAPLUS

CN 2-Furancarboxamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676127-95-0 CAPLUS

CN Urea, N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 676127-96-1 CAPLUS


CN Propanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676127-97-2 CAPLUS  
CN Butanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-  
(9CI) (CA INDEX NAME)



RN 676127-98-3 CAPLUS  
CN Propanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methyl- (9CI) (CA INDEX NAME)




RN 676127-99-4 CAPLUS  
CN Propanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 676128-00-0 CAPLUS  
CN Cyclopentanecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)






RN 676128-01-1 CAPLUS

CN Cyclohexanecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 676128-02-2 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 676128-03-3 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-methoxy- (9CI) (CA INDEX NAME)




RN 676128-04-4 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 676128-05-5 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 676128-06-6 CAPLUS

CN 1-Piperidinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-07-7 CAPLUS

CN 4-Morpholinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-08-8 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-nitro- (9CI) (CA INDEX NAME)




RN 676128-09-9 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-nitro- (9CI) (CA INDEX NAME)




RN 676128-10-2 CAPLUS

CN 1-Piperazinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-methyl- (9CI) (CA INDEX NAME)




RN 676128-11-3 CAPLUS


CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 676128-12-4 CAPLUS  
CN Benzamide, 4-bromo-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-13-5 CAPLUS  
CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methyl- (9CI) (CA INDEX NAME)



RN 676128-14-6 CAPLUS  
CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-nitro- (9CI) (CA INDEX NAME)




RN 676128-15-7 CAPLUS  
CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy-4-nitro- (CA INDEX NAME)



RN 676128-16-8 CAPLUS


CN Benamide, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-methoxy-4-nitro- (CA INDEX NAME)

Absolute stereochemistry.




RN 676128-17-9 CAPLUS

CN Benzo[b]thiophene-3-carboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-18-0 CAPLUS

CN 5-Benzofurancarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 676128-19-1 CAPLUS

CN 5-Isoxazolecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-20-4 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-21-5 CAPLUS

CN 3-Thiophenecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-22-6 CAPLUS

CN 4-Pyridinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-23-7 CAPLUS

CN 3-Pyridinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-24-8 CAPLUS

CN Methanesulfonamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-25-9 CAPLUS

CN 1-Propanesulfonamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-26-0 CAPLUS

CN 1-Butanesulfonamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-27-1 CAPLUS

CN Benzenesulfonamide, 2-bromo-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-28-2 CAPLUS

CN Benzenesulfonamide, 3-bromo-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-29-3 CAPLUS

CN Benzenesulfonamide, 4-bromo-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-30-6 CAPLUS

CN Benzenesulfonamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-fluoro- (9CI) (CA INDEX NAME)







RN 676128-31-7 CAPLUS  
CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-3-[[ (2-nitrophenyl)methyl]amino]-5-phenyl- (9CI) (CA INDEX NAME)




RN 676128-32-8 CAPLUS  
CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-3-[[ (3-nitrophenyl)methyl]amino]-5-phenyl- (9CI) (CA INDEX NAME)



RN 676128-33-9 CAPLUS  
CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-3-[[ (4-nitrophenyl)methyl]amino]-5-phenyl- (9CI) (CA INDEX NAME)




RN 676128-34-0 CAPLUS  
CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-3-[[ (2-methoxyphenyl)methyl]amino]-5-phenyl- (9CI) (CA INDEX NAME)




RN 676128-35-1 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-3-[[ (3-methoxyphenyl)methyl]amino]-5-phenyl- (9CI) (CA INDEX NAME)




RN 676128-36-2 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-5-phenyl-3-[[[2-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 676128-37-3 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-5-phenyl-3-[[[3-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 676128-38-4 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-5-phenyl-3-[[[4-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 676128-39-5 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 3-[(2-furanylmethyl)amino]-1,3-dihydro-5-phenyl- (9CI) (CA INDEX NAME)




RN 676128-40-8 CAPLUS

CN Propanamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methyl- (9CI) (CA INDEX NAME)




RN 676128-41-9 CAPLUS

CN Methanesulfonamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-42-0 CAPLUS

CN Cyclohexanecarboxamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-43-1 CAPLUS

CN Benzamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 676128-44-2 CAPLUS

CN Benzamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-methoxy- (9CI) (CA INDEX NAME)




RN 676128-45-3 CAPLUS

CN Benzamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-nitro- (9CI) (CA INDEX NAME)




RN 676128-46-4 CAPLUS

CN Benzeneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 676128-47-5 CAPLUS

CN Benzeneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 676128-48-6 CAPLUS

CN Benzeneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-methoxy- (9CI) (CA INDEX NAME)




RN 676128-49-7 CAPLUS

CN Benzeneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-nitro- (9CI) (CA INDEX NAME)




RN 676128-50-0 CAPLUS

CN Benzeneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-nitro- (9CI) (CA INDEX NAME)




RN 676128-51-1 CAPLUS

CN Benzeneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 676128-52-2 CAPLUS

CN Benzeneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 676128-53-3 CAPLUS

CN Benzeneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 676128-54-4 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 676128-55-5 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(2-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 676128-57-7 CAPLUS

CN Urea, N-(2-chlorophenyl)-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-59-9 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-61-3 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 676128-62-4 CAPLUS


CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(2-fluorophenyl)- (CA INDEX NAME)



RN 676128-63-5 CAPLUS

CN Urea, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-N'-(2-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 676128-64-6 CAPLUS


CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)






RN 676128-65-7 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 676128-67-9 CAPLUS

CN Benzamide, 5-acetyl-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-ethoxy- (9CI) (CA INDEX NAME)



RN 676128-69-1 CAPLUS


CN 4H-1,3-Benzodioxin-8-carboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-6-fluoro- (9CI) (CA INDEX NAME)



RN 676128-72-6 CAPLUS


CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,4,5-

trifluoro- (9CI) (CA INDEX NAME)




RN 676128-74-8 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)




RN 676128-76-0 CAPLUS

CN 1H-Indole-7-carboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-78-2 CAPLUS

CN 2-Naphthalenecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 676128-80-6 CAPLUS

CN Benzamide, N-[7-chloro-5-(2-fluorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 676128-81-7 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-[(2-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 676128-82-8 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 676128-83-9 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-[(3-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 676128-84-0 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 676128-85-1 CAPLUS

CN Benzamide, 4-chloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 676128-86-2 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-methoxy-3-nitro- (9CI) (CA INDEX NAME)




RN 676128-87-3 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-methoxy-2-nitro- (9CI) (CA INDEX NAME)




RN 676128-88-4 CAPLUS

CN Benzamide, 5-chloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 676128-89-5 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-fluoro-2-methoxy- (9CI) (CA INDEX NAME)




RN 676128-90-8 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-methoxy-2-nitro- (9CI) (CA INDEX NAME)




RN 676128-91-9 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-methoxy-4-nitro- (9CI) (CA INDEX NAME)




RN 676128-92-0 CAPLUS

CN Benzenepropanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 676128-93-1 CAPLUS

CN Benzenepropanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 676128-94-2 CAPLUS

CN Benzenepropanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-methoxy- (9CI) (CA INDEX NAME)




RN 676128-95-3 CAPLUS

CN Benzamide, N-[5-(3-chlorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 676128-99-7 CAPLUS

CN Benzamide, N-[2,3-dihydro-2-oxo-5-[4-(trifluoromethyl)phenyl]-1H-1,4-benzodiazepin-3-yl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 676129-00-3 CAPLUS

CN Benzamide, N-[2,3-dihydro-2-oxo-5-[3-(trifluoromethyl)phenyl]-1H-1,4-benzodiazepin-3-yl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 676129-01-4 CAPLUS

CN Benzamide, N-[2,3-dihydro-2-oxo-5-[3-(trifluoromethyl)phenyl]-1H-1,4-benzodiazepin-3-yl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 676129-02-5 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-ethoxy- (9CI) (CA INDEX NAME)




RN 676129-03-6 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,4-dimethoxy- (9CI) (CA INDEX NAME)



RN 676129-04-7 CAPLUS


CN Benzamide, 2-bromo-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-methoxy- (9CI) (CA INDEX NAME)



RN 676129-05-8 CAPLUS




CN Benzamide, N-[2,3-dihydro-5-(3-methoxyphenyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 676129-07-0 CAPLUS

CN Benzamide, N-(2,3-dihydro-8-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 676129-08-1 CAPLUS

CN Benzamide, 2-chloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 676129-09-2 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 676129-10-5 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 676129-11-6 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 676129-12-7 CAPLUS

CN Urea, N-[4-bromo-2-(trifluoromethyl)phenyl]-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676129-13-8 CAPLUS

CN Urea, N-[(4-bromophenyl)methyl]-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676129-14-9 CAPLUS

CN Urea, N-(2,3-dichlorophenyl)-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676129-15-0 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 676129-16-1 CAPLUS

CN Urea, N-(2-chloro-6-methylphenyl)-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676129-17-2 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 676129-18-3 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-[2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 676129-19-4 CAPLUS

CN Urea, N-(2,6-dichlorophenyl)-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676129-20-7 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-(1,1-dimethylethyl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 676129-21-8 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,5-dimethoxy- (9CI) (CA INDEX NAME)




RN 676129-22-9 CAPLUS

CN Urea, N-(2,6-difluorophenyl)-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676129-23-0 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 676129-25-2 CAPLUS


CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 676129-27-4 CAPLUS  
 CN Urea, N-(3-chlorophenyl)-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676129-29-6 CAPLUS  
 CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy-4-(methylthio)- (9CI) (CA INDEX NAME)



RN 676129-30-9 CAPLUS  
 CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 676129-31-0 CAPLUS  
 CN Benzoic acid, 4-[[[2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 676129-32-1 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-fluoro- (9CI) (CA INDEX NAME)




RN 676129-33-2 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 676129-34-3 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-propoxy- (9CI) (CA INDEX NAME)




RN 676129-35-4 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-iodo- (9CI) (CA INDEX NAME)




RN 676129-36-5 CAPLUS

CN Benzoic acid, 4-[[2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]amino]carbonyl]-3-methoxy-, methyl ester (9CI) (CA INDEX NAME)




RN 676129-37-6 CAPLUS

CN Benzamide, 4-amino-5-chloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)



RN 676129-38-7 CAPLUS


CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(methylthio)- (9CI) (CA INDEX NAME)






RN 676129-39-8 CAPLUS

CN Benzamide, 5-(aminosulfonyl)-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 676129-40-1 CAPLUS

CN Benzenepropanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)




RN 676129-41-2 CAPLUS

CN Benzenepropanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- $\beta$ -hydroxy- (9CI) (CA INDEX NAME)




RN 676129-42-3 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(2-fluorophenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 676129-43-4 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy-N-methyl-4-nitro- (9CI) (CA INDEX NAME)




RN 676129-44-5 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 676129-45-6 CAPLUS

CN Urea, N-cyclohexyl-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676129-46-7 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-ethyl- (9CI) (CA INDEX NAME)




RN 676129-47-8 CAPLUS

CN Urea, N-butyl-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-  
(9CI) (CA INDEX NAME)




RN 676129-48-9 CAPLUS

CN 2-Furancarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4,5-dimethyl- (9CI) (CA INDEX NAME)




RN 676129-49-0 CAPLUS

CN 1-Piperidinecarboxamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676129-57-0 CAPLUS

CN 2-Furancarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-methyl- (9CI) (CA INDEX NAME)




RN 676129-63-8 CAPLUS

CN Cyclohexanecarboxamide, N-(8-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676129-64-9 CAPLUS

CN 2-Thiophenecarboxamide, N-(2,3-dihydro-8-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676129-65-0 CAPLUS


CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-2-thienyl- (9CI) (CA INDEX NAME)




RN 676129-66-1 CAPLUS  
CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-3-thienyl- (9CI) (CA INDEX NAME)




RN 676129-67-2 CAPLUS  
CN 2-Pyridinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)



RN 676129-68-3 CAPLUS  
CN 1H-Pyrazole-4-carboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676129-69-4 CAPLUS  
CN 3-Pyridinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-6-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 676129-70-7 CAPLUS

CN 1-Naphthalenecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-ethoxy- (9CI) (CA INDEX NAME)




RN 676129-71-8 CAPLUS

CN 9H-Fluorene-1-carboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-9-oxo- (9CI) (CA INDEX NAME)




RN 676129-72-9 CAPLUS

CN 1H-Benzimidazole-1-carboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 676129-75-2 CAPLUS

CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 676129-76-3 CAPLUS

CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 676129-77-4 CAPLUS

CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, 2-methylpropyl ester (9CI) (CA INDEX NAME)




RN 676129-78-5 CAPLUS

CN 2-Thiopheneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-α-oxo- (9CI) (CA INDEX NAME)



RN 676129-79-6 CAPLUS

CN 3-Pyridinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 6 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:1042073 CAPLUS Full-text

DN 143:339599

TI Pharmaceutical composition comprising a benzodiazepine derivative and an inhibit or of the RSV fusion protein

IN Powell, Kenneth; Kelsey, Richard; Carter, Malcolm; Alber, Dagmar; Wilson, Lara; Henderson, Elisa; Chambers, Phil; Taylor, Debra; Tyms, Stan; Dowdell, Verity

PA Arrow Therapeutics Limited, UK

SO PCT Int. Appl., 83 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2005089769	A1	20050929	WO 2005-GB1018	20050318
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2005224157	A1	20050929	AU 2005-224157	20050318
	CA 2558112	A1	20050929	CA 2005-2558112	20050318
	EP 1727550	A1	20061206	EP 2005-718061	20050318
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	CN 1933842	A	20070321	CN 2005-80008927	20050318
	BR 2005007654	A	20070710	BR 2005-7654	20050318
	MX 2006PA10711	A	20061116	MX 2006-PA10711	20060919
	IN 2006CN03430	A	20070706	IN 2006-CN3430	20060919
	US 2007142403	A1	20070621	US 2007-593666	20070312
PRAI	GB 2004-6282	A	20040319		
	WO 2005-GB1018	W	20050318		

OS MARPAT 143:339599

AB A pharmaceutical composition which comprises a pharmaceutically acceptable carrier or diluent and: (a) an inhibitor of the RSV fusion protein; and (b) a benzodiazepine derivative capable of inhibiting RSV replication is highly active against RSV.

IT 4173-63-1, N-[7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]acetamide 103373-17-7, 2-Chloro-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 103373-21-3, 3,4-Dichloro-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 108895-98-3, [2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]carbamic acid benzyl ester 116842-74-1, Pyrazine-2-carboxylic acid N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 119506-69-3, 1-(3-Methoxyphenyl)-3-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]urea 150964-48-0, N-[2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 168162-29-6 206115-23-3, 1-[2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-3-m-tolylurea 368870-46-6 368870-47-7, Furan-2-carboxylic acid N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 368870-49-9,



Thiophene-2-carboxylic acid N-[7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 368870-50-2, Furan-2-carboxylic acid N-[7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676127-99-4 676128-01-1, Cyclohexanecarboxylic acid N-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676128-02-2, 3-Methoxy N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676128-03-3, 4-Methoxy N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676128-04-4, 2-Methoxy N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676128-05-5, N-[2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-3-trifluoromethylbenzamide 676128-06-6, Piperidine-1-carboxylic acid N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676128-07-7, Morpholine-4-carboxylic acid N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676128-08-8, 4-Nitro-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676128-09-9, 3-Nitro-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676128-10-2, 4-Methylpiperazine-1-carboxylic acid N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676128-11-3, N-[2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-2-trifluoromethylbenzamide 676128-12-4, 4-Bromo-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676128-13-5, 2-Methyl-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676128-14-6, 2-Nitro-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676128-15-7, 2-Methoxy-4-nitro-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676128-16-8, (S)-2-Methoxy-4-nitro-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676128-17-9, Benzo[b]thiophene-3-carboxylic acid N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676128-18-0, 2,3-Dihydrobenzofuran-5-carboxylic acid N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676128-19-1, Isoxazole-5-carboxylic acid N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676128-20-4, Benzo[b]thiophene-2-carboxylic acid N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676128-21-5, Thiophene-3-carboxylic acid N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676128-22-6, N-[2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]isonicotinamide 676128-23-7, N-[2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]nicotinamide 676128-24-8, N-[2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]methanesulfonamide 676128-25-9, Propane-1-sulfonic acid N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676128-26-0, Butane-1-sulfonic acid N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676128-27-1, 2-Bromo-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzenesulfonamide 676128-28-2, 3-Bromo-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzenesulfonamide 676128-29-3, 4-Bromo-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzenesulfonamide 676128-30-6, 2-Fluoro-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzenesulfonamide 676128-31-7, 3-(2-Nitrobenzylamino)-5-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one 676128-32-8, 3-(3-Nitrobenzylamino)-5-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one 676128-33-9, 3-(4-Nitrobenzylamino)-5-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one 676128-34-0, 3-(2-Methoxybenzylamino)-5-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one


676128-35-1, 3-(3-Methoxybenzylamino)-5-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one 676128-36-2, 5-Phenyl-3-(2-trifluoromethylbenzylamino)-1,3-dihydrobenzo[e][1,4]diazepin-2-one 676128-37-3, 5-Phenyl-3-(3-trifluoromethylbenzylamino)-1,3-dihydrobenzo[e][1,4]diazepin-2-one 676128-38-4, 5-Phenyl-3-(4-trifluoromethylbenzylamino)-1,3-dihydrobenzo[e][1,4]diazepin-2-one 676128-39-5, 3-[(Furan-2-ylmethyl)amino]-5-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one 676128-40-8, N-[7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]isobutyramide 676128-41-9, N-[7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]methanesulfonamide 676128-42-0, Cyclohexanecarboxylic acid N-[7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676128-43-1, N-[7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-2-methoxybenzamide 676128-44-2, N-[7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-4-methoxybenzamide 676128-45-3, N-[7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-2-nitrobenzamide 676128-46-4, 2-(2-Methoxyphenyl)-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]acetamide 676128-47-5, 2-(3-Methoxyphenyl)-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]acetamide 676128-48-6, 2-(4-Methoxyphenyl)-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]acetamide 676128-49-7, 2-(4-Nitrophenyl)-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]acetamide 676128-50-0, 2-(3-Nitrophenyl)-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]acetamide 676128-51-1, N-[2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-2-(2-trifluoromethylphenyl)acetamide 676128-52-2, N-[2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-2-(3-trifluoromethylphenyl)acetamide 676128-53-3, N-[2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-2-(4-trifluoromethylphenyl)acetamide 676128-54-4, 1-(2-Methoxyphenyl)-3-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]urea 676128-55-5, 1-(2-Nitrophenyl)-3-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]urea 676128-57-7, 1-(2-Chlorophenyl)-3-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]urea 676128-59-9, 1-(4-Chlorophenyl)-3-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]urea 676128-61-3, 1-[2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-3-p-tolylurea 676128-62-4, 1-(2-Fluorophenyl)-3-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]urea 676128-63-5 676128-64-6, 1-(4-Fluorophenyl)-3-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]urea 676128-65-7, 4-Methanesulfonyl-2-methoxy-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676128-66-8, (S)-4-Methanesulfonyl-2-methoxy-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676128-67-9, 5-Acetyl-2-ethoxy-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676128-68-0, (S)-5-Acetyl-2-ethoxy-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676128-69-1, 6-Fluoro-4H-benzo[1,3]dioxin-8-carboxylic acid N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676128-70-4, (S)-6-Fluoro-4H-benzo[1,3]dioxin-8-carboxylic acid N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676128-71-5, (S)-2-Methoxy-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-4-trifluoromethylbenzamide 676128-72-6, 2,4,5-Trifluoro-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676128-73-7, (S)-2,4,5-Trifluoro-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676128-74-8, 2-Hydroxy-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-

yl]benzamide 676128-75-9, (S)-2-Hydroxy-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676128-76-0, 1H-Indole-7-carboxylic acid N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676128-77-1, (S)-1H-Indole-7-carboxylic acid N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676128-78-2, 3-Methoxynaphthalene-2-carboxylic acid N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676128-79-3, (S)-3-Methoxynaphthalene-2-carboxylic acid N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676128-80-6, N-[7-Chloro-5-(2-fluorophenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-4-methoxybenzamide 676128-81-7, 1-(2-Fluorobenzyl)-3-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]urea 676128-82-8, 1-(4-Methoxybenzyl)-3-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]urea 676128-83-9, 1-(3-Methylbenzyl)-3-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]urea 676128-84-0, 1-[2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-3-(4-trifluoromethylphenyl)urea 676128-85-1, 4-Chloro-2-methoxy-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676128-86-2, 4-Methoxy-3-nitro-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676128-87-3, 3-Methoxy-2-nitro-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676128-88-4, 5-Chloro-2-methoxy-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676128-89-5, 5-Fluoro-2-methoxy-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676128-90-8, 5-Methoxy-2-nitro-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676128-91-9, 3-Methoxy-4-nitro-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676128-92-0, 3-(2-Methoxyphenyl)-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]propionamide 676128-93-1, 3-(3-Methoxyphenyl)-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]propionamide 676128-94-2, 3-(4-Methoxyphenyl)-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]propionamide 676128-95-3, N-[5-(3-Chlorophenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-2-methoxybenzamide 676128-96-4, N-[5-(3-Chlorophenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-4-methoxybenzamide 676128-97-5, N-[5-(3-Chlorophenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-2-nitrobenzamide 676128-98-6, N-[5-(3-Chlorophenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-4-nitrobenzamide 676128-99-7, 4-Methoxy-N-[2-oxo-5-(4-trifluoromethylphenyl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676129-00-3, 2-Methoxy-N-[2-oxo-5-(3-trifluoromethylphenyl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676129-01-4, 4-Methoxy-N-[2-oxo-5-(3-trifluoromethylphenyl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676129-02-5, 2-Ethoxy-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676129-03-6, 2,4-Dimethoxy-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676129-04-7, 2-Bromo-5-methoxy-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676129-05-8, 2-Methoxy-N-[5-(3-methoxyphenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676129-06-9, N-[5-(3-Methoxyphenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-4-nitrobenzamide 676129-07-0, 2-Methoxy-N-[8-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676129-08-1, 2-Chloro-4-methanesulfonyl-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676129-09-2, 2-Dimethylamino-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676129-10-5, 1-(3,5-Dimethylphenyl)-3-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]urea 676129-11-6

, 1-[2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-3-(4-trifluoromethoxyphenyl)urea 676129-12-7, 1-(4-Bromo-2-trifluoromethylphenyl)-3-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]urea 676129-13-8, 1-(4-Bromobenzyl)-3-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]urea 676129-14-9, 1-(2,3-Dichlorophenyl)-3-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]urea 676129-15-0, 1-(2,6-Dimethylphenyl)-3-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]urea 676129-16-1, 1-(2-Chloro-6-methylphenyl)-3-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]urea 676129-17-2, 1-(4-Nitrophenyl)-3-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]urea 676129-18-3, 1-(2-Methylsulfanylphenyl)-3-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]urea 676129-19-4, 1-(2,6-Dichlorophenyl)-3-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]urea 676129-20-7, 5-tert-Butyl-2-methoxy-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676129-21-8, 2,5-Dimethoxy-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676129-22-9, 1-(2,6-Difluorophenyl)-3-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]urea 676129-23-0, 1-(3-Fluorophenyl)-3-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]urea 676129-25-2, 1-[2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-3-(3-trifluoromethylphenyl)urea 676129-27-4, 1-(3-Chlorophenyl)-3-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]urea 676129-29-6, 2-Methoxy-4-methylsulfanyl-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676129-30-9, 4-Methanesulfonyl-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676129-31-0, N-[2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]terephthalamic acid methyl ester 676129-32-1, 2-Fluoro-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676129-33-2, 2,6-Difluoro-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676129-34-3, N-[2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-2-propoxybenzamide 676129-35-4, 2-Iodo-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676129-36-5, 3-Methoxy-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]terephthalamic acid methyl ester 676129-37-6, 4-Amino-5-chloro-2-methoxy-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676129-38-7, 2-Methylsulfanyl-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676129-39-8, 2-Methoxy-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-5-sulfamoylbenzamide 676129-40-1, 2-Hydroxy-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-3-phenylpropionamide 676129-41-2, 3-Hydroxy-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-3-phenylpropionamide 676129-42-3, 3-(2-Fluorophenyl)-1-methyl-1-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]urea 676129-43-4, 2-Methoxy-N-methyl-4-nitro-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676129-44-5, 1-tert-Butyl-3-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]urea 676129-45-6, 1-Cyclohexyl-3-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]urea 676129-46-7, 1-Ethyl-3-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]urea 676129-47-8, 1-Butyl-3-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]urea 676129-48-9, 4,5-Dimethylfuran-2-carboxylic acid N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676129-49-0, Piperidine-1-carboxylic acid N-[7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-


benzo[e][1,4]diazepin-3-yl]amide 676129-50-3,  
N-[5-(3-Chlorophenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]acetamide 676129-51-4, N-[5-(3-Chlorophenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]isobutyramide 676129-52-5,  
Furan-2-carboxylic acid N-[5-(3-chlorophenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676129-53-6,  
Thiophene-2-carboxylic acid N-[5-(3-chlorophenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676129-54-7,  
Cyclohexanecarboxylic acid N-[5-(3-chlorophenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676129-55-8,  
Piperidine-1-carboxylic acid N-[5-(3-chlorophenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676129-56-9,  
N-[5-(3-Chlorophenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]isonicotinamide 676129-57-0, 5-Methylfuran-2-carboxylic acid N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676129-59-2, Thiophene-2-carboxylic acid N-[5-(3-methoxyphenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676129-60-5,  
Cyclohexanecarboxylic acid N-[5-(3-methoxyphenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676129-61-6,  
Piperidine-1-carboxylic acid N-[5-(3-methoxyphenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676129-62-7,  
Piperidine-4-carboxylic acid N-[5-(3-methoxyphenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676129-63-8,  
Cyclohexanecarboxylic acid N-[8-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676129-64-9,  
Thiophene-2-carboxylic acid N-[8-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676129-65-0,  
1-[2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-3-thiophen-2-ylurea 676129-66-1, 1-[2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-3-thiophen-3-ylurea 676129-67-2,  
Pyridine-2-carboxylic acid N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676129-68-3,  
1H-Pyrazole-4-carboxylic acid N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676129-69-4,  
6-Dimethylamino-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]nicotinamide 676129-70-7, 2-Ethoxynaphthalene-1-carboxylic acid N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676129-71-8, 9-Oxo-9H-fluorene-1-carboxylic acid N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676129-72-9, 2-Oxo-2,3-dihydrobenzimidazole-1-carboxylic acid N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676129-73-0, (S)-4,5-Dibromofuran-2-carboxylic acid N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676129-74-1, (S)-Benzofuran-2-carboxylic acid N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]amide 676129-75-2, [2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]carbamic acid methyl ester 676129-76-3, [2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]carbamic acid ethyl ester 676129-77-4, [2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]carbamic acid isobutyl ester 676129-78-5, 2-Oxo-N-[2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-2-thiophen-2-ylacetamide  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(antiviral benzodiazepine derivative as inhibitors of RSV fusion protein)

RN 4173-63-1 CAPLUS  
CN Acetamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (8CI, 9CI) (CA INDEX NAME)




RN 103373-17-7 CAPLUS

CN Benzamide, 2-chloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 103373-21-3 CAPLUS

CN Benzamide, 3,4-dichloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 108895-98-3 CAPLUS

CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 116842-74-1 CAPLUS

CN 2-Pyrazinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 119506-69-3 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 150964-48-0 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 168162-29-6 CAPLUS

CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 206115-23-3 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 368870-46-6 CAPLUS

CN 2-Thiophenecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 368870-47-7 CAPLUS

CN 2-Furancarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)



RN 368870-49-9 CAPLUS


CN 2-Thiophenecarboxamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)






RN 368870-50-2 CAPLUS

CN 2-Furancarboxamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676127-99-4 CAPLUS

CN Propanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 676128-01-1 CAPLUS

CN Cyclohexanecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 676128-02-2 CAPLUS


CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 676128-03-3 CAPLUS  
CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-methoxy- (9CI) (CA INDEX NAME)




RN 676128-04-4 CAPLUS  
CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)



RN 676128-05-5 CAPLUS  
CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 676128-06-6 CAPLUS  
CN 1-Piperidinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-07-7 CAPLUS

CN 4-Morpholinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-08-8 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-nitro- (9CI) (CA INDEX NAME)




RN 676128-09-9 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-nitro- (9CI) (CA INDEX NAME)




RN 676128-10-2 CAPLUS

CN 1-Piperazinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-methyl- (9CI) (CA INDEX NAME)




RN 676128-11-3 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 676128-12-4 CAPLUS

CN Benzamide, 4-bromo-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-13-5 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methyl- (9CI) (CA INDEX NAME)




RN 676128-14-6 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-nitro- (9CI) (CA INDEX NAME)



RN 676128-15-7 CAPLUS


CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy-4-nitro- (CA INDEX NAME)



RN 676128-16-8 CAPLUS


CN Benzamide, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-methoxy-4-nitro- (CA INDEX NAME)

Absolute stereochemistry.




RN 676128-17-9 CAPLUS


CN Benzo[b]thiophene-3-carboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-18-0 CAPLUS  
CN 5-Benzofurancarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 676128-19-1 CAPLUS  
CN 5-Isoxazolecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-20-4 CAPLUS  
CN Benzo[b]thiophene-2-carboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-21-5 CAPLUS  
CN 3-Thiophenecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-22-6 CAPLUS  
 CN 4-Pyridinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-23-7 CAPLUS  
 CN 3-Pyridinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)



RN 676128-24-8 CAPLUS  
 CN Methanesulfonamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-25-9 CAPLUS  
 CN 1-Propanesulfonamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-26-0 CAPLUS

CN 1-Butanesulfonamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-27-1 CAPLUS

CN Benzenesulfonamide, 2-bromo-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)



RN 676128-28-2 CAPLUS


CN Benzenesulfonamide, 3-bromo-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)



RN 676128-29-3 CAPLUS




CN Benzenesulfonamide, 4-bromo-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-30-6 CAPLUS

CN Benzenesulfonamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-fluoro- (9CI) (CA INDEX NAME)




RN 676128-31-7 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-3-[[ (2-nitrophenyl)methyl]amino]-5-phenyl- (9CI) (CA INDEX NAME)




RN 676128-32-8 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-3-[[ (3-nitrophenyl)methyl]amino]-5-phenyl- (9CI) (CA INDEX NAME)




RN 676128-33-9 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-3-[[ (4-nitrophenyl)methyl]amino]-5-phenyl- (9CI) (CA INDEX NAME)




RN 676128-34-0 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-3-[[ (2-methoxyphenyl)methyl]amino]-5-phenyl- (9CI) (CA INDEX NAME)




RN 676128-35-1 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-3-[[ (3-methoxyphenyl)methyl]amino]-5-phenyl- (9CI) (CA INDEX NAME)




RN 676128-36-2 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-5-phenyl-3-[[[2-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 676128-37-3 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-5-phenyl-3-[[[3-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 676128-38-4 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-5-phenyl-3-[[[4-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 676128-39-5 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 3-[(2-furanylmethyl)amino]-1,3-dihydro-5-phenyl- (9CI) (CA INDEX NAME)




RN 676128-40-8 CAPLUS

CN Propanamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methyl- (9CI) (CA INDEX NAME)




RN 676128-41-9 CAPLUS

CN Methanesulfonamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-42-0 CAPLUS

CN Cyclohexanecarboxamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-43-1 CAPLUS

CN Benzamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 676128-44-2 CAPLUS

CN Benzamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-methoxy- (9CI) (CA INDEX NAME)




RN 676128-45-3 CAPLUS

CN Benzamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-nitro- (9CI) (CA INDEX NAME)




RN 676128-46-4 CAPLUS

CN Benzeneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 676128-47-5 CAPLUS

CN Benzeneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 676128-48-6 CAPLUS

CN Benzeneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-methoxy- (9CI) (CA INDEX NAME)




RN 676128-49-7 CAPLUS

CN Benzeneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-nitro- (9CI) (CA INDEX NAME)




RN 676128-50-0 CAPLUS

CN Benzeneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-nitro- (9CI) (CA INDEX NAME)




RN 676128-51-1 CAPLUS

CN Benzeneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 676128-52-2 CAPLUS

CN Benzeneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 676128-53-3 CAPLUS

CN Benzeneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 676128-54-4 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 676128-55-5 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(2-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 676128-57-7 CAPLUS

CN Urea, N-(2-chlorophenyl)-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-59-9 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-61-3 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 676128-62-4 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(2-fluorophenyl)- (CA INDEX NAME)






RN 676128-63-5 CAPLUS


CN Urea, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-N'-(2-fluorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 676128-64-6 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 676128-65-7 CAPLUS


CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 676128-66-8 CAPLUS


CN Benzamide, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-methoxy-4-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 676128-67-9 CAPLUS


CN Benzamide, 5-acetyl-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-ethoxy- (9CI) (CA INDEX NAME)



RN 676128-68-0 CAPLUS


CN Benzamide, 5-acetyl-N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-ethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676128-69-1 CAPLUS


CN 4H-1,3-Benzodioxin-8-carboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-6-fluoro- (9CI) (CA INDEX NAME)



RN 676128-70-4 CAPLUS

CN 4H-1,3-Benzodioxin-8-carboxamide, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-6-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 676128-71-5 CAPLUS


CN Benzamide, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-methoxy-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676128-72-6 CAPLUS


CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,4,5-trifluoro- (9CI) (CA INDEX NAME)



RN 676128-73-7 CAPLUS


CN Benzamide, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2,4,5-trifluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676128-74-8 CAPLUS


CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)



RN 676128-75-9 CAPLUS


CN Benzamide, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676128-76-0 CAPLUS


CN 1H-Indole-7-carboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)



RN 676128-77-1 CAPLUS


CN 1H-Indole-7-carboxamide, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676128-78-2 CAPLUS


CN 2-Naphthalenecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-methoxy- (9CI) (CA INDEX NAME)



RN 676128-79-3 CAPLUS


CN 2-Naphthalenecarboxamide, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 676128-80-6 CAPLUS

CN Benzamide, N-[7-chloro-5-(2-fluorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 676128-81-7 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-[(2-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 676128-82-8 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 676128-83-9 CAPLUS


CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-[(3-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 676128-84-0 CAPLUS


CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-[4-

(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 676128-85-1 CAPLUS

CN Benzamide, 4-chloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 676128-86-2 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-methoxy-3-nitro- (9CI) (CA INDEX NAME)




RN 676128-87-3 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-methoxy-2-nitro- (9CI) (CA INDEX NAME)




RN 676128-88-4 CAPLUS

CN Benzamide, 5-chloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 676128-89-5 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-fluoro-2-methoxy- (9CI) (CA INDEX NAME)




RN 676128-90-8 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-methoxy-2-nitro- (9CI) (CA INDEX NAME)



RN 676128-91-9 CAPLUS


CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-methoxy-4-nitro- (9CI) (CA INDEX NAME)






RN 676128-92-0 CAPLUS

CN Benzenepropanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 676128-93-1 CAPLUS

CN Benzenepropanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 676128-94-2 CAPLUS

CN Benzenepropanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-methoxy- (9CI) (CA INDEX NAME)




RN 676128-95-3 CAPLUS

CN Benzamide, N-[5-(3-chlorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 676128-96-4 CAPLUS

CN Benzamide, N-[5-(3-chlorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 676128-97-5 CAPLUS

CN Benzamide, N-[5-(3-chlorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]-2-nitro- (9CI) (CA INDEX NAME)




RN 676128-98-6 CAPLUS

CN Benzamide, N-[5-(3-chlorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]-4-nitro- (9CI) (CA INDEX NAME)




RN 676128-99-7 CAPLUS

CN Benzamide, N-[2,3-dihydro-2-oxo-5-[4-(trifluoromethyl)phenyl]-1H-1,4-benzodiazepin-3-yl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 676129-00-3 CAPLUS

CN Benzamide, N-[2,3-dihydro-2-oxo-5-[3-(trifluoromethyl)phenyl]-1H-1,4-benzodiazepin-3-yl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 676129-01-4 CAPLUS

CN Benzamide, N-[2,3-dihydro-2-oxo-5-[3-(trifluoromethyl)phenyl]-1H-1,4-benzodiazepin-3-yl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 676129-02-5 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-ethoxy- (9CI) (CA INDEX NAME)




RN 676129-03-6 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,4-dimethoxy- (9CI) (CA INDEX NAME)




RN 676129-04-7 CAPLUS

CN Benzamide, 2-bromo-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-methoxy- (9CI) (CA INDEX NAME)




RN 676129-05-8 CAPLUS

CN Benzamide, N-[2,3-dihydro-5-(3-methoxyphenyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 676129-06-9 CAPLUS

CN Benzamide, N-[2,3-dihydro-5-(3-methoxyphenyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]-4-nitro- (9CI) (CA INDEX NAME)




RN 676129-07-0 CAPLUS

CN Benzamide, N-(2,3-dihydro-8-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 676129-08-1 CAPLUS

CN Benzamide, 2-chloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 676129-09-2 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 676129-10-5 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 676129-11-6 CAPLUS


CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 676129-12-7 CAPLUS


CN Urea, N-[4-bromo-2-(trifluoromethyl)phenyl]-N'-(2,3-dihydro-2-oxo-5-phenyl-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)

1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676129-13-8 CAPLUS

CN Urea, N-[(4-bromophenyl)methyl]-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676129-14-9 CAPLUS

CN Urea, N-(2,3-dichlorophenyl)-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676129-15-0 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 676129-16-1 CAPLUS

CN Urea, N-(2-chloro-6-methylphenyl)-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676129-17-2 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 676129-18-3 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-[2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)



RN 676129-19-4 CAPLUS


CN Urea, N-(2,6-dichlorophenyl)-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)






RN 676129-20-7 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-(1,1-dimethylethyl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 676129-21-8 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,5-dimethoxy- (9CI) (CA INDEX NAME)




RN 676129-22-9 CAPLUS

CN Urea, N-(2,6-difluorophenyl)-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676129-23-0 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 676129-25-2 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(3-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)




RN 676129-27-4 CAPLUS

CN Urea, N-(3-chlorophenyl)-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676129-29-6 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy-4-(methylthio)- (9CI) (CA INDEX NAME)




RN 676129-30-9 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 676129-31-0 CAPLUS

CN Benzoic acid, 4-[[2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 676129-32-1 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-fluoro- (9CI) (CA INDEX NAME)




RN 676129-33-2 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 676129-34-3 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-propoxy- (9CI) (CA INDEX NAME)




RN 676129-35-4 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-iodo- (9CI) (CA INDEX NAME)




RN 676129-36-5 CAPLUS

CN Benzoic acid, 4-[[[(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)amino]carbonyl]-3-methoxy-, methyl ester (9CI) (CA INDEX NAME)




RN 676129-37-6 CAPLUS

CN Benzamide, 4-amino-5-chloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 676129-38-7 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 676129-39-8 CAPLUS

CN Benzamide, 5-(aminosulfonyl)-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 676129-40-1 CAPLUS

CN Benzenepropanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)




RN 676129-41-2 CAPLUS

CN Benzenepropanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- $\beta$ -hydroxy- (9CI) (CA INDEX NAME)




RN 676129-42-3 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(2-fluorophenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 676129-43-4 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy-N-methyl-4-nitro- (9CI) (CA INDEX NAME)




RN 676129-44-5 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 676129-45-6 CAPLUS


CN Urea, N-cyclohexyl-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676129-46-7 CAPLUS  
 CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-ethyl-  
 (9CI) (CA INDEX NAME)



RN 676129-47-8 CAPLUS  
 CN Urea, N-butyl-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-  
 (9CI) (CA INDEX NAME)




RN 676129-48-9 CAPLUS  
 CN 2-Furancarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4,5-dimethyl- (9CI) (CA INDEX NAME)




RN 676129-49-0 CAPLUS

CN 1-Piperidinecarboxamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676129-50-3 CAPLUS

CN Acetamide, N-[5-(3-chlorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)



RN 676129-51-4 CAPLUS


CN Propanamide, N-[5-(3-chlorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 676129-52-5 CAPLUS


CN 2-Furancarboxamide, N-[5-(3-chlorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)






RN 676129-53-6 CAPLUS

CN 2-Thiophenecarboxamide, N-[5-(3-chlorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)




RN 676129-54-7 CAPLUS

CN Cyclohexanecarboxamide, N-[5-(3-chlorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)




RN 676129-55-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-(3-chlorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)




RN 676129-56-9 CAPLUS

CN 4-Pyridinecarboxamide, N-[5-(3-chlorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)




RN 676129-57-0 CAPLUS

CN 2-Furancarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-methyl- (9CI) (CA INDEX NAME)




RN 676129-59-2 CAPLUS

CN 2-Thiophenecarboxamide, N-[2,3-dihydro-5-(3-methoxyphenyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)




RN 676129-60-5 CAPLUS

CN Cyclohexanecarboxamide, N-[2,3-dihydro-5-(3-methoxyphenyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)




RN 676129-61-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[2,3-dihydro-5-(3-methoxyphenyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)




RN 676129-62-7 CAPLUS

CN 4-Piperidinecarboxamide, N-[2,3-dihydro-5-(3-methoxyphenyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)




RN 676129-63-8 CAPLUS

CN Cyclohexanecarboxamide, N-(8-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676129-64-9 CAPLUS

CN 2-Thiophenecarboxamide, N-(2,3-dihydro-8-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676129-65-0 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-2-thienyl- (9CI) (CA INDEX NAME)



RN 676129-66-1 CAPLUS


CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-3-thienyl- (9CI) (CA INDEX NAME)



RN 676129-67-2 CAPLUS


CN 2-Pyridinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-

3-yl)- (9CI) (CA INDEX NAME)




RN 676129-68-3 CAPLUS

CN 1H-Pyrazole-4-carboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676129-69-4 CAPLUS

CN 3-Pyridinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-6-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 676129-70-7 CAPLUS

CN 1-Naphthalenecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-ethoxy- (9CI) (CA INDEX NAME)




RN 676129-71-8 CAPLUS

CN 9H-Fluorene-1-carboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-9-oxo- (9CI) (CA INDEX NAME)



RN 676129-72-9 CAPLUS


CN 1H-Benzimidazole-1-carboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 676129-73-0 CAPLUS

CN 2-Furancarboxamide, 4,5-dibromo-N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 676129-74-1 CAPLUS


CN 2-Benzofurancarboxamide, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 676129-75-2 CAPLUS

CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 676129-76-3 CAPLUS

CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 676129-77-4 CAPLUS

CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, 2-methylpropyl ester (9CI) (CA INDEX NAME)



RN 676129-78-5 CAPLUS


CN 2-Thiopheneacetamide, N-((2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- $\alpha$ -oxo- (9CI) (CA INDEX NAME)




RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 7 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2005:14369 CAPLUS Full-text  
 DN 142:114110  
 TI Preparation of benzodiazepine CGRP receptor antagonists  
 IN Burgey, Christopher S.; Stump, Craig A.; Williams, Theresa M.  
 PA Merck & Co., Inc., USA  
 SO PCT Int. Appl., 86 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005000807	A2	20050106	WO 2004-US20206	20040624
	WO 2005000807	A3	20060105		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004252150	A1	20050106	AU 2004-252150	20040624
	CA 2529227	A1	20050106	CA 2004-2529227	20040624
	EP 1641781	A2	20060405	EP 2004-776996	20040624
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	CN 1812982	A	20060802	CN 2004-80017952	20040624
	JP 2007516182	T	20070621	JP 2006-517597	20040624
	US 2006148790	A1	20060706	US 2005-562298	20051222
	US 7196079	B2	20070327		
PRAI	US 2003-482674P	P	20030626		
	WO 2004-US20206	W	20040624		
OS	CASREACT 142:114110; MARPAT 142:114110				
GI					



I



II

AB Title compds. I [R1 = H, alk(en/yn)yl, etc.; R2 = H, alkyl, cycloalkyl, etc.; R7 = H, alk(en/yn)yl, etc.; W = O, amino, alkyl; X = C, S; Y = O, NCN, etc.;



R3 = H, alkyl, CN, etc.; R6 = H, alkyl, cycloalkyl, etc.; G-J = N, N-alkyl, etc.] are prepared. For instance, II is prepared from (R)-3-amino-1-ethyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine oxalate, p-nitrophenylchloroformate and 3-(piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one hydrochloride. Compds. I exhibit affinity for the CGRP receptor with an IC50 of less than 50µM. I, alone or in combination with other agents, are useful for the treatment of diseases in which the CGRP is involved, such as headache, migraine and cluster headache.


IT 108895-98-3

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of benzodiazepine CGRP receptor antagonists for headaches)

RN 108895-98-3 CAPLUS

CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



L19 ANSWER 8 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:995964 CAPLUS Full-text

DN 141:424183

TI Preparation of 4-bromo-5-(2-chloro-benzoylamino)-1H-pyrazole-3-carboxylic acid amide derivatives and related compounds as bradykinin B1 receptor antagonists for the treatment of inflammatory diseases

IN Tung, Jay S.; Garofalo, Albert W.; Pleiss, Michael A.; Wu, Jing; Wone, David W. G.; Guinn, Ashley C.; Dressen, Darren B.; Neitz, R. Jeffrey; Marugg, Jennifer; Neitzel, Martin

PA Elan Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 374 pp.


CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 3


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	----	-----	-----
PI	WO 2004098589	A1	20041118	WO 2004-US13219	20040430
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2524269	A1	20041118	CA 2004-2524269	20040430
	US 2005020659	A1	20050127	US 2004-837231	20040430
	EP 1633348	A1	20060315	EP 2004-750891	20040430
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	JP 2006526015	T	20061116	JP 2006-513431	20040430
	US 2006281733	A1	20061214	US 2005-555519	20051102
PRAI	US 2003-467695P	P	20030502		
	US 2004-539546P	P	20040127		
	WO 2004-US13219	W	20040430		
OS	MARPAT 141:424183				
GI					



I



II




III

AB Disclosed are compds. I and II [Z1 = O, S, NH; Q = NR4R5, OH, alkyl, cycloalkyl, etc.; R1 = H, alkyl, aryl, etc.; R2, R3 = H, alkyl, aryl, etc.; R4, R5 = H, alkyl, alkoxy, cycloalkyl, etc.; or NR4R5 = (un)substituted heterocyclyl, heteroaryl; X = H, halo, alkyl, NO2, etc.; with provisos] that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. The general procedures for synthesis of the compds. I and II were given. E.g., a multi-step synthesis (no characterization data given for the intermediates) of the amide III, was described. The compds. I and II were tested for potency and efficacy to inhibit the bradykinin B1 receptor in a cell-based fluorescent calcium-mobilization assay. Their potency was demonstrated by results of less than 50  $\mu$ M. Certain of the compds. I and II exhibit increased potency and are also expected to exhibit increased duration of action. The pharmaceutical compns. comprising the title compds. are described and claimed.

IT 108895-98-3 155452-87-2, (7-Chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)carbamic acid phenylmethyl ester  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of 4-bromo-5-(2-chloro-benzoylamino)-1H-pyrazole-3-carboxylic acid amides as bradykinin B1 receptor antagonists for the treatment of inflammatory diseases)


RN 108895-98-3 CAPLUS

CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 155452-87-2 CAPLUS

CN Carbamic acid, (7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)




RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L19 ANSWER 9 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2004:985331 CAPLUS Full-text  
 DN 142:114435  
 TI Design and Synthesis of a Potent and Selective Peptidomimetic Inhibitor of Caspase-3  
 AU Micale, Nicola; Vairagoundar, Rajendran; Yakovlev, Alexander G.; Kozikowski, Alan P.  
 CS Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, Chicago, IL, 60612, USA  
 SO Journal of Medicinal Chemistry (2004), 47(26), 6455-6458  
 CODEN: JMCMAR; ISSN: 0022-2623  
 PB American Chemical Society  
 DT Journal  
 LA English  
 OS CASREACT 142:114435  
 GI



AB The authors report the synthesis and characterization of a benzodiazepine-based peptidomimetic I as a novel potent and selective inhibitor of caspase-3, a member of the caspase family of cysteine proteases which plays an important role in many human disorders. I is a monocyclic conformationally constrained form of the peptide aldehyde Ac-DEVD-H, where a 1,4-benzodiazepine nucleus is introduced internally to the peptidic sequence.  
 IT 108895-98-3P 168162-29-6P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and biol. activity of a benzodiazepine-based peptidomimetic as a potent and selective inhibitor of caspase-3)  
 RN 108895-98-3 CAPLUS  
 CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 168162-29-6 CAPLUS  
 CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 11 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2003:490975 CAPLUS Full-text  
 DN 139:69297  
 TI Benzodiazepinone derivatives as bradykinin B2 receptor antagonists,  
 preparation thereof, and use for treating pain  
 IN Leung, Carmen; Santhakumar, Vijayaratnam; Tomaszewski, Mirosław; Woo,  
 Simon  
 PA Astrazeneca AB, Swed.  
 SO PCT Int. Appl., 203 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003051275	A2	20030626	WO 2002-SE2309	20021211
	WO 2003051275	A3	20031030		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002359126	A1	20030630	AU 2002-359126	20021211
PRAI	SE 2001-4248	A	20011214		
	WO 2002-SE2309	W	20021211		
OS	MARPAT 139:69297				
GI					



AB A method is claimed of treating pain in a warm-blooded animal, comprising the step of administering a therapeutically effective amount of benzodiazepinones (shown as I; variables defined below; e.g. N-(7-chloro-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(5-isoquinolinyl)thiourea), pharmaceutically acceptable salts thereof, diastereomers thereof, enantiomers thereof, or mixts. thereof. For I: R1 = (un)substituted acyl, alkyloxycarbonyl, alkyl, heteroalkyl, cycloalkyl, aryl, heterocyclyl; aryl-C1-6-alkyl, and heterocyclyl-C1-6-alkyl, or a divalent C1-12 group that together with a 2nd N of X form a ring; X is a divalent group including a 1st N atom and the 2nd N atom, wherein a 1st group is linked to the 1st N atom and R1 is linked to the 2nd N atom, and wherein the 1st and 2nd N atoms are separated by either one C atom, or two C atoms wherein said two C atoms have a double bond there between. R3 is (un)substituted aryl, C1-12alkyl, C3-12cycloalkyl, or heterocyclyl; R4 = H, halogen, (un)substituted alkyl, (un)substituted heteroalkyl, nitro, cyano, hydroxy, OR6, SR6, S(O)R6, S(O)2R6, C(O)R6, C(S)R6, NR7R6, C(O)N7R6, NR7C(O)R6, SO2NR7R6, NR7SO2R6, or C(O)OR6; and R5, R6 and R7 = H, (un)substituted C1-6alkyl. Thirty-three examples of I were tested for binding to B2 bradykinin and ranged from 43-3110 nM (dissociation constant); no individual values are reported. Although the methods of preparation are not claimed, 26 example preps. of I and 31 of intermediates are included.

More than 1100 examples of I prepared combinatorially are tabulated with LCMS anal. results.


IT 108895-98-3, (2,3-Dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)carbamic acid phenylmethyl ester 155452-87-2,  
(7-Chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)carbamic acid phenylmethyl ester

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of benzodiazepinone derivs. as bradykinin B2 receptor antagonists and use for treating pain)


RN 108895-98-3 CAPLUS

CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 155452-87-2 CAPLUS

CN Carbamic acid, (7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



L19 ANSWER 12 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2003:168838 CAPLUS Full-text  
DN 138:205345

TI Preparation of cyclic amino acid compounds for inhibiting  $\beta$ -amyloid peptide release and/or its synthesis

IN Audia, James E.; Dressman, Bruce A.; Shi, Qing

PA Elan Pharmaceuticals, Inc., USA; Eli Lilly and Company

SO U.S., 70 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 6528505	B1	20030304	US 1999-338180	19990622
	US 6552013	B1	20030422	US 1999-338121	19990622
	US 6569851	B1	20030527	US 1999-338191	19990622
	US 2003162768	A1	20030828	US 2002-317081	20021212
	US 6696438	B2	20040224		
	US 2003149022	A1	20030807	US 2002-326081	20021223
	US 6838455	B2	20050104		
	US 2004106598	A1	20040603	US 2003-392332	20030320
	US 6906056	B2	20050614		
	US 2005192265	A1	20050901	US 2004-2922	20041203
	US 2005192269	A1	20050901	US 2004-2951	20041203
	US 2005267150	A1	20051201	US 2004-2921	20041203
PRAI	US 1998-160067P	P	19980622		
	US 1998-155238P	P	19980930		
	US 1998-150704P	P	19980930		
	US 1998-162757	A	19980930		
	US 1999-338121	A3	19990622		
	US 1999-338180	A3	19990622		
	US 1999-338191	A3	19990622		
	US 2003-392332	A3	20030320		

OS MARPAT 138:205345

AB Fused azepinone amino acid derivs. R'R''NCHR1CONHCHR2CONH-W and R':NC(:R1)CONHCHR2CONH-W [R1 and R' combine to form a nitrogen-containing optionally-substituted (un)saturated heterocyclyl or heteroaryl group; R'' is H, (un)substituted alkyl or aryl; R2 is (un)substituted (cyclo)alkyl, alkenyl, alkynyl, (hetero)aryl, or heterocyclyl; W is (un)substituted mono- or dibenzo- or dicyclohexano(hydro)azepin-2-on-3-yl] were prepared for inhibition  $\beta$ -amyloid peptide release and/or its synthesis, and accordingly have utility in treating Alzheimer's disease. Thus, 5(S)-[(N-L-prolyl-L-alanyl)amino]-7-methyl-5,7-dihydro-6H- dibenz[b,d]azepin-6-one was prepared by acylation of 5(S)-amino-7-methyl-5,7- dihydro-6H-dibenz[b,d]azepin-6-one hydrochloride with Boc-Pro-Ala-OH (Boc = tert-butoxycarbonyl), followed by deprotection. Compds. of the invention inhibit  $\beta$ -amyloid peptide production by at least 30% as compared to the control when employed at 10  $\mu$ g/mL.


IT 108895-98-3 155452-87-2 168162-29-6

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of cyclic amino acid compds. for inhibiting  $\beta$ -amyloid peptide release and/or its synthesis)


RN 108895-98-3 CAPLUS

CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 155452-87-2 CAPLUS

CN Carbamic acid, (7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 168162-29-6 CAPLUS

CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RE.CNT 121 THERE ARE 121 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L19 ANSWER 13 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2003:35360 CAPLUS Full-text  
 DN 138:90080  
 TI Preparation of heterocyclic compounds and their use for inhibiting  
 $\beta$ -amyloid peptide release  
 IN Thorsett, Eugene D.; Porter, Warren J.; Nissen, Jeffrey S.; Latimer, Lee  
 H.; Audia, James E.; Droste, James  
 PA Athena Neurosciences, Inc., USA; Eli Lilly and Company  
 SO U.S., 99 pp.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 6506782	B1	20030114	US 1998-32019	19980227
	US 2003130188	A1	20030710	US 2002-246558	20020919
	US 6849650	B2	20050201		
PRAI	US 1998-32019	A3	19980227		
OS	MARPAT 138:90080				
GI					




I

AB Disclosed are modified heterocyclic di- and tripeptide analogs which inhibit  $\beta$ -amyloid peptide release and/or its synthesis and, accordingly, have utility in treating Alzheimer's disease. Compds. of formula  $R_1NHCHR_2(CONHCHR_6)_pCONHCHR_5C(:NR_4)R_4$  [ $R_1$  = H or acyl;  $R_2$ ,  $R_5$ ,  $R_6$  = (un)substituted alk(en)(yn)yl, cycloalkyl, (hetero)aryl, heterocyclyl;  $p$  = 0 or 1;  $R_3$  and  $R_4$  combine to form a heterocyclic ring, which may be substituted] are claimed. Also disclosed are pharmaceutical compns. comprising a compound which inhibits  $\beta$ -amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compns. Title compds., e.g. I, were prepared in a multistep synthesis and inhibited  $\beta$ -amyloid peptide production by at least 30% as compared to control.


IT 155452-87-2  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of heterocyclic compds. and their use for inhibiting  $\beta$ -amyloid peptide release)

RN 155452-87-2 CAPLUS  
 CN Carbamic acid, (7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 14 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2002:323125 CAPLUS Full-text  
 DN 137:78931  
 TI Synthesis of N-(2,3-dihydro-1-[14C]methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-benzamide and N-(2,3-dihydro-1-[14C]methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N-[14C]methyl-benzamide as novel carbon-14 labeled CCK antagonists  
 AU Matloubi, Hojatollah; Khalaj, Ali; Dowlatabadi, Reza; Shirvani, Gholamhossein  
 CS Chemical Division, Nuclear Research Center/AEOI, Tehran, Iran  
 SO Journal of Labelled Compounds & Radiopharmaceuticals (2002), 45(4), 347-350  
 CODEN: JLCRD4; ISSN: 0362-4803  
 PB John Wiley & Sons Ltd.  
 DT Journal  
 LA English  
 OS CASREACT 137:78931  
 AB Two benzodiazepine CCK antagonists N-(2,3-dihydro-1-[14C]methyl-2-oxo-5-phenyl-1H 1,4-benzodiazepin-3-yl)-benzamide and N-(2,3-dihydro-1- [14C]methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-[14C]methyl- benzamide 3 were synthesized in high yields through the reaction of N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-benzamide with [14C] Me iodide in different situations.  
 IT 150964-48-0  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of carbon-14-labeled (1,4-benzodiazepinyl)benzamide CCK antagonists by methylation with [14C]methyl iodide)  
 RN 150964-48-0 CAPLUS  
 CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI)  
 (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 15 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2001:868430 CAPLUS Full-text

DN 136:6019

TI Benzodiazepine derivatives as amyloid precursor protein modulators

IN Castro Pineiro, Jose Luis; Churcher, Ian; Guiblin, Alexander Richard; Harrison, Timothy; Kerrad, Sonia; Madin, Andrew; Nadin, Alan John; Owens, Andrew Pate; Sparey, Timothy Jason; Teall, Martin Richard; Williams, Susannah

PA Merck Sharp & Dohme Limited, UK

SO PCT Int. Appl., 165 pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001090084	A1	20011129	WO 2001-GB2251	20010521
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW	
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
	CA 2409998	A1	20011129	CA 2001-2409998	20010521
	EP 1294702	A1	20030326	EP 2001-934131	20010521
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR	
	JP 2003534333	T	20031118	JP 2001-586273	20010521
	AU 784150	B2	20060209	AU 2001-60437	20010521
	US 2004082572	A1	20040429	US 2002-296428	20021122
	US 7105509	B2	20060912		
PRAI	GB 2000-12671	A	20000524		
	WO 2001-GB2251	W	20010521		
OS	MARPAT 136:6019				
GI					



AB Benzodiazepines I [AB = (un)substituted C:N, 1,2,4-triazole-3,4-diyl, CONH, NHCO; X = O, S, NR; RR1 = CH:CH, CH2CH2; Y = (un)substituted alkylene; R1 = H, (un)substituted alkyl, cycloalkyl, alkenyl, alkynyl; R2 = (un)substituted


alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, OH, NH<sub>2</sub>; R<sub>3</sub> = H, alkyl; R<sub>2</sub>R<sub>3</sub> = alkylene; R<sub>4</sub> = aryl, heteroaryl, alkyl, polyfluoroalkyl, cycloalkyl, cycloalkylalkyl; R<sub>5</sub> = halogen, CN, NO<sub>2</sub>, alkyl, polyfluoroalkyl, OH, alkoxy; n = 0-3] were prepared. The compds. modulate the processing of amyloid precursor protein by  $\gamma$ -secretase, and hence find use in the treatment or prevention of conditions associated with the deposition of  $\beta$ -amyloid, such as Alzheimer's disease (no data). Thus, the amide II was prepared from tert.-Bu 1-methyl-2,5-dioxo-1,2,3,5-tetrahydro-4H-1,4-benzodiazepine-4-carboxylate by grignard reaction with 2-(4-bromophenyl)-4,4-dimethyl-4,5-dihydrooxazole, dehydration, amidation, and acylation.

IT 108895-98-3 168162-29-6

RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of acylaminobenzodiazepines as amyloid precursor protein modulators)


RN 108895-98-3 CAPLUS

CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 168162-29-6 CAPLUS

CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 16 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2001:596439 CAPLUS Full-text

DN 135:318489

TI A short and efficient synthesis of novel N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-carboxamides

AU Khalaj, Ali; Pirali, Morteza; Matloubi, Hogatollah; Dowlatabadi, Reza

CS Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

SO Monatshefte fuer Chemie (2001), 132(6), 747-752

CODEN: MOCMB7; ISSN: 0026-9247

PB Springer-Verlag Wien

DT Journal

LA English

OS CASREACT 135:318489

AB Several novel N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-carboxamides were prepared by acyl coupling of 2-aminobenzophenones with  $\alpha$ -(benzotriazol-1-yl)-N-acylglycines followed by displacement of the benzotriazole ring with ammonia and cyclization of the resulting monoacyl amins. In addition to high yields and shorter reaction sequences due to avoiding deprotection and acylation of the protected 3-amino-1,4-benzodiazepin-2-one intermediates, the present approach did not involve the use of toxic and odoriferous materials as is the case with other methods.

IT 150964-48-0P 368870-46-6P 368870-47-7P


368870-49-9P 368870-50-2P

RL: SPN (Synthetic preparation); PREP (Preparation)

(synthesis of N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-carboxamides)


RN 150964-48-0 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 368870-46-6 CAPLUS

CN 2-Thiophenecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 368870-47-7 CAPLUS

CN 2-Furancarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 368870-49-9 CAPLUS

CN 2-Thiophenecarboxamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 368870-50-2 CAPLUS

CN 2-Furancarboxamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L19 ANSWER 17 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2001:321155 CAPLUS Full-text  
 DN 135:137477  
 TI 1,4-Benzodiazepine Peripheral Cholecystokinin (CCK-A) Receptor Agonists  
 AU Sherrill, R. G.; Berman, J. M.; Birkemo, L.; Croom, D. K.; Dezube, M.;  
 Ervin, G. N.; Grizzle, M. K.; James, M. K.; Johnson, M. F.; Queen, K. L.;  
 Rimele, T. J.; Vanmiddlesworth, F.; Sugg, E. E.  
 CS Department of Medicinal Chemistry, GlaxoWellcome Research and Development,  
 Research Triangle Park, NC, 27709, USA  
 SO Bioorganic & Medicinal Chemistry Letters (2001), 11(9), 1145-1148  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PB Elsevier Science Ltd.  
 DT Journal  
 LA English  
 OS CASREACT 135:137477  
 AB A series of 1,4-benzodiazepines, N-1-substituted with an N-isopropyl-N-  
 phenylacetamide moiety, was synthesized and screened for CCK-A agonist  
 activity. In vitro agonist activity on isolated guinea pig gallbladder along  
 with in vivo induction of satiety following i.p. administration in a rat  
 feeding assay was demonstrated.  
 IT 108895-98-3  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (synthesis and peripheral cholecystokinin (CCK-A) receptor agonists  
 activity of 1,4-benzodiazepine)  
 RN 108895-98-3 CAPLUS  
 CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-,  
 phenylmethyl ester (9CI) (CA INDEX NAME)



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 18 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2000:175798 CAPLUS Full-text  
 DN 132:222556  
 TI Preparation of benzodiazepine derivatives as c-Src tyrosine kinase SH2  
 ligands  
 IN Deprez, Pierre; Lesuisse, Dominique; Mandine, Eliane  
 PA Hoechst Marion Roussel, Fr.  
 SO PCT Int. Appl., 73 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA French  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000014073	A1	20000316	WO 1999-FR2124	19990907
	W: JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	FR 2782997	A1	20000310	FR 1998-11194	19980908
PRAI	FR 1998-11194	A	19980908		
OS	MARPAT 132:222556				
GI					




AB Title compds. [I; R = NHCOZR3; R1 = H, (ar)alkyl, aryl(alkyl)carbamoylmethyl, heterocyclyl(alkyl)carbamoylmethyl, etc.; R2 = H, NHRb, CO2Rb, NHCO2Rb, etc.; Rb = H, alk(en)yl, aryl(alkyl), etc.; R3 = P(O)(ORd)(ORe), OP(O)(ORd)(ORe), B(ORd)(ORe), etc.; Rb, Rd, Re = H, alk(en)yl, aryl, etc.; Z = CHR4Z1 or (CH2)nZ1; R4 = H, (acyl)amino, tetrazolyl, etc.; z1 = arylene or heterocyclylene; n = 0-2] were prepared Thus, I (R = NHCO2CH2Ph, R1 = R2 = H) was N-alkylated by BrCH2CO2Et and the saponified product amidated by 4-(H2N)C6H4OPh to give, after N-deprotection, I [R = NH2, R1 = CH2CONHC6H4(OPh)-4, R2 = H] which was amidated by HO2CCH(NHCO2CMe3)CH2C6H4[OP(O)(OCH2Ph)2]-4 to give, after O-deprotection, I [R = NHCOCH(NHCO2CMe3)CH2C6H4[OP(O)(OCH2Ph)2]-4, R1 = CH2CONHC6H4(OH)-4, R2 = H]. Data for biol. activity of I were given.

IT 108895-98-3  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of benzodiazepine derivs. as c-Src tyrosine kinase SH2 ligands)

RN 108895-98-3 CAPLUS

CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)





L19 ANSWER 19 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1999:819353 CAPLUS Full-text

DN 132:64534

TI Preparation of cyclic amino acid compounds for inhibiting  $\beta$ -amyloid peptide release and/or its synthesis

IN Thompson, Richard C.; Wilkie, Stephen; Stack, Douglas R.; Vanmeter, Eldon E.; Shi, Qing; Britton, Thomas C.; Audia, James E.; Reel, Jon K.; Mabry, Thomas E.; Dressman, Bruce A.; Cwi, Cynthia L.; Henry, Steven S.; Mcdaniel, Stacey L.; Stucky, Russell D.; Porter, Warren J.

PA Elan Pharmaceuticals, Inc., USA; Eli Lilly & Company; et al.

SO PCT Int. Appl., 714 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9967221	A1	19991229	WO 1999-US14193	19990622
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2325389	A1	19991229	CA 1999-2325389	19990622
	AU 9947101	A	20000110	AU 1999-47101	19990622
	EP 1089980	A1	20010411	EP 1999-930594	19990622
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002518483	T	20020625	JP 2000-555875	19990622
	US 2005192265	A1	20050901	US 2004-2922	20041203
PRAI	US 1998-102507	A2	19980622		
	WO 1999-US14193	W	19990622		
	US 2003-392332	A3	20030320		

OS MARPAT 132:64534

AB Cyclic compds., e.g., R1R15'NC(Q)NR15(Y)n(CH)pC(X)W [R1 = (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, or cycloalkenyl, aryl, heterocyclyl, heteroaryl; R15 = H, alkyl, substituted alkyl, aryl, heteroaryl, heterocyclyl; R15' = H, OH, alkyl, substituted alkyl, heterocyclyl, heteroaryl; W together with (CH)pC(X) forms an (un)substituted cycloalkyl or cycloalkenyl, heterocyclyl, which are optionally fused to form a bi- or multi-fused ring systems; X = oxo, thioxo, hydroxyl, thiol, or hydro (H,H); Y = CHR2CONH, where R2 = (un)substituted alkyl, alkenyl, or alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl; p = 0 or 1], were prepared for inhibition of  $\beta$ -amyloid peptide release and/or its synthesis. Thus, (S)-3-[[N-(2-thiophenecarbonyl)-L-alaninyl]amino]-2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepin-2-one was prepared via acylation of (S)-3-(L-alaninylamino)-2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepin-2-one with 2-thiophenecarboxylic acid. Compds. of the invention inhibit  $\beta$ -amyloid peptide production by at least 30% as compared to the control.


IT 108895-98-3 155452-87-2

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of cyclic amino acid compds. for inhibiting  $\beta$ -amyloid peptide release)


RN 108895-98-3 CAPLUS

CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 155452-87-2 CAPLUS

CN Carbamic acid, (7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 20 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1999:819352 CAPLUS Full-text

DN 132:64533

TI Preparation of cyclic amino acid compounds for inhibiting  $\beta$ -amyloid peptide release and/or its synthesis

IN Audia, James E.; Thompson, Richard C.; Wilkie, Stephen C.; Britton, Thomas C.; Porter, Warren J.; Huffman, George W.; Latimer, Lee H.

PA Elan Pharmaceuticals, Inc., USA; Eli Lilly & Company

SO PCT Int. Appl., 271 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9967220	A1	19991229	WO 1999-US14007	19990621
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2325388	A1	19991229	CA 1999-2325388	19990621
	AU 9952047	A	20000110	AU 1999-52047	19990621
	EP 1089981	A1	20010411	EP 1999-937164	19990621
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002518482	T	20020625	JP 2000-555874	19990621
	US 6509331	B1	20030121	US 1999-337484	19990621
	US 2003153550	A1	20030814	US 2002-267017	20021007
	US 6774125	B2	20040810		
PRAI	US 1998-102728	A2	19980622		
	US 1998-155265P	P	19980622		
	US 1999-337484	A3	19990621		
	WO 1999-US14007	W	19990621		

OS MARPAT 132:64533

AB Compds. R1(Z)mNH(Y)nW [W is a fused ring system, e.g., benzo- or dibenzoazepinones or -diazepinones; Y = CHR2CONH or (CHR2')aNH, where R2 = (un)substituted alkyl, alkenyl, or alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, R2' = H or R2; R1 = (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, or cycloalkenyl, aryl, heteroaryl, heterocyclyl, Z = -T-CX'X''CO, where T is selected from the group consisting of a bond covalently linking R1 to -CX'X''-, oxygen, sulfur and -NR6 (R6 = H, acyl, alkyl, aryl, heteroaryl), X' is H, OH, F, X'' is H, OH, F or X' and X' and X'' together form an oxo group; m = 0 or 1; n = 1 or 2] were prepared for inhibition of  $\beta$ -amyloid peptide release and/or its synthesis. Thus, 1-(L-alaninylamino)-4,5,6,7-tetrahydro-3,7-methano-3H-3-benzazonin-2(1H)-one was prepared via coupling of N-tert-butoxycarbonyl-L-alanine with 1-amino-4,5,6,7-tetrahydro-3,7-methano-3H-3-benzazonin-2(1H)-one. Compds. of the invention inhibit  $\beta$ -amyloid peptide production by at least 30% as compared to the control when employed at 10  $\mu$ g/mL.


IT 108895-98-3 155452-87-2

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of cyclic amino acid compds. for inhibiting  $\beta$ -amyloid peptide release)


RN 108895-98-3 CAPLUS

CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 155452-87-2 CAPLUS

CN Carbamic acid, (7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 21 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1999:819351 CAPLUS Full-text  
DN 132:64532

TI Preparation of cyclic amino acid compounds for inhibiting  $\beta$ -amyloid  
peptide release and/or its synthesis  
IN Audia, James E.; Porter, Warren J.; Thompson, Richard C.; Wilkie, Stephen  
C.; Stack, Douglas R.; Shi, Qing  
PA Elan Pharmaceuticals, Inc., USA; Eli Lilly & Company  
SO PCT Int. Appl., 287 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9967219	A1	19991229	WO 1999-US14096	19990622
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2324474	A1	19991229	CA 1999-2324474	19990622
	AU 9947079	A	20000110	AU 1999-47079	19990622
	EP 1089977	A1	20010411	EP 1999-930566	19990622
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002518481	T	20020625	JP 2000-555873	19990622
	US 6552013	B1	20030422	US 1999-338121	19990622
	US 2003149022	A1	20030807	US 2002-326081	20021223
	US 6838455	B2	20050104		
	US 2005192265	A1	20050901	US 2004-2922	20041203
PRAI	US 1998-102507	A2	19980622		
	US 1998-150704P	P	19980930		
	US 1998-162757	A2	19980930		
	US 1998-160067P	P	19980622		
	US 1999-338121	A3	19990622		
	WO 1999-US14096	W	19990622		
	US 2003-392332	A3	20030320		

OS MARPAT 132:64532

AB Compds. R1ZNH(Y)nW [W is a fused ring system, e.g., benzo- or dibenzoazepinones or -diazepinones; Y = CHR2CONH, where R2 = (un)substituted alkyl, alkenyl, or alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl; R1 = (un)substituted alkyl, alkenyl, cycloalkyl, or cycloalkenyl, aryl, heteroaryl, heterocyclyl; Z is represented by -T-CX'X''V- where T is selected from the group consisting of a bond covalently linking R1 to -CX'X''-, oxygen, sulfur and -NR6 (R6 = H, acyl, alkyl, aryl, heteroaryl), X' is H, OH, F, X'' is H, OH, F or X' and X'' together form an oxo group, V is alkylene or substituted alkylene or R1 and Z together form aryl or (un)substituted cycloalkyl, cycloalkenyl, or heterocyclyl; n = 1 or 2] were prepared for inhibition of  $\beta$ -amyloid peptide release and/or its synthesis. Thus, 5-(S)-[N'-[2-(3,5-difluorophenyl)ethyl]-L-alaninyl]amino-7-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one was prepared by reductive alkylation of 5-(S)-(L-alaninyl)amino-7-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one hydrochloride with 3,5-difluorophenylacetaldehyde using sodium cyanoborohydride. Compds. of the invention inhibit  $\beta$ -amyloid peptide production by at least 30% as compared to the control when employed at 10  $\mu$ g/mL.


IT 108895-98-3 155452-87-2 168162-29-6

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of cyclic amino acid compds. for inhibiting  $\beta$ -amyloid peptide release)


RN 108895-98-3 CAPLUS

CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 155452-87-2 CAPLUS

CN Carbamic acid, (7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 168162-29-6 CAPLUS

CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 22 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1999:819249 CAPLUS Full-text  
DN 132:64531

TI Preparation of cyclic amino acid compounds for inhibiting  $\beta$ -amyloid peptide release and/or its synthesis

IN Audia, James E.; Dressman, Bruce A.; Shi, Qing

PA Elan Pharmaceuticals, Inc., USA; Eli Lilly & Company

SO PCT Int. Appl., 256 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9966934	A1	19991229	WO 1999-US14211	19990622
	W:			AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW	
	RW:			GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
	CA 2324475	A1	19991229	CA 1999-2324475	19990622
	AU 9947104	A	20000110	AU 1999-47104	19990622
	EP 1093372	A1	20010425	EP 1999-930600	19990622
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI	
	JP 2002518451	T	20020625	JP 2000-555620	19990622
	US 2005192265	A1	20050901	US 2004-2922	20041203
PRAI	US 1998-102507	A2	19980622		
	US 1998-164451	A2	19980930		
	WO 1999-US14211	W	19990622		
	US 2003-392332	A3	20030320		

OS MARPAT 132:64531

AB Compds. R'R'NCHR1CONH(Y)nW and R':NC(:R1)CONH(Y)nW [W is a fused ring system, e.g., benzo- or dibenzazepinones or -diazepinones; Y = CHR2CONH, where R2 = (un)substituted alkyl, alkenyl, or alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl; R1 and R' form a nitrogen-containing heterocycle; R'' = H, alkyl, substituted alkyl, aryl; n = 1 or 2] were prepared for inhibition of  $\beta$ -amyloid peptide release and/or its synthesis. Thus, 5-(S)-[N'-(L-prolyl)-L-alaninyl]amino-7-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one was prepared via coupling of N-(N'-tert-butoxycarbonyl-L-prolyl)-L-alanine with 5-(S)-amino-7-methyl-5,7-dihydro-6H-dibenz[b,d]azepin-6-one. Compds. of the invention inhibit  $\beta$ -amyloid peptide production by at least 30% as compared to the control when employed at 10  $\mu$ g/mL.


IT 108895-98-3 155452-87-2 168162-29-6

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of cyclic amino acid compds. for inhibiting  $\beta$ -amyloid peptide release)


RN 108895-98-3 CAPLUS

CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 155452-87-2 CAPLUS

CN Carbamic acid, (7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 168162-29-6 CAPLUS

CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L19 ANSWER 23 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1998:608608 CAPLUS Full-text  
 DN 129:245485  
 TI Preparation of heterocyclic compounds and their use for inhibiting  
 $\beta$ -amyloid peptide release  
 IN Thorsett, Eugene D.; Porter, Warren J.; Nissen, Jeffrey S.; Latimer, Lee  
 H.; Audia, James E.; Droste, James J.  
 PA Athena Neurosciences, Inc., USA; Eli Lilly & Co.  
 SO PCT Int. Appl., 392 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9838177	A1	19980903	WO 1998-US3373	19980227
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	ZA 9801627	A	19991005	ZA 1998-1627	19980226
	CA 2278674	A1	19980903	CA 1998-2278674	19980227
	AU 9866622	A	19980918	AU 1998-66622	19980227
	EP 968198	A1	20000105	EP 1998-908637	19980227
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	TR 9902071	T2	20000121	TR 1999-2071	19980227
	BR 9807876	A	20000229	BR 1998-7876	19980227
	HU 200001293	A2	20000828	HU 2000-1293	19980227
	JP 2001513107	T	20010828	JP 1998-537732	19980227
	NO 9904016	A	19991018	NO 1999-4016	19990819
PRAI	US 1997-808263	A1	19970228		
	WO 1998-US3373	W	19980227		
OS	MARPAT 129:245485				
GI					



AB Disclosed are modified heterocyclic di- and tripeptide analogs which inhibit  $\beta$ -amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compns. comprising a compound which inhibits  $\beta$ -amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compns. Title


comps., e.g. I, were prepared in a multistep synthesis and inhibited  $\beta$ -amyloid peptide production by at least 30% as compared to control.

IT 155452-87-2

RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of heterocyclic comps. and their use for inhibiting  $\beta$ -amyloid peptide release)

RN 155452-87-2 CAPLUS

CN Carbamic acid, (7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RE.CNT 6      THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 24 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1998:479505 CAPLUS Full-text

DN 129:122870

TI Preparation of cycloalkyl, lactam, lactone and related compounds for inhibiting  $\beta$ -amyloid peptide release and/or its synthesis

IN Wu, Jing; Tung, Jay S.; Thorsett, Eugene D.; Pleiss, Michael A.; Nissen, Jeffrey S.; Neitz, Jeffrey; Latimer, Lee H.; John, Varghese; Freedman, Stephen; Britton, Thomas C.; Audia, James E.; Reel, Jon K.; Mabry, Thomas E.; Dressman, Bruce A.; Cwi, Cynthia L.; Droste, James J.; Henry, Steven S.; Mcdaniel, Stacey L.; Scott, William Leonard; Stucky, Russell D.; Porter, Warren J.

PA Athena Neurosciences, Inc., USA; Eli Lilly & Co.

SO PCT Int. Appl., 889 pp.

CODEN: PIXXD2


DT Patent

LA English


FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9828268	A2	19980702	WO 1997-US22986	19971222
	WO 9828268	A3	19981008		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	ZA 9711537	A	19980625	ZA 1997-11537	19971222
	CA 2272305	A1	19980702	CA 1997-2272305	19971222
	AU 9857007	A	19980717	AU 1998-57007	19971222
	AU 749658	B2	20020627		
	EP 951466	A2	19991027	EP 1997-953208	19971222
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	CN 1242007	A	20000119	CN 1997-180901	19971222
	BR 9714517	A	20000704	BR 1997-14517	19971222
	JP 2000511932	T	20000912	JP 1998-528867	19971222
	JP 3812952	B2	20060823		
	HU 200001232	A2	20001028	HU 2000-1232	19971222
	HU 200001232	A3	20010228		
	NZ 335583	A	20010330	NZ 1997-335583	19971222
	CN 1616432	A	20050518	CN 2004-10057888	19971222
	TW 568914	B	20040101	TW 1997-86119638	19971223
	IN 1997CA02433	A	20050325	IN 1997-CA2433	19971223
	MX 9905844	A	20000731	MX 1999-5844	19990621
	NO 9903098	A	19990820	NO 1999-3098	19990622
	US 2002045747	A1	20020418	US 2001-916282	20010730
	US 2002055500	A1	20020509	US 2001-916440	20010730
	US 6653303	B1	20031125	US 2003-336824	20030106
	US 6667305	B1	20031223	US 2003-336745	20030106
	US 6683075	B1	20040127	US 2003-336806	20030106
	US 2004043977	A1	20040304	US 2003-336687	20030106
	US 2004058900	A1	20040325	US 2003-336767	20030106
	US 2005203080	A1	20050915	US 2003-733877	20031212
	US 7153847	B2	20061226		
	US 2005182046	A1	20050818	US 2004-777247	20040213
	US 2005215541	A1	20050929	US 2004-951992	20040929
	US 6951854	B2	20051004		

	US 2005272666	A1	20051208	US 2004-1610	20041202
	US 2006079499	A1	20060413	US 2004-1608	20041202
PRAI	US 1996-64851P	P	19961223		
	US 1996-780025	A1	19961223		
	US 1997-996422	A3	19971222		
	WO 1997-US22986	W	19971222		
	US 2001-915263	A1	20010726		
	US 2001-915342	A3	20010727		
	US 2001-915362	A3	20010727		
	US 2001-915379	A3	20010727		
	US 2001-915480	A3	20010727		
	US 2001-915564	A3	20010727		
	US 2001-916440	A1	20010730		
	US 2003-336687	B3	20030106		
	US 2003-336767	A3	20030106		
OS	MARPAT 129:122870				
AB	Disclosed are compds. R1ZmNHYNCHpR2C(X)R3 [R1 = (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, or cycloalkenyl or aryl, heteroaryl, or heterocyclic; R2 and R3 form a cycloalkyl, cycloalkenyl, heterocyclic, substituted cycloalkyl, or substituted cycloalkenyl ring which is optionally fused; X = oxo, thioxo, hydroxyl, thiol, or hydro; Y = CHR4CONH where R4 = (un)substituted alkyl, alkenyl, or alkynyl or cycloalkyl, aryl, heteroaryl, or heterocyclic; Z is TCX'X''CO where T is a bond, O, S, NR5 (R5 = H, acyl, alkyl, aryl, or heteroaryl), X' and X'' are H, OH, or F or X'X'' = oxo; m, p = 0, 1; n = 0, 1, 2] which inhibit $\beta$ -amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Thus, 3-[[N'-(3,4-methylenedioxyphenylacetyl)-L-alaninyl]amino]-2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepin-2-one was prepared by coupling of 3-(L-alaninylamino)-2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepin-2-one with 3,4-methylenedioxyphenylacetic acid.				
IT	108895-98-3 155452-87-2 168162-29-6				
	RL: RCT (Reactant); RACT (Reactant or reagent)				
	(preparation of cycloalkyl, lactam, lactone and related compds. for inhibiting $\beta$ -amyloid peptide release and/or its synthesis)				
RN	108895-98-3 CAPLUS				
CN	Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)				




RN	155452-87-2	CAPLUS
CN	Carbamic acid, (7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)	



RN 168162-29-6 CAPLUS

CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L19 ANSWER 25 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1998:471464 CAPLUS Full-text

DN 129:109332

TI Preparation of boronophenyl analogs of phosphotyrosines for inhibiting SH2 domain interactions of peptides

IN Bachovchin, William W.

PA Tufts University, USA

SO U.S., 42 pp., Cont.-in-part of U.S. 5,580,979.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 5776902	A	19980707	US 1995-454920	19950531
	US 5580979	A	19961203	US 1994-214643	19940315
PRAI	US 1994-214643	A2	19940315		

AB Peptidomimetics having one or more amino acid residues with side chains RO(R1O)B(CH2)mC6H4(CH2)n (R, R1 = H, alkyl or together form a heterocyclic ring; m = 0-8, n = 1-3), which may have addnl. substituents in the benzene ring, were prepared for inhibiting kinases, phosphatases and SH2 domains, e.g., an interaction between a protein containing an SH2 domain and a phosphotyrosine-containing polypeptide. The synthesis of 1,3-dihydro-1-[(methoxy-L-isoleucyl)carbonylmethyl]-5-phenyl-3(R,S)-[acetyl(phosphono-L-tyrosyl)amino]-2H-1,4-benzodiazepin-2-one is described and its ability to inhibit the interaction between a peptide and an SH2 domain was determined


IT 108895-98-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of boronophenyl analogs of phosphotyrosines for inhibiting SH2 domain interactions of peptides)

RN 108895-98-3 CAPLUS

CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 26 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1998:394349 CAPLUS Full-text

DN 129:54608

TI Inhibitors of interleukin-1 $\beta$  converting enzyme

IN Golec, Julian M. C.; Lauffer, David J.; Livingston, David J.; Mullican, Michael D.; Murcko, Mark A.; Nyce, Philip L.; Robidoux, Andrea L. C.; Wannamaker, Marion W.

PA Vertex Pharmaceuticals Incorporated, USA; Golec, Julian M. C.; Lauffer, David J.; Livingston, David J.; Mullican, Michael D.; Murcko, Mark A.; Nyce, Philip L.; Robidoux, Andrea L. C.; Wannamaker, Marion W.

SO PCT Int. Appl., 135 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 9824805	A1	19980611	WO 1997-US22289	19971205
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2274249	A1	19980611	CA 1997-2274249	19971205
	AU 9858960	A	19980629	AU 1998-58960	19971205
	EP 944645	A1	19990929	EP 1997-954531	19971205
	EP 944645	B1	20050309		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2001505883	T	20010508	JP 1998-525818	19971205
	AT 290545	T	20050315	AT 1997-954531	19971205
	PT 944645	T	20050630	PT 1997-954531	19971205
	ES 2239788	T3	20051001	ES 1997-954531	19971205
	US 6329365	B1	20011211	US 1999-326495	19990604
	US 2003069228	A1	20030410	US 2001-35850	20011023
	US 6573259	B2	20030603		
	US 2004048855	A1	20040311	US 2003-424576	20030425
	US 6974809	B2	20051213		
PRAI	US 1996-32792P	P	19961206		
	US 1997-42660P	P	19970404		
	US 1997-53001P	P	19970626		
	WO 1997-US22289	W	19971205		
	US 1999-326495	A3	19990604		
	US 2001-35850	A3	20011023		
OS	MARPAT 129:54608				
GI					




AB The present invention relates to novel classes of compds. I [RC:CR is an optionally substituted aryl or heteroaryl ring; R1 = aryl, heteroaryl, alkylaryl, alkylheteroaryl; R2 = bond, CO, COCO, SO2, OCO, NHCO, NHSO2, NHCOCO, CH:CHCO, OCH2CO, NHCH2CO, etc.; R3 = aryl, heteroaryl, cycloalkyl, alkyl, dialkylamino; Y = R5CO(CH2)mCH2CH(COR6) or related lactones or semicarbazones, where R5 = OH, alkoxy, NHOH, etc.; R6 = H, HOCH2, aroyloxymethyl, etc.; m = 0 or 1] which were prepared as inhibitors of interleukin-1 $\beta$  converting enzyme. (ICE). Thus, (3S)-3-[3(R,S)-[(benzyloxycarbonyl)amino]-1,3-dihydro-2-oxo-5-phenyl-2H-1,4-benzodiazepin-1-acetylamino]-4-oxobutyric acid, prepared from 3(R,S)-[(benzyloxycarbonyl)amino]-1,3-dihydro-2-oxo-5-phenyl-2H-1,4-benzodiazepin-1-acetic acid and (3S)-3-(1-fluorenylmethoxycarbonylamino)-4-oxobutyric acid tert-Bu ester semicarbazone, showed ICE inhibition constant  $K_i$  = 650 nM and  $IC_{50}$  = 20,000 nM.

IT 108895-98-3  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (inhibitors of interleukin-1 $\beta$  converting enzyme)

RN 108895-98-3 CAPLUS

CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT



L19 ANSWER 27 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1998:378858 CAPLUS Full-text

DN 129:144548

TI Modeling of the CCK antagonist activity of benzodiazepines on gastrin receptors

AU Huche, Michel; Legendre, Jean-Jacques

CS rue Pierre et Marie Curie, 11, E.N.S.C.P., Laboratoire de Modelisation Appliquee a la Chimie, Paris, Cedex, 75231, Fr.

SO Chemometrics and Intelligent Laboratory Systems (1998), 41(1), 43-56  
CODEN: CILSEN; ISSN: 0169-7439

PB Elsevier Science B.V.

DT Journal

LA English


AB The gastrin CCK antagonist activity of 67 benzodiazepines has been studied by mol. modeling. Construction and optimization by GenMol and MOPAC has allowed us to obtain mols. of absolute min. energy. Five geometrical parameters and pharmacophores were selected for a processing by neural system. They allow a good prediction of activity of a compound belonging to this series: the correlation coeffs. are  $r=0.970$  for the calcn. and  $r=0.926$  for the prediction. A second database, limited to 23 compds., constituted by a sample of the precedent one, allowed us, by selecting four parameters to obtain a satisfactory linear and nonlinear correlation for these compds. The correlation coeffs. obtained by neural system are  $r=0.990$  for the calcn. and  $r=0.981$  for the prediction.

IT 103373-21-3 150964-48-0

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)  
(modeling of CCK antagonist activity of benzodiazepines on gastrin receptors)


RN 103373-21-3 CAPLUS

CN Benzamide, 3,4-dichloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 150964-48-0 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI)  
(CA INDEX NAME)




RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 28 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1998:249001 CAPLUS Full-text  
 DN 128:292237  
 TI Synthesis and evaluation of <sup>11</sup>C-labeled nonpeptide antagonists for  
 cholecystokinin receptors: [<sup>11</sup>C]L-365,260 and [<sup>11</sup>C]L-365,346  
 AU Haradahira, Terushi; Inoue, Osamu; Kobayashi, Kaoru; Suzuki, Kazutoshi  
 CS Natl. Inst. Radiol. Sci., Chiba, 263, Japan  
 SO Nuclear Medicine and Biology (1998), 25(3), 203-208  
 CODEN: NMBIEO; ISSN: 0969-8051  
 PB Elsevier Science Inc.  
 DT Journal  
 LA English  
 AB <sup>11</sup>C-labeled cholecystokinin (CCK) receptor antagonists, 3R(+)-N-(2,3-dihydro-  
 1-[<sup>11</sup>C]methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepine-3-yl)-N'-(3-  
 methylphenyl)urea ([<sup>11</sup>C]L-365,260) and its (S)-enantiomer ([<sup>11</sup>C]L-365,346),  
 have been synthesized and evaluated in vivo for use in CCK receptor studies  
 with positron emission tomog. (PET). Selective N-methylation of a racemic  
 precursor with [<sup>11</sup>C]iodomethane and subsequent optical resolution of the  
 racemate with HPLC afforded optically pure [<sup>11</sup>C]L-365,260 and [<sup>11</sup>C]L-365,346,  
 which are selective for CCK-B (central-type) receptors and CCK-A (peripheral-  
 type) receptors, resp. Biodistribution studies in mice showed very low brain  
 uptakes (<0.8% dose/g) of the radioactivities after i.v. injections of these  
 compds., although that of brain CCK-B receptor-selective [<sup>11</sup>C]L365,260 was 2-  
 fold that of [<sup>11</sup>C]L-365,346. In peripheral organs, uptake of the  
 radioactivity in the pancreas was the highest among the organs tested after  
 the injection of [<sup>11</sup>C]L-365,346 and was 3-fold that of [<sup>11</sup>C]L-365,260. It was  
 also observed that high uptake of [<sup>11</sup>C]L-365,346 in rat pancreas was  
 significantly inhibited by a simultaneous injection with a large dose of L-  
 365,346 (3 mg/kg). These preliminary results suggest that the nonpeptide CCK  
 antagonist [<sup>11</sup>C]L-365,346 may be useful for probing pancreatic CCK-A receptors  
 by PET. Owing to the very low brain permeability however, [<sup>11</sup>C]L-365,260 may  
 have no potential as a PET tracer for probing brain CCK-B receptors.  
 IT 206115-23-3P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (synthesis and evaluation of <sup>11</sup>C-labeled nonpeptide antagonists for  
 cholecystokinin receptors: [<sup>11</sup>C]L-365,260 and [<sup>11</sup>C]L-365,346)  
 RN 206115-23-3 CAPLUS  
 CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(3-  
 methylphenyl)- (9CI) (CA INDEX NAME)




RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 29 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1998:207520 CAPLUS Full-text  
 DN 129:12304  
 TI Modeling of the CCK antagonist activity of benzodiazepines on pancreatic receptors  
 AU Huche, Michel; Legendre, Jean Jacques  
 CS Lab. Modelisation Appliquee Chimie, Paris, F-75231, Fr.  
 SO Quantitative Structure-Activity Relationships (1997), 16(6), 435-446  
 CODEN: QSARDI; ISSN: 0931-8771  
 PB Wiley-VCH Verlag GmbH  
 DT Journal  
 LA English  
 AB The pancreatic CCK antagonist activity of 73 benzodiazepines was studied by mol. modeling. Construction and optimization by GenMol and MOPAC allowed us to obtain mols. of absolute min. energy. Seven geometrical parameters and pharmacophores were selected for a processing by neuronal system. They allow a good prediction of activity of a compound belonging to this series: the correlation coeffs. are 0.971 for the calcn. and 0.952 for the prediction. A second database, limited to 23 compds., constituted by a sample of the former one, allowed us, by selecting four parameters to obtain a satisfactory linear and not-linear correlation for these compds. The correlation coeffs. obtained by neuronal system are 0.977 for the calcn. and 0.967 for the prediction.  
 IT 116842-74-1 116842-76-3  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)  
 (modeling of the CCK antagonist activity of benzodiazepines on pancreatic receptors)  
 RN 116842-74-1 CAPLUS  
 CN 2-Pyrazinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 116842-76-3 CAPLUS  
 CN Benzenepropanamide,  $\alpha$ -amino-N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L19 ANSWER 30 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1998:55621 CAPLUS Full-text  
 DN 128:128038  
 TI Preparation of benzodiazepines as selective IKs antagonists  
 IN Lynch, Joseph J., Jr.; Salata, Joseph J.  
 PA Merck & Co., Inc., USA  
 SO PCT Int. Appl., 202 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9800405	A1	19980108	WO 1997-US11131	19970625
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2257948	A1	19980108	CA 1997-2257948	19970625
	AU 9735066	A	19980121	AU 1997-35066	19970625
	AU 722110	B2	20000720		
	EP 907644	A1	19990414	EP 1997-931437	19970625
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	JP 2000510155	T	20000808	JP 1998-504289	19970625
PRAI	US 1996-20747P	P	19960628		
	GB 1996-17894	A	19960828		
	WO 1997-US11131	W	19970625		
OS	MARPAT 128:128038				
GI					



I



II



III

AB The title compds. [I; A = thieno, pyrido, (un)substituted benzo; X = O, S, N(NH2), N(OH), H2; Y = O, N(CN), H2; Z = (un)substituted C1-6 alkylene, C2-4 alkenylene, C3-6 cycloalkylene, etc.; p = 0-2; R1 = (un)substituted Ph, C5-7 cycloalkyl, 5-10 membered heterocyclyl, etc.; R2 = (un)substituted Ph, C1-4

alkyl, C5-7 cycloalkyl, etc.; R3 = H, (un)substituted C1-6 alkyl, CF3; R4 = H, (un)substituted C1-6 alkyl, tetrazol-5-yl; R5 = H, O; R2R5 = II], useful as selective IKs antagonists, were prepared. Thus, reaction of (E)-3-phenyl-2-propenoyl chloride with 3(R)-amino-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one in the presence of Et3N in CH2Cl2 afforded 21% the title compound (E)-(+)-(3R)-III. Compds. I have an IC50 of < 100 nM as IKs blockers and are at least 10 times more potent in the blockade of IKs than of blockade of IKr. Method of preventing, treating, terminating and protecting against cardiac arrhythmias, such as atrial, supraventricular and ventricular ectopy, tachycardia, flutter or fibrillation, including atrial, supraventricular and ventricular arrhythmias resulting from myocardial ischemic injury in a patient in need thereof, comprising administration of a selective IKs antagonist and a beta-adrenergic receptor blocking agent, administered in combined therapy either simultaneously, sep. or sequentially is presented. Addnl., a pharmaceutical preparation comprising a selective IKs antagonist and a beta-adrenergic receptor blocking agent, wherein these compds. are administered simultaneously, sep. or sequentially is presented.


IT 108895-98-3

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of benzodiazepines as selective IKs antagonists)


RN 108895-98-3 CAPLUS

CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)




RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 31 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1997:41882 CAPLUS Full-text  
 DN 126:117956  
 TI (3R)-N-(1-(tert-Butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-[3-(methylamino)phenyl]urea (YF476): A Potent and Orally Active Gastrin/CCK-B Antagonist  
 AU Semple, Graeme; Ryder, Hamish; Rooker, David P.; Batt, Andrzej R.; Kendrick, David A.; Szelke, Michael; Ohta, Mitsuaki; Satoh, Masato; Nishida, Akito; Akuzawa, Shinobu; Miyata, Keiji  
 CS Ferring Research Institute, Chilworth Research Centre, Chilworth/Southampton, SO16 7NP, UK  
 SO Journal of Medicinal Chemistry (1997), 40(3), 331-341  
 CODEN: JMCMAR; ISSN: 0022-2623  
 PB American Chemical Society  
 DT Journal  
 LA English  
 GI



I

AB A number of new 1,4-benzodiazepin-2-one-based gastrin/CCK-B receptor antagonists related to the archetypal analog L-365,260, and more closely to the recently reported compound YM022, have been synthesized and evaluated for biol. activity. The compds. were screened for their ability to inhibit the binding of [<sup>125</sup>I]CCK-8 to gastrin/CCK-B receptors prepared from rat brains and that of [<sup>3</sup>H]L-364,718 to CCK-A receptors from rat pancreas, and were shown to be potent and selective ligands for the gastrin/CCK-B receptor. Functional studies in vivo demonstrated the compds. to be antagonists of the receptor as evidenced by their ability to inhibit pentagastrin-induced gastric acid secretion in anesthetized rats. More extensive evaluation in vivo included determination of ED<sub>50</sub> values in the rat acid secretion model for selected compds. and an examination of the effect of these compds. on pentagastrin-induced gastric acid secretion in Heidenhain pouch dogs following oral and i.v. administration. Two compds., namely (3R)-I (R = NHMe) (YF476) and (3R)-I (R = NMe<sub>2</sub>)·HCl, showed potent dose-dependent effects in both models with the former showing excellent oral bioavailability and an ED<sub>50</sub> of 21 nmol/kg po in dogs. YF476 is currently under clin. investigation for the treatment of gastro-esophageal reflux disease.  
 IT 108895-98-3P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (1,4-benzodiazepin-3-ylureas as gastrin/CCK-B antagonists)  
 RN 108895-98-3 CAPLUS  
 CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 32 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1996:365469 CAPLUS Full-text

DN 125:33692

TI Preparation of oxobenzodiazepinylureas as CCK and gastrin antagonists

IN Sato, Yoshinari; Sakane, Kazuo; Tabuchi, Seiichiro; Mitsui, Hitoshi; Katsumi, Ikuyo; Satoh, Yuichi

PA Fujisawa Pharmaceutical Co., Ltd., Japan; Nippon Shokubai Co., Ltd.

SO PCT Int. Appl., 302 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9604254	A2	19960215	WO 1995-JP1497	19950727
	WO 9604254	A3	19960620		
	W: CA, CN, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2196062	A1	19960215	CA 1995-2196062	19950727
	EP 804425	A2	19971105	EP 1995-926512	19950727
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
	JP 10504545	T	19980506	JP 1995-506388	19950727
	US 5763437	A	19980609	US 1997-776196	19970129
PRAI	GB 1994-15311	A	19940729		
	GB 1995-1726	A	19950130		
	WO 1995-JP1497	W	19950727		
OS	MARPAT 125:33692				
GI					



AB Title compds. [I; R = C(:Y)ZR<sub>2</sub>; R<sub>1</sub> = (un)substituted aryl, (un)substituted cycloalkyl; R<sub>2</sub> = (un)substituted aryl, (un)substituted cycloalkyl, etc.; R<sub>5</sub> = Z<sub>1</sub>R<sub>3</sub>; R<sub>3</sub> = tetrahydrofuryl, thienyl, quinolyl, XR<sub>4</sub>, etc.; R<sub>4</sub> = thiomorpholinyl, pyridyl, cyclohydrocarbyl, etc.; X = CO, CO<sub>2</sub>, CONH, etc.; Y = O or S; Z = bond, (alkyl)imino; Z<sub>1</sub> = alkylene] were prepared Thus, I (R<sub>1</sub> = C<sub>6</sub>H<sub>4</sub>F-2)(II; R = CO<sub>2</sub>CH<sub>2</sub>Ph, R<sub>5</sub> = CH<sub>2</sub>CO<sub>2</sub>H)(preparation given) was amidated by 3-azabicyclo[3.2.2]nonane and the deprotected product N-acylated by 3-MeC<sub>6</sub>H<sub>4</sub>NCO to give II [R = CONHC<sub>6</sub>H<sub>4</sub>Me-3, R<sub>5</sub> = CH<sub>2</sub>COR<sub>4</sub>, R<sub>4</sub> = 3-azabicyclo[3.2.2]nonan-3-yl] which gave 98.0% inhibition of CCK-8 binding at guinea pig cerebral cortex membrane preparation at 10<sup>-8</sup>M in vitro.


IT 168162-29-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of oxobenzodiazepinylureas as CCK and gastrin antagonists)

RN 168162-29-6 CAPLUS


CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)






L19 ANSWER 33 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1996:184016 CAPLUS Full-text  
 DN 124:233140  
 TI Preparation of 3-[2(S)-amino-3-mercaptopropionylamino]-2,3-dihydro-2-oxo-1H-1,4-benzodiazepine derivatives as inhibitors of farnesyl-protein transferase  
 IN Wai, John S.; Culberson, J. Christopher; Graham, Samuel L.  
 PA Merck and Co., Inc., USA  
 SO PCT Int. Appl., 32 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9532191	A1	19951130	WO 1995-US6286	19950516
	W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2190846	A1	19951130	CA 1995-2190846	19950516
	AU 9525176	A	19951218	AU 1995-25176	19950516
	AU 691290	B2	19980514		
	EP 760813	A1	19970312	EP 1995-919234	19950516
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	JP 10500688	T	19980120	JP 1995-530425	19950516
	US 5753650	A	19980519	US 1996-737191	19961106
PRAI	US 1994-247122	A	19940520		
	WO 1995-US6286	W	19950516		
OS	MARPAT 124:233140				
GI					



I



II

AB The title compds., 3-(L-cysteinylamino)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepine derivs. [I; R1 = H, C1-4 alkyl; R2 = H, (un)substituted C1-4 alkyl, C3-6 cycloalkyl, heterocyclyl, or aryl; R3 - R5 = H, C1-4 alkyl, halo; provided that R2 = H when R3 is other than H; R6 = C1-4 alkyl, aralkyl; X = O, H2] or pharmaceutically acceptable salts or disulfides thereof, which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras, and block the ability of Ras to transform normal cells to cancer cells, are prepared The invention is further directed to chemotherapeutic compns. containing the compds. I and methods for inhibiting farnesyl-protein transferase and treatment of cancer. Thus, alkylation of 2,3-dihydro-2-oxo-1H-1,4-benzodiazepine (II; R = R6 = H) by 4-methoxybenzyl chloride in the presence of K2CO3 in DMF at 60° overnight to II (R = 4-methoxybenzyl, R1 = H) followed by treatment with potassium bis(trimethylsilyl)amide in toluene/THF

at -78° and azidation with 2,4,6-triisopropylbenzenesulfonyl chloride at -78° gave the azide II (R = 4-methoxybenzyl, R1 = N3). Reduction of the latter azide with Ph3P in aqueous THF at room temperature overnight to the amine II (R = 4-methoxybenzyl, R1 = NH2) followed by acylation with benzyl chloroformate in the presence of 4-dimethylaminopyridine and diisopropylethylamine in CH2Cl2 at room temperature and methylation with MeI in the presence of sodium bis(trimethylsilyl)amide in THF at -78° for 1 h and at room temperature for 2 h gave II (R = 4-methoxybenzyl, R1 = NMeCO2CH2Ph). Deprotection of the latter compound with ammonium cerium(IV) nitrate in a mixture of H2O and MeCN to II (R = H, R1 = NMeCO2CH2Ph) and treatment with a mixture of 30% HBr/AcOH and CH2Cl2 at room temperature for 2 h to II.HBr (R = H, R1 = NHMe) followed by condensation with N-tert-butoxycarbonyl-S-trityl-L-cysteine in the presence of diisopropylethylamine and bis(2-oxo-3-oxazolidinyl)phosphinic chloride in CH2Cl2 at 0° overnight gave the precursor II [R = H, R1 = Boc-Cys(Tri)-NHMe; wherein Tri = trityl], which was treated with CF3CO2H in CH2Cl2 to give, after purification by HPLC using a C-18 Vydac protein-peptide column, each one of the pure diastereomers II.1.25CF3CO2H (R = H, R1 = H-Cys-NHMe). The latter faster and slower eluting diastereomer inhibited the farnesylation of RAS-CVLS by [3H]isoprenoid farnesyl pyrophosphate in the presence of farnesyl-protein transferase from bovine brain with IC50 value of 2.6 and 0.11 µM, resp.


IT 108895-98-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of (cysteinyldiamino)dihydrooxobenzodiazepine derivs. as inhibitors of farnesyl-protein transferase and anticancer agents)


RN 108895-98-3 CAPLUS

CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



L19 ANSWER 34 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1995:998140 CAPLUS Full-text  
 DN 124:176161  
 TI Preparation of 1,4-benzodiazepin-2-one-1-acetamides as cholecystokinin-A  
 receptor agonists  
 IN Aquino, Christopher Joseph; Dezube, Milana; Sugg, Elizabeth Ellen;  
 Sherrill, Ronald George; Willson, Timothy Mark; Szewczyk, Jerzy Ryszard  
 PA Glaxo Wellcome Inc., USA  
 SO PCT Int. Appl., 121 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9528399	A1	19951026	WO 1995-EP1335	19950413
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9524462	A	19951110	AU 1995-24462	19950413
	EP 755394	A1	19970129	EP 1995-918554	19950413
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 09511998	T	19971202	JP 1995-526694	19950413
	ZA 9503111	A	19960123	ZA 1995-3111	19950418
	US 5795887	A	19980818	US 1996-718552	19961011
PRAI	GB 1994-7468	A	19940415		
	GB 1994-7499	A	19940415		
	GB 1994-20699	A	19941014		
	GB 1994-20702	A	19941014		
	WO 1995-EP1335	W	19950413		
OS	MARPAT 124:176161				
GI					



AB Title compds. [I; R = (CH<sub>2</sub>)<sub>n</sub>(NH)<sub>p</sub>(CO)<sub>q</sub>(NH)<sub>r</sub>R<sub>3</sub>; R<sub>1</sub> = (cyclo)alkyl, (un)substituted Ph; R<sub>2</sub> = (cyclo)alkyl, (un)substituted Ph, alkenyl, etc.; NR<sub>1</sub>R<sub>2</sub> = tetrahydroquinolyl, substituted benzazepinyl; R<sub>3</sub> = H, = (cyclo)alkyl, (un)substituted Ph, heteroaryl, etc.; R<sub>4</sub> = H, alkyl, alkoxy, etc.; R<sub>6</sub> =

(CH<sub>2</sub>)<sub>m</sub>R<sub>5</sub>; R<sub>5</sub> = H, = (cyclo)alkyl, (un)substituted Ph, -heteroaryl, etc.; R<sub>7</sub> = H; R<sub>6</sub>R<sub>7</sub> = O; R<sub>8</sub> = H, (un)substituted alkyl, NH<sub>2</sub>, CO<sub>2</sub>H, etc.; R<sub>7</sub>R<sub>8</sub> = bond; R<sub>9</sub>,R<sub>10</sub> = H or halo; m,n = 0-3; p,q,r, = 0 or 1] were prepared. Thus, 3-benzyloxycarbonylamino-5-(3-pyridyl)-1,3-dihydrobenzo[e][1,4]diazepin-2-one was N-alkylated by BrCH<sub>2</sub>CON(CHMe<sub>2</sub>)C<sub>6</sub>H<sub>4</sub>(OMe)-4 (preparation given) and the deprotected product condensed with PhNCO to give title compound II (R<sub>4</sub> = NHCONHPh, R<sub>5</sub> = 3-pyridyl). II (R<sub>4</sub> = 1H-indazol-3-ylmethyl, R<sub>5</sub> = 2-pyridyl) (preparation not given) gave 100% inhibition of guinea pig gall bladder segment contraction at 30μM in vitro and 2.5% rat gastric emptying at 0.1mol/kg i.p.


IT 108895-98-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 1,4-benzodiazepin-2-one-1-acetamides as cholecystokin-A receptor agonists)

RN 108895-98-3 CAPLUS

CN Carbañic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



L19 ANSWER 35 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1995:995049 CAPLUS Full-text

DN 124:118002

TI Preparation of phosphotyrosine-containing peptides as inhibitors of SH2 domain interactions of protein

IN Bachovchin, William W.

PA Trustees of Tufts University, USA

SO PCT Int. Appl., 95 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9525118	A2	19950921	WO 1995-US3225	19950315
	WO 9525118	A3	19951116		
	W: CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5580979	A	19961203	US 1994-214643	19940315
PRAI	US 1994-214643	A	19940315		
OS	MARPAT 124:118002				

GI For diagram(s), see printed CA Issue.

AB The title peptidomimetics [I; X = C(X1), CHY; wherein X1 = O, S; Y = H, alkyl, hydroxyalkyl, alkoxyalkyl, CO2H, NH2, amide, nitrosyl, SH, sulfonyl, sulfonamide; ring A = 4-8 atoms-containing fused ring selected from an (un)substituted cycloalkyl, cycloalkenyl, aryl, or heterocyclyl; R1, R8 = H, halo, alkyl, alkenyl, alkynyl, CO2H, N3, (CH2)mR7, (CH2)mOH, alkoxyalkyl, alkenyloxyalkyl, (CH2)nO(CH2)mR7, (CH2)mSH, alkylthioalkyl, alkenylthioalkyl, (CH2)nS(CH2)mR7, (CH2)m NR4R5, (CH2)mCONR4R5, (CH2)m NHC(:NH)NH2, alkanoylalkyl, etc.; R2 = electron lone pair, H, alkyl, alkenyl, alkynyl, CO2H, (CH2)mR7, (CH2)mOH, alkoxyalkyl, alkenyloxyalkyl, (CH2)nO(CH2)mR7, (CH2)p SH, alkylthioalkyl, alkenylthioalkyl, (CH2)pS(CH2)mR7, (CH2)pNR4R5, (CH2)pCONR4R5, (CH2)p NHC(:NH)NH2, alkanoylalkyl, etc.; R3 = amino acid or peptide residue; wherein R4, R5 = H, alkyl, alkenyl, (CH2)mR7, alkanoyl, alkenoyl, CO(CH2)mR7; or NR4R5 = heterocyclyl containing 4-8 atoms; R7 = aryl, cycloalkyl, cycloalkenyl, heterocyclyl; m, n = 0-6; p = 1-6; R13 = H, alkyl; R14 = absent, halo, alkyl, alkoxy, alkylthio, NO2, CF3, cyano, OH; R17 = absent, amino-terminal blocking group, amino acid or peptide residue; Z = C, N; P-Tyr = phosphotyrosine or its analog] are prepared These peptidomimetics can selectively bind to a phosphotyrosine binding site of an SH2 domain and inhibit binding of protein containing said SH2 domain with a phosphotyrosine residue of a target phosphoprotein. Said SH2-containing protein is selected from Src, Lck, Fps, phosphatidylinositol-3-kinases, ras GTPase-activating protein, Fyn, Lck, Fgr, Fes, ZAP-70, Abl, etc. In particular, peptidyl diazepines inhibit intracellular signaling pathway for a oncogene, a cytokine, or a growth factor and modulate a function of said oncogene or a biol. activity of said cytokine or growth factor. Said peptidomimetics inhibit a tyrosine kinase or phosphatase. Thus, PhCH2O2CNHCH(SCHMe2)CO2H was treated with Me2CO2CCl and N-methylmorpholine in CH2Cl2 at 0° and condensed with 2-aminobenzophenone to give the benzophenone derivative (II; R = SCHMe2), which was treated with NH3 in THF in the presence of HgCl2 at 0° to give the amine II (R = NH2). The latter compound was cyclized by stirring with NH4OAc in glacial AcOH overnight to give the benzodiazepinone derivative (III; R18 = H, R19 = NHCO2CH2Ph), which was treated with NaH in DMF and alkylated by Et bromoacetate to give III (R18 = EtO2CCH2, R19 = NHCO2CH2Ph). This compound was saponified with NaOH in aqueous dioxane to the acid III (R18 = HO2CCH2, R19 = NHCO2CH2Ph), which was condensed with H-Ile-OMe using Me2CO2CCl and N-methylmorpholine in THF to give III (R18 = CH2CO-Ile-OMe, R19 = NHCO2CH2Ph). The latter compound was hydrogenolyzed in the presence of 10% Pd-C under H atmospheric in MeOH to the amine III (R18 = CH2CO-Ile-OMe, R19 = NH2), which

was condensed with Fmoc-Tyr[P(O)(OMe)<sub>2</sub>]-OH using Me<sub>2</sub>CO<sub>2</sub>CCl and N-methylmorpholine in THF to give III [R18 = CH<sub>2</sub>CO-Ile-OMe, R19 = Fmoc-Tyr[P(O)(OMe)<sub>2</sub>]-NH] and treated with bromotrimethylsilane in CH<sub>2</sub>Cl<sub>2</sub> containing isobutylene to give the title compound III [R18 = CH<sub>2</sub>CO-Ile-OMe, R19 = Fmoc-Tyr[P(O)(OH)<sub>2</sub>]-NH] (IV). In the IDEXX lck-SH2 binding assay using a glutathione-S-transferase (GST)/SH2 fusion protein, IV inhibited the binding of fluorescein isothiocyanate (FITC)-labeled peptide EPQYEEIPIYL with IC<sub>50</sub> of 48.2 μM.

IT 108895-98-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of phosphotyrosine-containing peptide mimetics as inhibitors of SH2

domain interactions of protein)

RN 108895-98-3 CAPLUS

CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



L19 ANSWER 36 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1995:886117 CAPLUS Full-text

DN 123:286105

TI Preparation of 4-(alkanoylamino)imidazo[1,2-a][1,4]benzodiazepines and analogs as Class III antiarrhythmics

IN Baldwin, John J.; Claremon, David A.; Elliott, Jason M.; Liverton, Nigel; Remy, David C.; Selnick, Harold G.

PA Merck and Co., Inc., USA

SO PCT Int. Appl., 53 pp.



CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9514694	A1	19950601	WO 1994-US13546	19941121
	W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, US, UZ				
	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2176020	A1	19950601	CA 1994-2176020	19941121
	AU 9512936	A	19950613	AU 1995-12936	19941121
	AU 686715	B2	19980212		
	EP 730596	A1	19960911	EP 1995-904124	19941121
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	JP 09500397	T	19970114	JP 1994-515224	19941121
	JP 2840454	B2	19981224		
	US 5679672	A	19971021	US 1996-646249	19960514
PRAI	US 1993-155669	A1	19931122		
	WO 1994-US13546	W	19941121		
OS	MARPAT 123:286105				
GI					



AB Title compds. [I; A = atoms to complete an (un)substituted 5- or 6-membered ring containing  $\leq 1$  addnl. N or O atoms; R1 = cycloalkyl, (un)substituted Ph; R2 = Ph, NR3R4, (cyclo)alkyl; R3,R4 = (cyclo)alkyl; Z = alkenylene, (heteroatom interrupted)alkylene] were prepared Thus, 2,3-dihydro-5-(1-methylethyl)-1H-1,4-benzodiazepin-2-one [2 step preparation from 2-(H2N)C6H3COCHMe2 and BrCH2COBr given] was N-protected and the product converted in 5 steps to 4-amino-2,3-dihydro-5-(1-methylethyl)-1H-1,4-benzodiazepin-2-thione which was amidated by 2,4-Cl2C6H3CH2CH2CO2H and the

product condensed with (S)-MeCH(NH<sub>2</sub>)CH<sub>2</sub>OH to give, after cyclization, title  
comps. (+)- and (-)-II. I have IC<sub>50</sub> of <1000nM as IKs and/or IKr blockers.  
IT 108895-98-3  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of 4-(alkanoylamino)imidazo[1,2-a][1,4]benzodiazepines and  
analogs as Class III antiarrhythmics)  
RN 108895-98-3 CAPLUS  
CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-,  
phenylmethyl ester (9CI) (CA INDEX NAME)





L19 ANSWER 37 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1995:812809 CAPLUS Full-text

DN 123:228227

TI Preparation of 1-acylmethyl-2-oxo-3-phenylureido-5-heterocyclyl-1,4-benzodiazepines useful as CCK-B and/or gastrin receptor antagonists.

IN Semple, Graeme; Ryder, Hamish; Szelke, Michael; Satoh, Masato; Ohta, Mitsuaki; Miyata, Keiji; Nishida, Akito; Ishii, Masato

PA Yamanouchi Pharmaceutical Co. Ltd., Japan; Ferring Research Ltd.

SO PCT Int. Appl., 77 pp.




CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9506040	A1	19950302	WO 1994-GB1859	19940825
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN				
	RW: KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	GB 2282595	A	19950412	GB 1993-17693	19930825
	CA 2169089	A1	19950302	CA 1994-2169089	19940825
	AU 9474661	A	19950321	AU 1994-74661	19940825
	AU 687433	B2	19980226		
	ZA 9406474	A	19960325	ZA 1994-6474	19940825
	EP 715624	A1	19960612	EP 1994-924368	19940825
	EP 715624	B1	19980408		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	CN 1129442	A	19960821	CN 1994-193134	19940825
	HU 73978	A2	19961028	HU 1996-205	19940825
	JP 09504005	T	19970422	JP 1994-507439	19940825
	AT 164840	T	19980415	AT 1994-924368	19940825
	ES 2117797	T3	19980816	ES 1994-924368	19940825
	FI 9600836	A	19960422	FI 1996-836	19960223
	NO 9600747	A	19960425	NO 1996-747	19960223
	US 5728829	A	19980317	US 1996-591567	19960502
PRAI	GB 1993-17693	A	19930825		
	WO 1994-GB1859	W	19940825		
OS	CASREACT 123:228227; MARPAT 123:228227				
GI					



II

AB Title compds. [I; R4 = alkyl, cycloalkyl, aryl; R10 = halo, OH, Me, OMe, NR11R12, NO2, NHCHO, CO2H, cyano; R11, R12 = H, alkyl; NR11R12 = Q1; a = 1-6; R2 = aromatic 5- or 6-membered (substituted) heterocyclyl containing  $\geq 2$  heteroatoms of which  $\geq 1$  is N], were prepared Thus, title compound (II), prepared from 2-aminophenyl 2-thiazolyl ketone via 3-amino-1-tert-butylcarbonylmethyl-2,3-dihydro-5-(2-thiazolyl)-1H-1,4- benzodiazepin-2-one, at 0.1  $\mu\text{mol/kg}$  in rats inhibited pentagastrin-stimulated gastric acid secretion by 55.2%. Tablets were prepared containing II.


IT 168162-29-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of benzodiazepinones useful as CCK-B and/or gastrin receptor antagonists)

RN 168162-29-6 CAPLUS


CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L19 ANSWER 38 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1995:336735 CAPLUS Full-text  
 DN 122:160619  
 TI An Improved Synthesis and Resolution of 3-Amino-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-ones  
 AU Sherrill, Ronald G.; Sugg, Elizabeth E.  
 CS Department of Medicinal Chemistry, Glaxo Research Institute, Research Triangle Park, NC, 27707, USA  
 SO Journal of Organic Chemistry (1995), 60(3), 730-4  
 CODEN: JOCEAH; ISSN: 0022-3263  
 PB American Chemical Society  
 DT Journal  
 LA English  
 OS CASREACT 122:160619  
 GI



I



II


AB A novel synthesis of (±)-3-amino-5-phenyl-1,4-benzodiazepin-2-one (6b) in 66% overall yield from 2-aminobenzophenone is described. This sequence employs α-benzotriazo-1-yl glycine as an aminoglycine synthon to prepare the key intermediate 3-benzyloxycarbonylamino-1,4-benzodiazepin-2-one (6a) in 73% overall yield. The racemic amine 6b is resolved via an improved diastereomeric derivatization employing the p-nitrophenyl carbonate of α-methylbenzyl alc. The resolution protocol was assessed through the synthesis of selective CCK antagonists, MK-329 (I) and L-365,260 (II).

IT 108895-98-3P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (synthesis and resolution of aminodihydrophenyl benzodiazepinones)

RN 108895-98-3 CAPLUS

CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



L19 ANSWER 39 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1994:621049 CAPLUS Full-text

DN 121:221049

TI Three-Dimensional Molecular Shape Analysis-Quantitative Structure-Activity Relationship of a Series of Cholecystokinin-A Receptor Antagonists

AU Tokarski, John S.; Hopfinger, Anton J.

CS College of Pharmacy, University of Illinois, Chicago, IL, 60612-7231, USA

SO Journal of Medicinal Chemistry (1994), 37(21), 3639-54

CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English


AB The three-dimensional mol. shape anal.-quant. structure-activity relationship (3D-MSA-QSAR) technique has been applied to develop correlations between the calculated physicochem. properties and the in vitro activities of a series of 3-(acylamino)-5-phenyl-2H-1,4-benzodiazepine cholecystokinin-A (CCK-A) antagonists. 3D-MSA-QSARs were developed for varying subsets of 53 analogs (J. Med. Chemical 1988, 31, 2235-2246). An active conformation is hypothesized for these compds. using the loss in biol. activity-loss in conformational stability principle. After placing all compds. in the active conformation and performing pairwise mol. shape anal., it was determined that not any one analog serves as the best shape reference compound. Nonidentical vols. of allowed receptor space are mapped out by different antagonists. A shape reference compound that consists of selected overlapped structures expands the definition of the accessible receptor space. This type of mutant improves the predicted activity of analogs over the value predicted if only one compound is chosen as the reference. Mol. shape, as represented by common overlap steric volume and nonoverlap steric volume, is the major factor contributing to the affinity of this class of compds. Intramol. conformational stability, as measured by the difference in energy of the active conformation and the global min. energy conformation, is also important. It is further concluded from the 3D-MSA-QSAR models that part of the binding pocket for the 3-amido substituent has a preference for lipophilicity. The method used in this study of fragmenting the antagonist into spheres of varying radii and measuring lipophilicity isolates the substructure with highest probability of interacting with the receptor. Two indicator variables marking the presence of an N-Me group and an o-fluoro atom on the 5'-Ph substituent of the benzodiazepine ring structure also contribute significantly to the 3D-MSA-QSAR models. The 3D-MSA-QSAR results have led to the proposal of a 3D pharmacophore model for the benzodiazepine CCK-A antagonists.

IT 103373-17-7 103373-21-3

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)  
(three-dimensional mol. shape anal.-QSAR of benzodiazepine cholecystokinin-A receptor antagonists)


RN 103373-17-7 CAPLUS

CN Benzamide, 2-chloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 103373-21-3 CAPLUS

CN Benzamide, 3,4-dichloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)



L19 ANSWER 40 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1994:605398 CAPLUS Full-text  
 DN 121:205398  
 TI Preparation of benzodiazepine analogs as antagonists of cholecystokinin and gastrin  
 IN Bock, Mark G.; Evans, Ben E.; Freidinger, Roger M.  
 PA Merck and Co., Inc., USA  
 SO U.S., 14 pp. Cont.-in-part of U.S. Ser. No. 824,764, abandoned.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 5324726	A	19940628	US 1992-968624	19921029
PRAI	US 1989-452012	B2	19891218		
	US 1990-621500	B1	19901207		
	US 1992-824764	B2	19920117		
OS	MARPAT 121:205398				
GI					




AB Title compds. I (R1 = C1-6 alkyl, alkenyl, alkynyl, HO2C-C1-4 alkylidene, NC-C1-4 alkylidene, etc.; R2 = H, alkyl, (substituted) Ph, pyridyl, heterocyclyl-CONH(CH2)2-3NH, etc.; R7 = 2-aminopyridyl, substituted Ph, (substituted) heterocyclyl, O, S, HN, alkylamino, etc.; X1 = H, O2N, F3C, NC, HO, halo, alkyl, etc.; r = 1,3), are prepared I as also claimed for treatment of gastric secretion, appetite regulation, gastrointestinal motility, pancreatic secretion, and dopaminergic function. 3(R)-amino-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one and 3-methylphenyl isocyanate were mixed in THF to give (R)-I [R1 = Me, T2 = Ph, R3 = NHCONH(3-MeC6H4)]. I showed CCK and gastrin antagonism.

IT 108895-98-3

RL: RCT (Reactant); RACT (Reactant or reagent)  
 (reaction of, in preparation of CCK and gastrin antagonists)

RN 108895-98-3 CAPLUS

CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



L19 ANSWER 41 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1994:483390 CAPLUS Full-text

DN 121:83390

TI Benzodiazepine CCK-B receptor antagonists

IN Ryder, Hamish; Semple, Graeme; Kendrick, David Alan; Szelke, Michael;  
Satoh, Masato; Ohta, Mitsuaki; Miyata, Keiji; Nishida, Akito

PA Yamanouchi Pharmaceutical Co. Ltd., Japan; Ferring Research Ltd.

SO PCT Int. Appl., 120 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9316999	A1	19930902	WO 1993-GB404	19930226
	W: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
	GB 2264492	A	19930901	GB 1992-4221	19920227
	GB 2264492	B	19960925		
	CA 2129990	A1	19930902	CA 1993-2129990	19930226
	CA 2129990	C	20060110		
	AU 9336391	A	19930913	AU 1993-36391	19930226
	AU 672390	B2	19961003		
	EP 628033	A1	19941214	EP 1993-905480	19930226
	EP 628033	B1	20030723		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	HU 67963	A2	19950529	HU 1994-2212	19930226
	HU 224012	B1	20050428		
	JP 07505121	T	19950608	JP 1993-506433	19930226
	JP 2571344	B2	19970116		
	RU 2139282	C1	19991010	RU 1994-38255	19930226
	AT 245632	T	20030815	AT 1993-905480	19930226
	NO 9403133	A	19940824	NO 1994-3133	19940824
	NO 311215	B1	20011029		
	FI 9403941	A	19941026	FI 1994-3941	19940826
	US 5688943	A	19971118	US 1994-284462	19940914
PRAI	GB 1992-4221	A	19920227		
	GB 1992-12740	A	19920616		
	WO 1993-GB404	W	19930226		

OS MARPAT 121:83390

GI



I

AB The title compds. [I; R1 = CH2CHOH(CH2)aR4, CH2CO(CH2)aR5; R4, R5 = alkyl, cycloalkyl, saturated heterocyclic groups; a = 0, 1; R2, R3 = (un)substituted aromatic carbocyclic and heterocyclic residues; W, X = halogen, H, alkyl, alkoxy], which are gastrin and/or CCK-B receptor antagonists and useful for

the prevention or treatment of diseases induced by failure of physiologic functions controlled by gastrin or central CCK-B receptors, are prepared. Thus, (3R)-3-benzoyloxycarbonylamino-1-cyclopentylcarbonylmethyl-2,3-dehydro-5-phenyl-1H-1,4-benzodiazepin-2-one was hydrogenated, reacted with S-mandelic acid and 3,5-dichlorosalicylaldehyde, the precipitate treated with NaOH solution, and condensed with m-tolyl isocyanate, producing N-[(3R)-cyclopentylcarbonylmethyl-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-N'-(3-ethylphenyl)urea (II). II demonstrated 50% inhibitory concentration for rat brain-derived CCK-B receptors of 0.07 nM and 2500 nM for CCK-A receptors.


IT 108895-98-3 155452-87-2

RL: RCT (Reactant); RACT (Reactant or reagent)

(reaction of, in preparation of benzodiazepinecholecystokinin and gastrin receptor antagonists)


RN 108895-98-3 CAPLUS

CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 155452-87-2 CAPLUS

CN Carbamic acid, (7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)





L19 ANSWER 42 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1994:270467 CAPLUS Full-text

DN 120:270467

TI (Ureido)benzodiazepinone cholecystokinin-B and gastrin receptor antagonists

IN Ryder, Hamish; Semple, Graeme; Kendrick, David A.; Szelke, Michael; Satoh, Masato; Ohta, Mitsuaki; Miyata, Keiji; Nishida, Akito

PA Yamanouchi Pharmaceutical Co. Ltd., Japan; Ferring Research Institute

SO Brit. UK Pat. Appl., 37 pp.


CODEN: BAXXDU

DT Patent


LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	GB 2264492	A	19930901	GB 1992-4221	19920227
	GB 2264492	B	19960925		
	IL 104853	A	19971120	IL 1993-104853	19930225
	CA 2129990	A1	19930902	CA 1993-2129990	19930226
	CA 2129990	C	20060110		
	WO 9316999	A1	19930902	WO 1993-GB404	19930226
	W: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
	AU 9336391	A	19930913	AU 1993-36391	19930226
	AU 672390	B2	19961003		
	ZA 9301381	A	19931215	ZA 1993-1381	19930226
	EP 628033	A1	19941214	EP 1993-905480	19930226
	EP 628033	B1	20030723		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	HU 67963	A2	19950529	HU 1994-2212	19930226
	HU 224012	B1	20050428		
	JP 07505121	T	19950608	JP 1993-506433	19930226
	JP 2571344	B2	19970116		
	RU 2139282	C1	19991010	RU 1994-38255	19930226
	AT 245632	T	20030815	AT 1993-905480	19930226
	EP 1342719	A1	20030910	EP 2003-10776	19930226
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
	PT 628033	T	20031231	PT 1993-905480	19930226
	ES 2203616	T3	20040416	ES 1993-905480	19930226
	CN 1075717	A	19930901	CN 1993-101848	19930227
	CN 1051079	B	20000405		
	TW 438783	B	20010607	TW 1993-82102213	19930324
	NO 9403133	A	19940824	NO 1994-3133	19940824
	NO 311215	B1	20011029		
	FI 9403941	A	19941026	FI 1994-3941	19940826
	US 5688943	A	19971118	US 1994-284462	19940914
	US 5962451	A	19991005	US 1997-867422	19970606
PRAI	GB 1992-4221	A	19920227		
	GB 1992-12740	A	19920616		
	EP 1993-905480	A3	19930226		
	WO 1993-GB404	W	19930226		
OS	MARPAT 120:270467				
GI					






- AB The title compds. I [R1 = CH<sub>2</sub>CHOH(CH<sub>2</sub>)<sub>a</sub>R<sub>4</sub>, CH<sub>2</sub>CO(CH<sub>2</sub>)<sub>a</sub>R<sub>5</sub>; R<sub>4</sub>, R<sub>5</sub> = alkyl, cycloalkyl, (un)substituted saturated heterocyclic groups; a = 0, 1; R<sub>2</sub>, R<sub>3</sub> = aromatic carbocyclic and heterocyclic residues], which are cholecystokin-B and gastrin receptor antagonists, useful in the treatment of diseases mediated by the central cholecystokin-B receptor, are prepared and I-containing pharmaceutical formulations presented. Thus, N-[(1-cyclopentylcarbonylmethyl)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)urea (II), prepared from cyclopentanecarboxylic acid in three steps, demonstrated 50% inhibitory concentration against rat brain-derived cholecystokin-B receptors of 0.2 nM.
- IT 108895-98-3  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (reaction of, in preparation of cholecystokin-B and gastrin receptor antagonists)
- RN 108895-98-3 CAPLUS
- CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



L19 ANSWER 43 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1994:245179 CAPLUS Full-text  
 DN 120:245179  
 TI Preparation of benzodiazepine derivatives as cholecystokinin B and gastrin  
 receptor antagonists  
 IN Satoh, Masato; Okamoto, Yoshinori; Koshio, Hiroyuki; Nishida, Akito;  
 Miyata, Keiji; Ohta, Mitsuaki; Ryder, Hamish; Kendrick, David A.; Semple,  
 Graeme; Szelke, Michael  
 PA Yamanouchi Pharmaceutical Co., Ltd., Japan; Ferring B.V.  
 SO PCT Int. Appl., 91 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9400438	A1	19940106	WO 1993-JP844	19930622
	W: AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, PT, RO, RU, SD, SK, UA, US, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9343570	A	19940124	AU 1993-43570	19930622
	AU 670597	B2	19960725		
	EP 647632	A1	19950412	EP 1993-913562	19930622
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	HU 68208	A2	19950628	HU 1994-3785	19930622
	JP 2726158	B2	19980311	JP 1993-502202	19930622
	FI 9405989	A	19941221	FI 1994-5989	19941221
	NO 9405033	A	19950224	NO 1994-5033	19941223
PRAI	JP 1992-189826	A	19920624		
	WO 1993-JP844	A	19930622		
OS	MARPAT 120:245179				
GI					




AB The title compds. I [R1 = H, alkyl, OH; R2 = Ph having one or more substituents, pyridyl, etc. (further details on substituents of said Ph are given); R3 = Ph, pyridyl; a proviso is given] were prepared I inhibit gastric juice secretion. Treatment of benzodiazepine II with 40% HBr in AcOH, followed by reaction with m-tolyl isocyanate, gave benzodiazepine III. The title compds. in vitro exhibited an IC50 of 0.16 to 2.14 mM against cholecystokinin B binding. Formulations containing I are given.


IT 108895-98-3  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (reaction of, in preparation of cholecystokinin B and gastrin receptor antagonist)

RN 108895-98-3 CAPLUS


CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



L19 ANSWER 44 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1994:217628 CAPLUS Full-text  
 DN 120:217628  
 TI Development of 1,4-benzodiazepine cholecystokinin type B antagonists  
 AU Bock, Mark G.; DiPardo, Robert M.; Evans, Ben E.; Rittle, Kenneth E.;  
 Whitter, Willie L.; Garsky, Victor M.; Gilbert, Kevin F.; Leighton, James  
 L.; Carson, Kenneth L.; et al.  
 CS Dep. Med., Merck Res. Lab., West Point, PA, 19486, USA  
 SO Journal of Medicinal Chemistry (1993), 36(26), 4276-92  
 CODEN: JMCMAR; ISSN: 0022-2623  
 DT Journal  
 LA English  
 GI



AB A series of 3-(arylsureido)-5-phenyl-1,4-benzodiazepines, nonpeptidal  
 antagonists of the peptide hormone cholecystokinin (CCK), are described.  
 Derived by reasoned modification of the CCK-A selective 3-carboxamido-1,4-  
 benzodiazepine, MK-329, the development of potent, orally effective compds. in  
 which selectivity for the CCK-B receptor subtype was achieved. The principal  
 lead structure that emerged from these studies is L-365,260 (I), a compound  
 which has been submitted for clin. evaluation. Details of the ability to  
 modulate the receptor interactions of these benzodiazepines by appropriate  
 structure modifications are discussed which imply the possibility of further  
 refining the CCK-B receptor affinity and selectivity of this class of compds.  
 IT 108895-98-3  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (reactant, in preparation of cholecystokinin type B antagonists)  
 RN 108895-98-3 CAPLUS  
 CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-,  
 phenylmethyl ester (9CI) (CA INDEX NAME)



L19 ANSWER 45 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1993:640902 CAPLUS Full-text

DN 119:240902

TI A QSAR study on some cholecystokinin antagonists

AU Gupta, S. P.; Saha, R. N.

CS Dep. Chem., Birla Inst. Technol. Sci., Pilani, 333031, India

SO QSAR Des. Bioact. Compd. (1992), 285-99. Editor(s): Kuchar, M. Publisher: Prous, Barcelona, Spain.

CODEN: 59DBAA

DT Conference

LA English

AB A series of 3-amidobenzodiazepines were screened for cholecystokinin (CCK) antagonist activity in vitro. The activities were measured in terms of IC<sub>50</sub>, the molar concentration of compound required for half-maximum inhibition of binding of [125I]-CCK-33 or [125I]-CCK-8 (+) to CCK receptors in rat pancreatic or guinea pig brain tissues, or for half-max inhibition of binding of [125I]-gastrin to guinea pig gastric glands. Efforts were made to correlate these activities by least square method with physicochem. parameters, mainly Hansch hydrophobic constant  $\pi$  and Hammett electronic constant  $\sigma$ . QSAR anal. indicates that the peripheral CCK receptor and gastrin receptor are not much different structurally and behave almost in the same manner with their ligands. The brain CCK receptor is, however, quite different from these two and those its made of interaction with its ligands also differs.


IT 103373-17-7 103373-21-3 150964-48-0D, derivs.

RL: BIOL (Biological study)

(cholecystokinin antagonist activity of, QSAR study of)


RN 103373-17-7 CAPLUS

CN Benzamide, 2-chloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 103373-21-3 CAPLUS

CN Benzamide, 3,4-dichloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 150964-48-0 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)



L19 ANSWER 46 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1993:580835 CAPLUS Full-text  
 DN 119:180835  
 TI (Phenylureido)benzodiazepinone antagonists of gastrin and/or  
 cholecystokinin  
 IN Carr, Robin Arthur Ellis; Pass, Martin; Shah, Pritom  
 PA Glaxo Group Ltd., UK  
 SO Eur. Pat. Appl., 31 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 538945	A1	19930428	EP 1992-203188	19921019
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	WO 9308175	A1	19930429	WO 1992-EP2385	19921019
	W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
	AU 9227596	A	19930521	AU 1992-27596	19921019
	CN 1074216	A	19930714	CN 1992-113397	19921023
	ZA 9208200	A	19930813	ZA 1992-8200	19921023
PRAI	GB 1991-22540	A	19911024		
	GB 1991-22551	A	19911024		
	GB 1991-22591	A	19911024		
	WO 1992-EP2385	A	19921019		
OS	MARPAT 119:180835				
GI					




AB The title compds. I [R1 = CH2CONR4R5, XYR6, Ph, C3-7 cycloalkyl, (un)substituted alkyl; R4, R5 = H, Ph, C1-4 alkyl; NR4R5 = (un)substituted 5-7-membered heterocyclic ring; X = C1-3 (un)branched alkylene; Y = CO, C(OR9)2, C(SR9)2; R9 = C1-3 alkyl or 2R9 groups together may form a C2-4 alkylene chain; R6 = C1-6 alkyl, (un)substituted Ph, C3-7 cycloalkyl, adamantyl; R2 = NR7SO2CF3, SO2NR7COR8, CONR7SO2R8; R7 = H, C1-4 alkyl; R8 = C1-4 alkyl; R3 = (un)substituted Ph; n = 0, 1], useful for treating gastrin- or cholecystokinin-moderated diseases, are prepared and pharmaceutical formulations containing I are presented. Thus, 3-amino-2,3-dihydro-N-methyl-2-oxo-N,5-diphenyl-1H-1,4-benzodiazepine-1- acetamide was coupled with 3-(1H-tetrazol-5-yl)benzenamine hydrochloride, forming 2,3-dihydro-N-methyl-2-oxo-N,5-diphenyl-3-[[[3-(1H-tetrazol-5- yl)phenyl]amino]carbonyl]amino]-1H-1,4-benzodiazepine-1-acetamide (II). II demonstrated guinea pig cholecystokinin-B antagonist activity in an isolated ileum longitudinal muscle-myenteric plexus preparation of pKb 11.6.

IT 108895-98-3  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (reaction of, in preparation of (phenylureido)benzodiazepinedione

antagonists of gastrin and/or cholecystokinin)

RN 108895-98-3 CAPLUS

CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-,  
phenylmethyl ester (9CI) (CA INDEX NAME)





L19 ANSWER 47 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1993:124569 CAPLUS Full-text

DN 118:124569

TI Preparation of triazolobenzodiazepines as CCK and gastrin antagonists

IN Freidinger, Roger M.; Evans, Ben E.; Bock, Mark G.

PA Merck and Co., Inc., USA

SO Eur. Pat. Appl., '93 pp.


CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 514125	A1	19921119	EP 1992-304253	19920512
	R: CH, DE, FR, GB, IT, LI, NL				
	US 5185331	A	19930209	US 1991-699850	19910514
	CA 2068433	A1	19921115	CA 1992-2068433	19920512
	JP 05246852	A	19930924	JP 1992-165277	19920514
PRAI	US 1991-699850	A	19910514		
OS	MARPAT 118:124569				
GI					



AB Title compds. [I; R1 = H, OH, (cyclo)alkyl, alkenyl, (substituted) Ph, etc.; R2 = H, (carboxy)alkyl, (substituted) Ph, etc.; (CH2)nR7, (CH2)nCOR7, NHCH2CH2NHR7, etc.; R7 = (hetero)aryl(vinyl), etc.; R9,R10 = H, OH, Me; R13 = H, alkyl, acyl, etc.; R9R13 or R10R13 = bond; X1 = H, NO2, CF3, halo, alkyl, etc.; n = 2-6; r = 1, 2] were prepared Thus, benzodiazepinone II (R2 = 2-FC6H4) (III; R = CO2CH2Ph, X = O) was converted in 2 steps to III (R = H, X = S) which was N-acylated by indole-2-carboxylic acid and the product converted to III (R = 2-indolylcarbonyl, X = NHNH2). The latter was cyclocondensed with HC(OMe)3 to give title compound IV (R2 = 2-FC6H4) which had IC50 of 0.0009 and 0.053  $\mu$ M against CCK binding at pancreas and brain prepns., resp., in vitro.


IT 108895-98-3

RL: RCT (Reactant); RACT (Reactant or reagent)

(reaction of, in preparation of CCK and gastrin antagonists)


RN 108895-98-3 CAPLUS

CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



L19 ANSWER 48 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1993:101997 CAPLUS Full-text  
 DN 118:101997  
 TI Preparation of N-(2-oxo-1,4-benzodiazepin-3-yl)ureas as cholecystokinin  
 and gastrin antagonists  
 IN Bock, Mark G.; Freidinger, Roger M.  
 PA Merck and Co., Inc., USA  
 SO Eur. Pat. Appl., 22 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 508797	A1	19921014	EP 1992-303192	19920409
	R: CH, DE, FR, GB, IT, LI, NL				
	US 5218115	A	19930608	US 1992-848820	19920310
	CA 2065703	A1	19921011	CA 1992-2065703	19920408
	JP 06080650	A	19940322	JP 1992-135545	19920410
PRAI	US 1991-683387	A	19910410		
	US 1991-763719	A	19910923		
	US 1992-848820	A	19920310		
OS	MARPAT 118:101997				
GI					




AB Title compds. [I; R = 2- or 4-imidazolyl, pyrrolidinocarbonyl, 5-methyl-1,2,4-triazol-2-yl; R1 = m-toluidino, 1-naphthylmethyl, 6-chloro- or methoxy-3-pyridylamino, etc.; R3 = H, 1 or 2 halo or Me; R5 = (substituted) Ph; Z = (CH2)1-3] were prepared. Thus, I (R = H, R1 = OCH2Ph, R3 = H, R5 = Ph, Z = bond) was condensed with 1-(2,4-dinitrophenyl)-4-(chloromethyl)imidazole (preparation given) and the 3-N-deprotected product condensed with 3-MeC6H4NCO to give, after deprotection, I (R = 1H-imidazol-4-yl, R1 = 3-MeC6H4NH, R3 = H, R5 = Ph, Z = CH2) which had IC50 of 0.011 and 0.0079  $\mu$ M against CCK binding at rat pancreas and guinea pig brain preps., resp., and 0.0036  $\mu$ M against gastrin binding at guinea pig gastric mucosal preparation.

IT 108895-98-3

RL: RCT (Reactant); RACT (Reactant or reagent)  
 (reaction of, in preparation of CCK and gastrin antagonists)


RN 108895-98-3 CAPLUS

CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)




L19 ANSWER 49 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1993:101996 CAPLUS Full-text  
 DN 118:101996  
 TI Preparation of N-(oxobenzodiazepinyl)ureas as CCK and gastrin antagonists  
 IN Bock, Mark G.; Freidinger, Roger M.; Dipardo, Robert M.  
 PA Merck and Co., Inc., USA  
 SO Eur. Pat. Appl., 18 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 508799	A1	19921014	EP 1992-303194	19920409
	R: CH, DE, FR, GB, IT, LI, NL				
	US 5218114	A	19930608	US 1992-848794	19920310
	CA 2065715	A1	19921011	CA 1992-2065715	19920408
	JP 06080649	A	19940322	JP 1992-135543	19920410
PRAI	US 1991-683005	A	19910410		
	US 1991-763732	A	19910923		
	US 1992-848794	A	19920310		
OS	MARPAT 118:101996				
GI					




I

AB Title compds. [I; R = 2- or 4-imidazolylmethyl, CH<sub>2</sub>CHClCH<sub>2</sub>OH, CH<sub>2</sub>CH(OH)CH<sub>2</sub>NMe<sub>2</sub>, etc.; R<sub>2</sub> = H, 1 or 2 halo or Me; R<sub>3</sub> = (substituted) Ph; R<sub>4</sub> = NHCONHC<sub>6</sub>H<sub>4</sub>Cl-4] were prepared Thus, I (R<sub>2</sub> = H, R<sub>3</sub> = Ph) (II; R = H, R<sub>4</sub> = NHCO<sub>2</sub>CH<sub>2</sub>Ph) was N-alkylated with (S)-(+)-glycidyl 3- nitrobenzenesulfonate and the deprotected product condensed with 4-ClC<sub>6</sub>H<sub>5</sub>NCO to give, after NH<sub>2</sub>OH.HCl treatment, II [R = CH<sub>2</sub>CH(OH)CH<sub>2</sub>Cl, R<sub>4</sub> = NHCONHC<sub>6</sub>H<sub>4</sub>Cl-4] which had IC<sub>50</sub> of 0.062 mM against CCK binding at guinea pig cerebral cortex preparation  
 IT 108895-98-3  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (reaction of, in preparation of CCK and gastrin antagonists)  
 RN 108895-98-3 CAPLUS  
 CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)




L19 ANSWER 50 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1992:531235 CAPLUS Full-text  
 DN 117:131235  
 TI New benzodiazepine analogs with cholecystokinin receptor antagonistic activity.  
 IN Bock, Mark G.; Evans, Ben E.; Freidinger, Roger M.  
 PA Merck and Co., Inc., USA  
 SO Eur. Pat. Appl., 24 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 490590	A1	19920617	EP 1991-311364	19911206
	R: CH, DE, FR, GB, IT, LI, NL				
	CA 2056809	A1	19920608	CA 1991-2056809	19911202
	JP 05025146	A	19930202	JP 1991-322023	19911205
PRAI	US 1990-623473	A	19901207		
	US 1991-718488	A	19910620		
OS	MARPAT 117:131235				
GI					



I




II

AB Benzodiazepinones I [R1 = carboxy-, amino-, carbamoyl-, cyano-, (un)etherified alkoxyalkyl; R2 = alkyl, (un)substituted Ph, pyridyl; R3 = acylamino; R9, R10 = H, HO, Me; R13 = alkyl, acyl, cycloalkyl; R9R10, R10R13 = bond; X1 = H, O2N, CF3, cyano, HO, alkyl, alkoxy, alkylthio, halo, carboxy, carboxyalkyl, carboxyalkoxy; X7 = O, S, H2, NH, substituted NH; n = 1, 2; p = 0, 1] and their 4-oxides were prepared Thus, urea II was prepared by condensation of (RS)-1,3-dihydro-1-methyl-3-(p- nitrophenoxycarbonyl)amino-5-phenyl-2H-1,4-benzodiazepin-2-one with 2-H2NC6H4CO2H in the presence of Et3N in DMF. II bound to cholecystokinin receptors from pancreas, brain and gastric glands with ED50's of 0.049, 0.0039, 0.009  $\mu$ M resp.

IT 108895-98-3  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (hydroxyethylation of, with oxirane)



RN 108895-98-3 CAPLUS

CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



L19 ANSWER 51 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1991:583378 CAPLUS Full-text  
 DN 115:183378  
 TI Preparation of benzodiazepin-2-ones as cholecystokinin (CKK) and gastrin antagonists  
 IN Bock, Mark G.; Evans, Ben E.; Freidinger, Roger M.  
 PA Merck and Co., Inc., USA  
 SO Eur. Pat. Appl., 22 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 434369	A1	19910626	EP 1990-313854	19901218
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
	CA 2032226	A1	19910619	CA 1990-2032226	19901213
	JP 06065215	A	19940308	JP 1990-419339	19901218
PRAI	US 1989-452012	A	19891218		
	US 1990-621500	A	19901207		
OS	MARPAT 115:183378				
GI					




AB Title compds. I; R1 = H, alkyl, alkenyl, alkynyl, carboxyalkyl, cyanoalkyl, carbamoylalkyl, aminoalkyl, etc.; R2 = H, alkyl, (substituted) Ph, pyridyl; R3 = NH(CH2)2-3NHCOR5, X3COX4X3R5, etc.; R4 = H, NO2, CF3, cyano, OH, alkyl, halo, alkylthio, alkoxy, carboxyalkyl, amino(alkyl), etc.; R5 = Q1-Q3, (substituted) Ph, etc.; X = O, S, NH, H2, alkylimino; X1 = S, O, CH2, imino; X2 = H, (modified) carboxy, carboxyalkoxy, carboxyalkyl, etc.; X3 = null, alkyl; X4 = O, imino; r = 1,2] were prepared Thus, 3-MeC6H4NCO and (3R)-amino-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one were stirred 8 h in THF at room temperature to give (R)-II. The latter inhibited 125I-CCK-33 binding to guinea pig cerebral cortex prepns. with IC50 of 0.02  $\mu$ M.


IT 108895-98-3  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (condensation of, with ethylene oxide)

RN 108895-98-3 CAPLUS


CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



L19 ANSWER 52 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1991:449647 CAPLUS Full-text  
 DN 115:49647  
 TI Synthesis of new benzodiazepine derivatives as potential cholecystokinin antagonists  
 AU Varnavas, Antonio; Rupena, Paolo; Lassiani, Lucia; Boccu, Enrico  
 CS Dip. Sci. Farm., Univ. Trieste, Trieste, 34127, Italy  
 SO Farmaco (1991), 46(2), 391-401  
 CODEN: FRMCE8; ISSN: 0014-827X  
 DT Journal  
 LA English  
 GI




AB 3(R,S)-Amino-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one derivs.  
 I [R = CH(NH<sub>2</sub>)CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>OH-4, C<sub>6</sub>H<sub>4</sub>OH-2, CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>OH-4, C<sub>6</sub>H<sub>3</sub>(OH)<sub>2</sub>-2,5, C<sub>6</sub>H<sub>2</sub>(OH)<sub>3</sub>-3,4,5, 3-hydroxy-1-naphthyl] were synthesized as potential cholecystokinin antagonists. In particular, these compds. were obtained by coupling aminobenzodiazepine II (R<sub>1</sub> = Me, R<sub>2</sub> = H) with RCO<sub>2</sub>H or DL-PhCH<sub>2</sub>O<sub>2</sub>CNHCH(CO<sub>2</sub>H)CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>OH-4. An alternative methylation procedure performed on II (R<sub>1</sub> = H, R<sub>2</sub> = PhCH<sub>2</sub>O<sub>2</sub>C) allowed the key intermediate II (R<sub>1</sub> = Me, R<sub>2</sub> = PhCH<sub>2</sub>O<sub>2</sub>C) to be obtained with a remarkable increase in yield.  
 IT 108895-98-3  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (methylation of)  
 RN 108895-98-3 CAPLUS  
 CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)





L19 ANSWER 53 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1990:459237 CAPLUS Full-text  
 DN 113:59237  
 TI Indolylcarbonylaminobenzodiazepinones as cholecystokinin antagonists  
 IN Sato, Yoshinari; Matuo, Teruaki  
 PA Fujisawa Pharmaceutical Co., Ltd., Japan  
 SO Eur. Pat. Appl., 53 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 349949	A2	19900110	EP 1989-112084	19890701
	EP 349949	A3	19910904		
	EP 349949	B1	19970108		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	US 4970207	A	19901113	US 1989-373171	19890629
	IL 90830	A	19950629	IL 1989-90830	19890630
	AT 147403	T	19970115	AT 1989-112084	19890701
	ES 2095833	T3	19970301	ES 1989-112084	19890701
	FI 8903226	A	19900108	FI 1989-3226	19890703
	FI 95699	B	19951130		
	FI 95699	C	19960311		
	AU 8937859	A	19900111	AU 1989-37859	19890705
	JP 02056481	A	19900226	JP 1989-176636	19890705
	JP 2536160	B2	19960918		
	DK 8903365	A	19900108	DK 1989-3365	19890706
	NO 8902799	A	19900108	NO 1989-2799	19890706
	NO 173014	B	19930705		
	NO 173014	C	19931013		
	HU 50331	A2	19900129	HU 1989-3435	19890706
	CN 1041941	A	19900509	CN 1989-104788	19890706
	CA 1334589	C	19950228	CA 1989-604941	19890706
	US 5382664	A	19950117	US 1993-103236	19930809
	JP 07224060	A	19950822	JP 1994-37275	19940308
PRAI	GB 1988-16207	A	19880707		
	GB 1988-20560	A	19880831		
	GB 1988-23660	A	19881007		
	US 1989-373171	A3	19890629		
	US 1990-553420	B2	19900717		
	US 1991-815041	A3	19911231		
OS	MARPAT 113:59237				
GI					



AB The title compds. [I; R1 = halo, (substituted) heterocyclyl, aryl, NHR5, SR6, OR7, CONHR8, ZR9; R2 = (substituted) aryl; R3 = H, halo; R4 = H, halo, alkoxy; R5 = H, alkanoyl, hydroxyalkyl; R6 = pyridyl, (substituted) alkyl; R7 = H, protecting group, alkyl, alkenyl, haloalkyl, aminoalkyl; R8 = CN,

carbamoylalkyl, (protected) carboxyalkyl, arylalkyl; R9 = H, alkyl; Z = CO, C:NR10; R10 = OH, alkoxy, amino, etc.; A = alkylene], were prepared as cholecystokinin (CCK) antagonists. Thus, 3RS-1,3-dihydro-3-acetoxy-5-phenyl-2H-1,4-benzodiazepinone was condensed with phthalimide and the product was condensed with 2-[(tetrahydropyran-2-yl)oxy]ethyl bromide. Hydrazinolysis of the product, condensation with indole-2-carboxylic acid, and acid hydrolysis gave 3RS-1,3-dihydro-1-(2-hydroxyethyl)-3-(2-indolylcarbonylamino)-5-phenyl-2H-1,4-benzodiazepin-2-one. The latter at 10<sup>-5</sup>M gave 91% inhibition of CCK-8-induced contraction of guinea pig fundic muscle.

IT 103343-61-9


RL: RCT (Reactant); RACT (Reactant or reagent)

(condensation of, with acetoxyethyl bromide, in preparation of cholecystikinin antagonist)

RN 103343-61-9 CAPLUS


CN Carbamic acid, [(1S)-2-[[[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L19 ANSWER 54 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1989:497296 CAPLUS Full-text  
 Correction of: 1987:67359  
 DN 111:97296  
 Correction of: 106:67359  
 TI Benzodiazepine derivatives and their pharmaceutical use  
 IN Freidinger, Roger M.; Bock, Mark G.; Evans, Ben E.  
 PA Merck and Co., Inc., USA  
 SO Eur. Pat. Appl., 290 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 167919	A2	19860115	EP 1985-107842	19850625
	EP 167919	A3	19861105		
	EP 167919	B1	19930505		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	CA 1332410	C	19941011	CA 1985-484488	19850619
	NO 8502558	A	19851227	NO 1985-2558	19850625
	NO 173651	B	19931004		
	NO 173651	C	19940112		
	AU 8544152	A	19860102	AU 1985-44152	19850625
	DK 8502872	A	19860225	DK 1985-2872	19850625
	DK 175264	B1	20040802		
	ES 544523	A1	19870416	ES 1985-544523	19850625
	AT 88998	T	19930515	AT 1985-107842	19850625
	ZA 8504764	A	19860226	ZA 1985-4764	19850626
	JP 61063666	A	19860401	JP 1985-138064	19850626
	ES 551504	A1	19870601	ES 1986-551504	19860131
	US 5004741	A	19910402	US 1988-269212	19881109
	AU 8944563	A	19900405	AU 1989-44563	19891110
	AU 640113	B2	19930819		
	AU 9211171	A	19920514	AU 1992-11171	19920221
	AU 9471615	A	19941222	AU 1994-71615	19940831
	AU 679085	B2	19970619		
PRAI	US 1984-624854	A	19840626		
	US 1985-705272	A	19850225		
	US 1985-741972	A	19850610		
	EP 1985-107842	A	19850625		
	US 1987-26420	A3	19870316		
OS	MARPAT 111:97296				
GI					




I



II


AB 1,4-Benzodiazepines I [n = 1,2; R = H, NO<sub>2</sub>, CF<sub>3</sub>, cyano, etc.; R<sub>1</sub> = alkyl, alkenyl, carboxyalkyl, aminoalkyl, etc.; Z = O, S, H<sub>2</sub>, NH, etc.; R<sub>2</sub>, R<sub>6</sub> = H, OH, Me; R<sub>3</sub> = substituted alkyl; R<sub>4</sub> = H, alkyl, acyl, etc.; R<sub>5</sub> = H, alkyl, (un)substituted Ph, etc.], which are cholecystokinin (CCK) inhibitors, were prepared 2-Amino-2'-fluorobenzophenone was treated with tryptophan acid chloride-HCl and NaOH to give benzodiazepinone (R)-II. (R)-II inhibited CCK binding in isolated rat pancreas with an IC<sub>50</sub> of 0.40 μM.

IT 103373-17-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation and reaction of)  
 RN 103373-17-7 CAPLUS  
 CN Benzamide, 2-chloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-  
 yl)- (9CI) (CA INDEX NAME)




IT 103343-61-9P 103373-17-7P 103373-21-3P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of, as cholecystokinin inhibitor)  
 RN 103343-61-9 CAPLUS  
 CN Carbamic acid, [(1S)-2-[[[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-  
 benzodiazepin-3-yl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, 1,1-dimethylethyl  
 ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 103373-17-7 CAPLUS  
 CN Benzamide, 2-chloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-  
 yl)- (9CI) (CA INDEX NAME)




RN 103373-21-3 CAPLUS  
 CN Benzamide, 3,4-dichloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-  
 3-yl)- (9CI) (CA INDEX NAME)




L19 ANSWER 55 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1989:135272 CAPLUS Full-text  
 DN 110:135272  
 TI Preparation of benzodiazepines as cholecystokinin and gastrin inhibitors  
 IN Evans, Ben E.; Freidinger, Roger M.; Bock, Mark G.  
 PA Merck and Co., Inc., USA  
 SO Eur. Pat. Appl., 254 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA English  
 FAN.CNT 2


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 284256	A1	19880928	EP 1988-302141	19880311
	EP 284256	B1	19940601		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	US 4820834	A	19890411	US 1987-26420	19870316
	IL 85668	A	19950330	IL 1988-85668	19880308
	AT 106401	T	19940615	AT 1988-302141	19880311
	ES 2052704	T3	19940716	ES 1988-302141	19880311
	AU 8813133	A	19880915	AU 1988-13133	19880315
	DK 8801395	A	19890106	DK 1988-1395	19880315
	DK 175575	B1	20041213		
	CA 1332411	C	19941011	CA 1988-561493	19880315
	JP 63238069	A	19881004	JP 1988-60643	19880316
	JP 3039783	B2	20000508		
	ZA 8801866	A	19881026	ZA 1988-1866	19880316
	US 5004741	A	19910402	US 1988-269212	19881109
	AU 9211171	A	19920514	AU 1992-11171	19920221
	AU 9471615	A	19941222	AU 1994-71615	19940831
	AU 679085	B2	19970619		
PRAI	US 1987-26420	A	19870316		
	US 1984-624854	A2	19840626		
	US 1985-705272	A2	19850225		
	US 1985-741972	A2	19850610		
	EP 1988-302141	A	19880311		
OS	CASREACT 110:135272; MARPAT 110:135272				
GI					



I



II



III

AB The title compds. [I; R1 = H, alkenyl, (un)substituted alkyl, etc.; R2 = H, alkyl, pyridyl, (un)substituted Ph, etc.; R3 = X11NR18(CH2)qR16, X11NR18COX11R7, NH(CH2)2-3NHR7, NH(CH2)2-3NHCOR7, etc.; R7 = naphthyl, (un)substituted Ph, heterocyclyl, etc.; R9, R10 = H, OH, Me; R13 = H, alkyl, acyl, O, cycloalkyl; R16 = naphthyl, 2-indolyl; R18 = H, alkyl; X1 = H, NO2, CF3, OH, alkyl, etc.; X7 = O, S, H2, etc.; X11 = bond, alkylidene (sic); p = 0, 1; q = 0-4; r = 1, 2], useful as cholecystokinin and gastrin receptor binding inhibitors, were prepared 3-Amino-1,3-dihydro- 5-phenyl-2H-1,4-benzodiazepine-2-one was stirred with L- PhCH2CH(CO2H)NHCO2CMe3 in DMF


containing EtN:C:N(CH<sub>2</sub>)<sub>3</sub>Me<sub>2</sub> and 1-hydroxybenzotriazole to give diaminobenzodiazepine II (R = CO<sub>2</sub>CMe<sub>3</sub>, R<sub>1</sub> = H) which was stirred 30 min with NaH in DMF followed by stirring 1 h with MeI to give II (R = CO<sub>2</sub>CMe<sub>3</sub>, R<sub>1</sub> = Me). The latter was stirred with HCl in EtOAc followed by flash chromatog. on silica gel to give sep., (3R)- and (3S)-II (R = H, R<sub>1</sub> = Me) the latter of which was treated successively with PhNCS and CF<sub>3</sub>CO<sub>2</sub>H to give aminobenzodiazepineone (3S)-III (R<sub>3</sub> = NH<sub>2</sub>). The latter was stirred 30 min with 2-indolecarbonyl chloride in CH<sub>2</sub>Cl<sub>2</sub> containing Et<sub>3</sub>N to give (3S)-III [R<sub>3</sub> = (2-indolylcarbonyl)amino] which had IC<sub>50</sub> of 0.0008 and 0.17 μM for cholecystikinin and gastrin binding in vitro, resp.

IT 103373-17-7P 103373-21-3P 119506-69-3P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, as cholecystikinin and/or gastrin inhibitor)


RN 103373-17-7 CAPLUS

CN Benzamide, 2-chloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 103373-21-3 CAPLUS

CN Benzamide, 3,4-dichloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 119506-69-3 CAPLUS


CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



L19 ANSWER 56 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1988:604385 CAPLUS Full-text  
 DN 109:204385  
 TI Methods for drug discovery: development of potent, selective, orally  
 effective cholecystokinin antagonists  
 AU Evans, B. E.; Rittle, K. E.; Bock, M. G.; DiPardo, R. M.; Freidinger, R.  
 M.; Whitter, W. L.; Lundell, G. F.; Veber, D. F.; Anderson, P. S.; et al.  
 CS Merck Sharp and Dohme Res. Lab., West Point, PA, 19486, USA  
 SO Journal of Medicinal Chemistry (1988), 31(12), 2235-46  
 CODEN: JMCMAR; ISSN: 0022-2623  
 DT Journal  
 LA English  
 OS CASREACT 109:204385  
 GI




AB 3-(Acylamino)-5-phenyl-2H-1,4-benzodiazepines (I, X = H or F; R1 = H, Me, CH2CO2Et, CH2CO2H; R2 = acylamino, indolylalkyl, heterocyclic containing groups, substituted benzoyl, etc.), antagonists of the peptide hormone cholecystokinin (CCK), are described. Developed by reasoned modification of the known anxiolytic benzodiazepines, these compds. provide highly potent, orally effective ligands selective for peripheral (CCK-A) receptors, with binding affinities approaching or equaling that of the natural ligand CCK-8. The distinction between CCK-A receptors on the one hand and CNS (CCK-B), gastrin, and central benzodiazepine receptors on the other is demonstrated by using the structure-activity profiles of the new compds. Details of the binding of these agents to CCK-A receptors are examined, and the method of development of these compds. is discussed in terms of its relevance to the general problem of drug discovery.  
 IT 103373-17-7P 103373-21-3P 116842-74-1P  
 116842-76-3P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation and receptor binding affinities of, as cholecystokinin antagonist)  
 RN 103373-17-7 CAPLUS  
 CN Benzamide, 2-chloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 103373-21-3 CAPLUS

CN Benzamide, 3,4-dichloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)



RN 116842-74-1 CAPLUS


CN 2-Pyrazinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)



RN 116842-76-3 CAPLUS


CN Benzenepropanamide,  $\alpha$ -amino-N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.







L19 ANSWER 57 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1988:521980 CAPLUS Full-text  
 DN 109:121980  
 TI Design of novel antagonists of cholecystokinin  
 AU Freidinger, R. M.; Bock, M. G.; Chang, R. S. L.; DiPardo, R. M.; Evans, B. E.; Garsky, V. M.; Lotti, V. J.; Rittle, K. E.; Veber, D. F.; Whitter, W. L.  
 CS Merck Sharp and Dohme Res. Lab., West Point, PA, 19486, USA  
 SO Special Publication - Royal Society of Chemistry (1988), 65(Top. Med. Chem.), 10-21  
 CODEN: SROCDO; ISSN: 0260-6291  
 DT Journal  
 LA English  
 AB Expts. measuring the receptor affinity of various compds., including benzodiazepine analogs, proglumide analogs, and cyclic hexapeptide cholecystokinin analogs, are described. Structure-activity relations of the compds. as cholecystokinin antagonists are discussed. Such compds. may be useful as drugs or as tools for studying the role of cholecystokinin in normal and pathol. processes.  
 IT 70890-53-8 103373-21-3  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
 (cholecystokinin antagonist activity of, structure in relation to)  
 RN 70890-53-8 CAPLUS  
 CN Acetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI)  
 (CA INDEX NAME)




RN 103373-21-3 CAPLUS  
 CN Benzamide, 3,4-dichloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




L19 ANSWER 58 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1988:94518 CAPLUS Full-text  
 DN 108:94518  
 TI Cholecystokinin antagonists. Synthesis and biological evaluation of  
 4-substituted 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepines  
 AU Bock, Mark G.; DiPardo, Robert M.; Evans, Ben E.; Rittle, Kenneth E.;  
 Veber, Daniel F.; Freidinger, Roger M.; Chang, Raymond S. L.; Lotti,  
 Victor J.  
 CS Dep. Med. Chem., Merck Sharp and Dohme Res. Lab., West Point, PA, 19486,  
 USA  
 SO Journal of Medicinal Chemistry (1988), 31(1), 176-81  
 CODEN: JMCMAR; ISSN: 0022-2623  
 DT Journal  
 LA English  
 OS CASREACT 108:94518  
 GI



I




II




III


AB 4-Substituted 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepines I-III (R = H, Me)  
 were prepared by standard methodol. These compds. were tested in vitro as  
 antagonists of the binding of [125I]cholecystokinin (IV) to rat pancreas and  
 guinea pig brain receptors and of the binding of [125I]gastrin to guinea pig  
 gastric glands. All compds. proved to have greater affinity for the  
 peripheral IV receptor with some analogs having IC50's in the subnanomolar  
 range. In vivo activity of selected compds. in mice is presented and the  
 structure/activity profile of this class of benzodiazepines as IV antagonists  
 is discussed.  
 IT 108895-98-3  
 RL: RCT (Reactant); RACT (Reactant or reagent) (thiolation of, with Lawessons  
 reagent)  
 RN 108895-98-3 CAPLUS  
 CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-,  
 phenylmethyl ester (9CI) (CA INDEX NAME)




L19 ANSWER 59 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1987:598272 CAPLUS Full-text  
 DN 107:198272  
 TI An expedient synthesis of 3-amino-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one  
 AU Bock, Mark G.; DiPardo, Robert M.; Evans, Ben E.; Rittle, Kenneth E.; Veber, Daniel F.; Freidinger, Roger M.  
 CS Merck Sharp Dohme Res. Lab., West Point, PA, 19486, USA  
 SO Tetrahedron Letters (1987), 28(9), 939-42  
 CODEN: TELEAY; ISSN: 0040-4039  
 DT Journal  
 LA English  
 OS CASREACT 107:198272  
 GI



AB Racemic title compound I was prepared in 4 steps from 2-H<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>COPh, which was converted to 2-PhCOC<sub>6</sub>H<sub>4</sub>NHCOCH<sub>2</sub>RNHCO<sub>2</sub>CH<sub>2</sub>Ph (II; R = SCHMe<sub>2</sub>) (III), followed by the novel Hg<sup>+2</sup> ion assisted displacement of the alkylthio group of III by NH<sub>3</sub> to give II (R = NH<sub>2</sub>), cyclization, and catalytic hydrogenation, to give I in 55-60% overall yield.  
 IT 108895-98-3P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation and catalytic hydrogenation of, aminobenzodiazepinone from)  
 RN 108895-98-3 CAPLUS  
 CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)




L19 ANSWER 60 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1987:576005 CAPLUS Full-text  
 DN 107:176005  
 TI A new amine resolution method and its application to 3-aminobenzodiazepines  
 AU Rittle, Kenneth E.; Evans, Ben E.; Bock, Mark G.; DiPardo, Robert M.; Whitter, Willie L.; Homnick, Carl F.; Veber, Daniel F.; Freidinger, Robert M.  
 CS Res. Lab., Merck Sharp and Dohme, West Point, PA, 19486, USA  
 SO Tetrahedron Letters (1987), 28(5), 521-2  
 CODEN: TELEAY; ISSN: 0040-4039  
 DT Journal  
 LA English  
 OS CASREACT 107:176005  
 GI




AB A new method for the resolution of amines was applied to 3-aminobenzodiazepine I (R = H). The method involves the synthesis and separation of a pair of phenylalanylamide diastereomers followed by removal of phenylalanine via the Edman degradation to give the individual enantiomers of I (R = Me) with high chiral purities.  
 IT 103343-61-9P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and N-methylation of)  
 RN 103343-61-9 CAPLUS  
 CN Carbamic acid, [(1S)-2-[[[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L19 ANSWER 61 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1987:515571 CAPLUS Full-text  
 DN 107:115571  
 TI Synthesis and resolution of 3-amino-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-ones  
 AU Bock, Mark G.; DiPardo, Robert M.; Evans, Ben E.; Rittle, Kenneth E.; Veber, Daniel F.; Freidinger, Roger M.; Hirshfield, Jordan; Springer, James P.  
 CS Merck Sharp and Dohme Res. Lab., West Point, PA, 19486, USA  
 SO Journal of Organic Chemistry (1987), 52(15), 3232-9  
 CODEN: JOCEAH; ISSN: 0022-3263  
 DT Journal  
 LA English  
 OS CASREACT 107:115571  
 GI




AB Two efficient synthetic routes to the 3-amino-1,4-benzodiazepin-2-ones I (R = H, Me) were developed. The first sequence was carried out in 55-60% overall yield and involved a novel Hg<sup>2+</sup> assisted NH<sub>3</sub> displacement of the (alkylthio)glycineamide, 2-PhCOC<sub>6</sub>H<sub>4</sub>NHCOCH(NHCO<sub>2</sub>CH<sub>2</sub>Ph)R<sub>1</sub> [II; R<sub>1</sub> = SCHMe<sub>2</sub>], to produce the key intermediate α-aminoglycinamide II (R<sub>1</sub> = NH<sub>2</sub>). The second approach features a practical two-step amination of the parent 1,4-benzodiazepine ring system to afford the title compound I (R = Me) in 49% overall yield from 2-aminobenzophenone. I (R = Me) was resolved via the separation of the corresponding diasteriomic phenylalaninamides. The desired (-)-I (R = Me) was then liberated by use of the Edman degradation  
 IT 108895-98-3P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and deprotection of)  
 RN 108895-98-3 CAPLUS  
 CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)




L19 ANSWER 62 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1987:84662 CAPLUS Full-text  
 DN 106:84662  
 TI 3-(Acylamino)benzodiazepines as cholecystokinin inhibitors  
 IN Bock, Mark G.; Veber, Daniel F.; DiPardo, Robert M.  
 PA Merck and Co., Inc., USA  
 SO U.S., 6 pp.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 4628084	A	19861209	US 1986-815620	19860102
PRAI	US 1986-815620		19860102		
OS	MARPAT 106:84662				
GI					



I



II


AB The title compds. [I; R1 = H, C1-6 alkyl, CH2CO2H, alkoxy-carbonylmethyl; R2 = C1-6 alkyl, aralkyl, alkoxy, aralkoxy, (substituted) aryl, indolyl; R3, R4 = H, halo] were prepared as cholecystokinin inhibitors (no data). Thus, Me2CHSCH(CO2H)NHCO2CH2Ph was condensed with 2-H2NC6H4COPh to give glycine derivative II. II was desulfurized and aminated with HgCl2-NH3 and the product cyclized to afford I (R1 = H, R2 = OCH2Ph, R3 = R4 = H).

IT 108895-98-3P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of, as cholecystokinin inhibitor)

RN 108895-98-3 CAPLUS


CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)




L19 ANSWER 63 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1987:67359 CAPLUS Full-text  
 DN 106:67359  
 TI Benzodiazepine derivatives and their pharmaceutical use  
 IN Freidinger, Roger M.; Bock, Mark G.; Evans, Ben E.  
 PA Merck and Co., Inc. , USA  
 SO Eur. Pat. Appl., 290 pp.  
 CODEN: EPXXDW

DT Patent  
 LA English

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 167919 A2		19860115	EP 1985-107842	19850625
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
PRAI	US 1984-624854	19840626			
	US 1985-705272	19850225			
	US 1985-741972	19850610			
GI					



I



II


AB 1,4-Benzodiazepines I [n = 1,2; R = H, NO<sub>2</sub>, CF<sub>3</sub>, cyano, etc.; R<sub>1</sub> = alkyl, alkenyl, carboxyalkyl, aminoalkyl, etc.; Z = O, S, H<sub>2</sub>, NH, etc.; R<sub>2</sub> and R<sub>6</sub> are H, OH, Me; R<sub>3</sub> = substituted alkyl; R<sub>4</sub> = H, alkyl, acyl, etc.; R<sub>5</sub> = H, alkyl, (un)substituted Ph, etc.], which inhibited cholecystokinin, were prepared 2-Aminophenyl 2-fluorophenyl ketone was teated with tryptophan and chloride hydrochloride and NaOH to give benzodiazepinone derivative II.

IT 103343-61-9P 103373-17-7P 103373-21-3P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of, as cholecystokinin inhibitor)

RN 103343-61-9 CAPLUS


CN Carbamic acid, [(1S)-2-[[[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 103373-17-7 CAPLUS

CN Benzamide, 2-chloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)



RN 103373-21-3 CAPLUS

CN Benzamide, 3,4-dichloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




IT 103373-17-7

RL: RCT (Reactant); RACT (Reactant or reagent)  
(reaction of)


RN 103373-17-7 CAPLUS

CN Benzamide, 2-chloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)







L19 ANSWER 64 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1980:51712 CAPLUS Full-text  
 DN 92:51712  
 TI Search for anticonvulsives among compounds metabolized to  
 1,4-benzodiazepines in the body of animals  
 AU Golovenko, N. Ya.; Karaseva, T. L.; Zhilina, Z. I.  
 CS Odess. Univ., Odessa, USSR  
 SO Khimiko-Farmatsevticheskii Zhurnal (1979), 13(8), 62-8  
 CODEN: KHFZAN; ISSN: 0023-1134  
 DT Journal  
 LA Russian  
 GI



AB The anticonvulsant ED50 doses of the 10 benzophenone derivs. I (R = Br, Cl, NO<sub>2</sub>; R<sub>1</sub> = O, NOH, etc.; R<sub>2</sub> = H, COMe, COCCl<sub>3</sub>, COCH<sub>2</sub>Cl, COCH<sub>2</sub>NHCOCH<sub>3</sub>, etc.) prepared and tested in mice ranged from 1.5 mg/kg for I (R = Br; R<sub>1</sub> = NOH; R<sub>2</sub> = COCH<sub>2</sub>Cl) to 225 mg/kg for I (R = Br; R<sub>1</sub> = O; R<sub>2</sub> = COMe). Structure-activity relations are discussed.  
 IT 4173-63-1  
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process) (metabolism of)  
 RN 4173-63-1 CAPLUS  
 CN Acetamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (8CI, 9CI) (CA INDEX NAME)




L19 ANSWER 65 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1979:557698 CAPLUS Full-text  
 DN 91:157698  
 TI 1,4-Benzodiazepines and their cyclic homologs and analogs. 30. Synthesis and properties of 3- and 7-amino-5-phenyl-1,2-dihydro-3H-1,4-benzodiazepin-2-ones  
 AU Zhilina, Z. I.; Bogatskii, A. V.; Andronati, S. A.; Danilina, N. I.  
 CS Fiz.-Khim. Inst., Odessa, 270080, USSR  
 SO Khimiya Geterotsiklicheskikh Soedinenii (1979), (4), 545-9  
 CODEN: KGSSAQ; ISSN: 0453-8234  
 DT Journal  
 LA Russian  
 OS CASREACT 91:157698  
 GI




AB The 3-aminobenzodiazepinones I (R = NH<sub>2</sub>; R<sub>1</sub> = H, Me, Br, Cl) (II) were prepared from 2,4-(Bz)R<sub>1</sub>C<sub>6</sub>H<sub>3</sub>NHCOCH<sub>2</sub>Cl by iodination to give 2,4-(Bz)R<sub>1</sub>C<sub>6</sub>H<sub>3</sub>NHCOCH<sub>2</sub>I, which underwent hydroxyamination to give 2,4-(Bz)R<sub>1</sub>C<sub>6</sub>H<sub>3</sub>NHCOCH<sub>2</sub>NHOH; treatment of the latter with Ac<sub>2</sub>O and then cyclocondensation in EtOH containing NH<sub>3</sub> and hydrolysis gave II. 7-Aminobenzodiazepinone I (R = H; R<sub>1</sub> = NH<sub>2</sub>) (III) was prepared by reduction of I (R<sub>1</sub> = NO<sub>2</sub>). II and III formed Schiff bases on condensation with benzaldehydes in aprotic solvents containing acid catalysts, e.g. ZnCl<sub>2</sub>. Treatment of I (R = AcNH; R<sub>1</sub> = Cl) with P<sub>2</sub>S<sub>5</sub> gave I [R = MeC(S)NH; R<sub>1</sub> = Cl], and diazotization-hydrolysis of I (R = NH<sub>2</sub>; R<sub>1</sub> = Br) gave I (R = HO). Polarog. reduction curves of the Schiff bases of II were determined

IT 4173-63-1P 70890-53-8P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and deacetylation of)  
 RN 4173-63-1 CAPLUS  
 CN Acetamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (8CI, 9CI) (CA INDEX NAME)



RN 70890-53-8 CAPLUS  
 CN Acetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)



L19 ANSWER 66 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1976:44185 CAPLUS Full-text

DN 84:44185

TI Intermediates for the preparation of 1,3-dihydro-2H-1,4-benzodiazepin-2-ones

IN McCaully, Ronald J.

PA American Home Products Corp., USA

SO U.S., 11 pp. Division of U.S. 3,763,171.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 3899527	A	19750812	US 1973-332861	19730215
PRAI	US 1969-802345	A3	19690206		

GI For diagram(s), see printed CA Issue.


AB The benzodiazepine I was prepared by cyclization of 4,2-Cl(PhCO)C6H3NHCOCH(NH2)NHCOMe, which was prepared by chlorination of 4,2-Cl(PhCO)C6H3NHCOCH(OH)NHCOMe (II) followed by amination. II was prepared from (HO)2CHCO2H and Ac2O followed by chlorination and reaction with 2,5-H2NC1C6H3COPh, or from diacetyl-d-tartaric anhydride and 2,5-H2NC1C6H3COPh.

IT 4173-63-1P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 4173-63-1 CAPLUS

CN Acetamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (8CI, 9CI) (CA INDEX NAME)



L19 ANSWER 67 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1976:4664 CAPLUS Full-text

DN 84:4664

TI Intermediates for the preparation of 1,3-dihydro-2H-1,4-benzodiazepin-2-ones

IN McCaully, Ronald J.

PA American Home Products Corp., USA

SO U.S., 11 pp. Division of U.S. 3,763,171.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 3896170	A	19750722	US 1973-332983	19730215
PRAI	US 1969-802345	A3	19690206		

GI For diagram(s), see printed CA Issue.


AB Acetamidophenyl aryl ketones I and II, used as intermediates in the synthesis of psycholeptic 1,3-dihydro-2H-1,4-benzodiazepin-2-ones III, were prepared. Thus, ketones IV and the propionyloxy analog of IV (R = H) were prepared from (HO)2CHCO2H and 4,2-Cl(H2N)C6H3COC6H4R-2 (IVa), IV or the propionyloxy analog ammonolyzed to give V (R1 = OH), and conversion to I and II via V (R1 = Cl). I was cyclized to III (R = H) by refluxing in MeOH containing a little HOAc. By a 2nd route, diacetyl-d-tartaric anhydride was treated with IVa (R = H) to give 2,4-BzClC6H3 NHCCH(OAc)CH(OAc)CO2H which was selectively hydrolyzed to the glycol and the product selectively oxidized (periodic acid) to give 2,4-BzClC6H3NHCCH(OH)2 which was treated with AcNH2 to give V (R1 = OH).

IT 4173-63-1P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 4173-63-1 CAPLUS

CN Acetamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (8CI, 9CI) (CA INDEX NAME)



L19 ANSWER 68 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1972:501297 CAPLUS Full-text

DN 77:101297

TI Acylaminoacetamidophenyl aryl ketone derivatives

IN McCaully, Ronald J.

PA American Home Products Corp.

SO Brit., 13 pp.

CODEN: BRXXAA

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	GB 1280231		19720705	GB 1969-34376	19690708
	US 3763171		19731002	US	19690226
	US 3850979		19741126	US 1973-332975	19730215
	US 3883591		19750513	US 1973-332862	19730215
PRAI	US 1969-802345		19690226		

GI For diagram(s), see printed CA Issue.


AB The oxazepam intermediate 3-acetamido-7-chloro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one (I) was prepared from (HO)2CHCO2H via II (R = R1 = AcO, R2 = R3 = H) or from RR1CHCOCl (III, R = R1 = AcO) and 5,2-Cl(H2N)C6H3Bz. Treatment of II (R = R1 = AcO, R2 = R3 = H) with NH3-MeOH gave 79% II (R = AcNH, R1 = OH, R2 = R3 = H) which was cyclized to I after chlorination and amination. I (R = AcO, EtCO2, AcNH, EtCONH; R1 = AcO, EtCO2, HCO2, OH, Cl, NH2; R2 = H, Cl; R3 = H, Me) and III (R = R1 = EtCO2) were also prepared Alternately saponification of II (R = R1 = AcO, R2 = R3 = H) gave II (R = R1 = OH, R2 = R3) which (4.037 g), treated with 0.591 g AcNH2 gave 2.72 g II (R = AcNH, R1 = OH, R2 = R3 = H). Diacetyl-D-tartaric anhydride treated with 5,2-Cl(H2N)C6H3Bz gave 85% 2,4-BzClC6H3NHCOCH(OAc)CH(OAc)CO2H which was deacetylated (69%) and oxidized with HIO4 to II (R = R1 = OH, R2 = R3 = H).

IT 4173-63-1P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 4173-63-1 CAPLUS

CN Acetamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (8CI, 9CI) (CA INDEX NAME)



L19 ANSWER 69 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1968:496265 CAPLUS Full-text

DN 69:96265

TI 2-(2-Amino-2-acetamido) acetamidobenzophenones

IN Bell, Stanley C.; Childress, Scott J.

PA American Home Products Corp.

SO U.S., 4 pp. Division of U.S. 3344136

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 3395181	A	19680730	US 1967-621034	19670306
PRAI	US 1967-621034	A	19670306		


AB The disclosure is the same but the claims are different.

IT 4173-63-1P


RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and antispasmodic activity of)

RN 4173-63-1 CAPLUS

CN Acetamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (8CI, 9CI) (CA INDEX NAME)



L19 ANSWER 70 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1968:436091 CAPLUS Full-text  
DN 69:36091  
TI 3-Substituted 1,4-benzodiazepin-2-ones  
AU Bell, Stanley C.; McCaully, Ronald J.; Gochman, Carl; Childress, Scott J.;  
Gluckman, Melvyn I.  
CS Res. Div., Wyeth Lab., Inc., Radnor, PA, USA  
SO Journal of Medicinal Chemistry (1968), 11(3), 457-61  
CODEN: JMCMAR; ISSN: 0022-2623  
DT Journal  
LA English  
AB The preparation of a number of 1,4-benzodiazepines substituted in the 3  
position is described. The rearrangement of 7-chloro-1,3-dihydro-5-phenyl-2H-  
1,4- benzodiazepin-2-one 4-oxide with diacetyl sulfide yields largely the 3-  
acetylthio compound Amines, ethers, and sulfides were prepared through the  
chloro intermediate. A 3-carbethoxybenzodiazepine was prepared and converted  
into oxazepam. The pharmacol. test data of new and previously published  
compsds. are given.  
IT 4173-63-1P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 4173-63-1 CAPLUS  
CN Acetamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-  
yl)- (8CI, 9CI) (CA INDEX NAME)



L19 ANSWER 71 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1968:78320 CAPLUS Full-text  
 DN 68:78320  
 TI 3-Acetamido-1,-3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-ones  
 IN Bell, Stanley Charles; Childress, Scott J.  
 PA American Home Products Corp.  
 SO U.S., 4 pp.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 3344136		19670926	US 1964-414583	19631203

GI For diagram(s), see printed CA Issue.


AB The title compds. (I) were prepared and used as anticonvulsants, sedatives, and muscle relaxants. Thus, 1 g. 4,2-ClBzC<sub>6</sub>H<sub>3</sub>NHCOCH(NH<sub>2</sub>)NHAc was added to 100 ml. EtOH saturated with NH<sub>3</sub>. The mixture was left 12-15 hrs. and concentrated in vacuo, the resultant residue was dissolved in C<sub>6</sub>H<sub>6</sub>, cooled, and left 3 days at 10° to give I (R = Ac) (Ia), m. 272-3°. Ia (1 g.) was dissolved in MeOH containing excess HCl, left 18 hrs., diluted with H<sub>2</sub>O, and made alkaline with NH<sub>4</sub>OH to give I (R = H), m. 202-3° (EtOH).

IT 4173-63-1P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)


RN 4173-63-1 CAPLUS

CN Acetamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (8CI, 9CI) (CA INDEX NAME)





L19 ANSWER 72 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1968:39214 CAPLUS Full-text  
 DN 68:39214  
 TI General method for preparing 2-acetamidoacetanilides having a second functional group in the 2 position and affording an access to 3-acetamido-1,3-dihydro-2H-1,4-benzodiazepin-2-ones  
 AU Bell, Stanley Charles; McCaully, Ronald J.; Childress, Scott J.  
 CS Wyeth Labs., Inc., Radnor, PA, USA  
 SO Journal of Organic Chemistry (1968), 33(1), 216-20  
 CODEN: JOCEAH; ISSN: 0022-3263  
 DT Journal  
 LA English  
 OS CASREACT 68:39214  
 AB Base-catalyzed elimination of HOAc from 2-(N-acetoxyacetamido)acetanilides to afford the reactive and unisolated 2-(acetylimino)acetanilides is described. Available nucleophiles add to the unsatd. imine bond to give 2-substituted 2-acetamidoacetanilides. Special cases are discussed, including a reaction of NH3 with an O-benzoyl-2-(N-acetoxyacetamido)- acetanilide that leads ultimately to a 3-acetamido-1,4-benzodiazepine. 9 references.  
 IT 4173-63-1P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 4173-63-1 CAPLUS  
 CN Acetamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (8CI, 9CI) (CA INDEX NAME)



L19 ANSWER 73 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1966:11573 CAPLUS Full-text

DN 64:11573

OREF 64:2115e-h,2116a

TI Diazepine derivatives for medical use

IN Archer, Giles A.; Fryer, Rodney I.; Reeder, Earl; Sternbach, Leo H.

PA F. Hoffmann-LaRoche & Co., A.-G.

SO 20 pp.

DT Patent

LA Unavailable

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	BE 659443		19650809	BE	
	NL 6501632			NL	
PRAI	US		19640211		

GI For diagram(s), see printed CA Issue.

AB New antispasmodic, analgetic, sedative, hypotensive, antidepressive, and muscle relaxing medicaments are salts of 5-phenyl-3H-1,4-benzodiazepin-2(1H)-ones (I). To a stirred solution of 34 millimoles of the Na derivative of 7-chloro-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2(1H)-one in 50 ml. dimethylformamide, 7.11 g. 1-bromo-3-chloropropane is added slowly at 0°. The mixture is stirred for 1 hr. at room temperature, poured into 1 l. water, and extracted with 3 + 100 ml. CH<sub>2</sub>Cl<sub>2</sub>. The extract is washed, dried, filtered with 50 g. Al<sub>2</sub>O<sub>3</sub>, evaporated and the residue is crystallized in Et<sub>2</sub>O-petroleum ether, giving 7-chloro-1-(3-chlorophenyl)-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one, m. 86-9°. Ten g. of this product in 35 ml. dimethylformamide is heated for 20 hrs. in an autoclave at 70°/7 atmospheric with 85 ml. methylamine. The product is poured into 150 ml. water and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic extract is washed with water and extracted with 3NHCl; the acid solution washed with CH<sub>2</sub>Cl<sub>2</sub>, and alkalized with Na<sub>2</sub>CO<sub>3</sub> gives the free base, which is extracted by CH<sub>2</sub>Cl<sub>2</sub>, washed, dried and the solvent evaporated to leave the oily base 7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1-(3-methylaminopropyl)-2H-1,4-benzodiazepin-2-one; di-HCl salt (II) m. 193-6° (decomposition). A solution of 5 g. II in 100 ml. acetic acid (50%) is hydrogenated over 0.5 g. PtO<sub>2</sub>. The hydrogenated base is extracted, with CH<sub>2</sub>Cl<sub>2</sub> after filtering off the catalyst and alkalizing; the oily base is transformed in the same way as above to the dihydrochloride of 7-chloro-5-(2-fluorophenyl)-1,3,4,5-tetrahydro-1-(3-methylaminopropyl)-2H-1,4-benzodiazepin-2-one, m. 210-35° (decomposition).


IT 4173-63-1P, 2H-1,4-Benzodiazepin-2-one, 3-acetamido-7-chloro-1,3-dihydro-5-phenyl-

RL: PREP (Preparation)

(preparation of)

RN 4173-63-1 CAPLUS

CN Acetamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (8CI, 9CI) (CA INDEX NAME)



L19 ANSWER 74 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1966:11572 CAPLUS Full-text

DN 64:11572

OREF 64:2115c-e

TI Preparation of 3-amino-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-ones

PA American Home Products Corp.

SO 9 pp.

DT Patent

LA Unavailable

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	NL 6414066		19650604	NL 1964-14066	19641203
	BE 656606			BE	
PRAI	US		19631203		

GI For diagram(s), see printed CA Issue.

AB The title compds. (Ia) are intermediates in the preparation of (Ib), which show anticonvulsive, sedative and muscle relaxant properties. Ia are prepared by treating a 2-[2-(N-acyloxyacylamido)acetamido]benzophenone (II) with NH<sub>4</sub>OH, followed by dehydration. Ib is obtained by hydrolysis of Ia. Thus, 1 g. II (Acyl = Ac) is added to 100 ml. EtOH saturated with NH<sub>3</sub>, the mixture left 12 hrs., concentrated in vacuo and the residue taken up in C<sub>6</sub>H<sub>6</sub>. The solution is cooled and working up of the white precipitate gives 0.65 g. Ia (R = Ac) (III), m. 272-3°. A solution of 1 g. III in MeOH, saturated with HCl, is left 12 hrs., then H<sub>2</sub>O added and the mixture made alkaline (NH<sub>4</sub>OH). Working up of the precipitate gives 0.45 g. Ib, m. 202-3° (EtOH). A suspension of 2 g. II (Acyl = Ac) in 20 ml. MeOH is added slowly at 50-60° to 100 ml. MeOH, saturated with NH<sub>3</sub>. The mixture is refluxed 2.5 hrs., and worked up as above to give 1.1 g. III; in analogous way, Ia (R = CHO), m. 243-5°, is obtained.


IT 4173-63-1P, 2H-1,4-Benzodiazepin-2-one, 3-acetamido-7-chloro-1,3-dihydro-5-phenyl-

RL: PREP (Preparation)

(preparation of)

RN 4173-63-1 CAPLUS

CN Acetamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (8CI, 9CI) (CA INDEX NAME)



L19 ANSWER 75 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1965:470956 CAPLUS Full-text

DN 63:70956

OREF 63:12988b-d

TI Novel elimination-addition reaction of a diacylated hydroxylamine

AU Bell, Stanley C.; McCaully, Ronald J.; Childress, Scott J.

CS Wyeth Labs., Radnor, PA, USA

SO Tetrahedron Letters (1965), (33), 2889-91

CODEN: TELEAY; ISSN: 0040-4039

DT Journal

LA English

GI For diagram(s), see printed CA Issue.

AB cf. CA 57, 2227b. Treatment of 4,2-Cl(Bz)C<sub>6</sub>H<sub>3</sub>NHCOCH<sub>2</sub>N(OAc)Ac with NH<sub>3</sub> in alc. yielded 4,2Cl(Bz)C<sub>6</sub>H<sub>3</sub>NHCOCH(NH<sub>2</sub>)NHAc (I), m. 140-2°, λ 2.99, 3.07, 3.11, 5.85, 6.11 μ, δ 2.04, 2.33, 5.2 (J 6 cps.), 11.57, 7.12 ppm. The splitting of the CH signal by the amide proton was eliminated by D exchange. It was presumed that attack by NH<sub>3</sub> on the α-CH<sub>2</sub> group abstracted a proton and led to elimination of the Ac anion from the neighboring N atom. NH<sub>3</sub> then added to the highly polarized C:N bond to give I. On gentle heating I was cyclized to 3-acetamido-7-chloro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one (II, R = NHAc) (III), m. 271-2°, λ 3.13, 5.85, 6.04 μ (KBr), δ 5.47 (J 8 cps.) (D<sub>3</sub>CSOCD<sub>3</sub>), methanolized at 20° with HCl catalysis to II (R = NH<sub>2</sub>), m. 205-6°, λ 2.99, 3.06, 5.88 μ, converted with HNO<sub>2</sub> to the known II (R = OH).


IT 4173-63-1F, 2H-1,4-Benzodiazepin-2-one, 3-acetamido-7-chloro-1,3-dihydro-5-phenyl-

RL: PREP (Preparation)


(preparation of)

RN 4173-63-1 CAPLUS

CN Acetamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (8CI, 9CI) (CA INDEX NAME)



=> d l1; d his; log y  
 L1 HAS NO ANSWERS  
 L1 STR



G1 Cy,Ak  
 G2 H,Ak  
 G3 Cy,Ak,S

Structure attributes must be viewed using STN Express query preparation.  
 (FILE 'HOME' ENTERED AT 17:21:26 ON 29 AUG 2007)  
 FILE 'REGISTRY' ENTERED AT 17:21:35 ON 29 AUG 2007  
 ACT A10528250/A

```

L1      STR
L2      7277 SEA FILE=REGISTRY SSS FUL L1
-----
FILE 'CAPLUS' ENTERED AT 17:22:01 ON 29 AUG 2007
L3      800 S L2
L4      5 S L3 AND CARTER?/IN
L5      5 S L4 AND HENDERSON?/IN
L6      4 S L5 AND KELSEY?/IN
L7      2 S L6 AND WILSON?/IN
L8      SEL L7 1- RN :      298 TERMS
FILE 'REGISTRY' ENTERED AT 17:23:25 ON 29 AUG 2007
L9      298 S L8 SUB=L2 SAM
FILE 'CAPLUS' ENTERED AT 17:23:58 ON 29 AUG 2007
L10     144231 S L9
FILE 'REGISTRY' ENTERED AT 17:24:44 ON 29 AUG 2007
L11     298 SORT L9 REF
L12     298 S L11
L13     298 S L12 SUB=L2 SAM
L14     50 S L2
L15     7277 S L2 FUL
L16     298 S L8
L17     13 S L1 SAM SUB=L16
L18     197 S L1 FUL SUB=L16
FILE 'CAPLUS' ENTERED AT 17:27:25 ON 29 AUG 2007
L19     75 S L18
  
```


COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	397.13	772.20
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-58.50	-58.50

STN INTERNATIONAL LOGOFF AT 17:29:55 ON 29 AUG 2007


App's

L19 ANSWER 10 OF 75 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2004:267311 CAPLUS Full-text  
 DN 140:287417  
 TI Preparation of aminobenzodiazepinones and pharmaceutical compositions  
 containing them for use against respiratory syncytial virus  
 IN Carter, Malcolm; Henderson, Elisa; Kelsey, Richard; Wilson, Lara;  
 Chambers, Phil; Taylor, Debra; Tyms, Stan  
 PA Arrow Therapeutics Limited, UK  
 SO PCT Int. Appl., 134 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2004026843	A1	20040401	WO 2003-GB4050	20030922	
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	CA 2499322	A1	20040401	CA 2003-2499322	20030922	
	AU 2003267587	A1	20040408	AU 2003-267587	20030922	
	EP 1539716	A1	20050615	EP 2003-748279	20030922	
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK		
	BR 2003014595	A	20050809	BR 2003-14595	20030922	
	CN 1694874	A	20051109	CN 2003-825190	20030922	
	JP 2006503054	T	20060126	JP 2004-537305	20030922	
	NZ 538870	A	20070427	NZ 2003-538870	20030922	
	ZA 2005002001	A	20060628	ZA 2005-2001	20050309	
	MX 2005PA02871	A	20051005	MX 2005-PA2871	20050315	
	IN 2005CN00400	A	20070406	IN 2005-CN400	20050316	
	NO 2005001908	A	20050419	NO 2005-1908	20050419	
	US 2006040923	A1	20060223	US 2005-528250	20050621	
PRAI	GB 2002-21923	A	20020920			
	GB 2003-2078	A	20030129			
	WO 2003-GB4050	W	20030922			
OS	MARPAT 140:287417					
GI						



I




II

AB Benzodiazepines (shown as I; variables defined below; e.g. II) and pharmaceutically acceptable salts thereof, are active against respiratory syncytial virus (RSV). For I: R1 = C1-6 alkyl, aryl or heteroaryl; R2 = H or C1-6 alkyl; each R3 = halogen, hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C1-6 haloalkyl, C1-6 haloalkoxy, amino, mono(C1-6 alkyl)amino, di(C1-6 alkyl)amino, nitro, cyano, -CO2RI, -CONRIRII, -NH-CO-RI, -S(O)RI, -S(O)2RI, -NH-S(O)2RI, -S(O)NRIRII or -S(O)2NRIRII wherein each RI and RII = H

or C1-6 alkyl; n = 0-3; R4 = H or C1-6 alkyl; R6 = C1-6 alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C1-6 alkyl)-, heteroaryl-(C1-6 alkyl)-, carbocyclyl-(C1-6 alkyl)-, heterocyclyl-(C1-6 alkyl)-, aryl-C(O)-C(O)-, heteroaryl-C(O)-C(O)-, carbocyclyl-C(O)-C(O)-, heterocyclyl-C(O)-C(O)- or -XR6. X = -CO-, -S(O)- or -S(O)2-; and R6 = C1-6 alkyl, hydroxy, C1-6 alkoxy, C1-6 alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C1-6 alkyl)-, heteroaryl-(C1-6 alkyl)-, carbocyclyl-(C1-6 alkyl)-, heterocyclyl-(C1-6 alkyl)-, aryl-(C1-6hydroxyalkyl)-, heteroaryl-(C1-6 hydroxyalkyl)-, carbocyclyl-(C1-6 hydroxyalkyl)-, heterocyclyl-(C1-6 hydroxyalkyl)-, aryl-(C1-6alkyl)-O-, heteroaryl-(C1-6alkyl)-O-, carbocyclyl-(C1-6 alkyl)-O-, heterocyclyl-(C1-6 alkyl)-O- or -NRIRII wherein each RI and RII = H, C1-6 alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl-(C1-6 alkyl)-, heteroaryl-(C1-6 alkyl)-, carbocyclyl-(C1-6 alkyl)- or heterocyclyl-(C1-6 alkyl)-. Although the methods of preparation are not claimed, .apprx.80 example preps. are included. For example, II was prepared by N-acetylation of 3-amino-5-phenyl-1,3- dihydrobenzo[e][1,4]diazepin-2-one; the reactant was prepared by deprotection of (2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3- yl)carbamic acid benzyl ester, which was prepared by cyclization of (2-aminophenyl)phenylmethanone with (benzotriazol-1-yl)(benzyloxycarbonylamino)acetic acid, which was prepared from glyoxylic acid monohydrate, benzotriazole and benzyl carbamate in toluene. Values for inhibition of RSV and toxicity were determined for >100 examples of I.

- IT 108895-98-3P, (2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamic acid benzyl ester  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (drug candidate; preparation of aminobenzodiazepinones and pharmaceutical compns. containing them for use against respiratory syncytial virus)
- RN 108895-98-3 CAPLUS
- CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



- IT 103373-21-3P, 3,4-Dichloro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 116842-74-1P,  
 Pyrazine-2-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 119506-69-3P,  
 1-(3-Methoxyphenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 150964-48-0P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 168162-29-6P,  
 (2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamic acid tert-butyl ester 206115-23-3P, 1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(m-tolyl)urea 368870-46-6P,  
 Thiophene-2-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 368870-49-9P,  
 Thiophene-2-carboxylic acid N-(7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-

benzo[e][1,4]diazepin-3-yl)amide 368870-50-2P,  
Furan-2-carboxylic acid N-(7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-02-2P,  
3-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-04-4P, 2-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-09-9P,  
3-Nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-15-7P, 2-Methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-16-8P,  
(S)-2-Methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-27-1P,  
2-Bromo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzenesulfonamide 676128-28-2P, 3-Bromo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzenesulfonamide 676128-29-3P,  
4-Bromo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzenesulfonamide 676128-30-6P,  
2-Fluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzenesulfonamide 676128-36-2P, 5-Phenyl-3-(2-trifluoromethylbenzylamino)-1,3-dihydrobenzo[e][1,4]diazepin-2-one 676128-37-3P,  
5-Phenyl-3-(3-trifluoromethylbenzylamino)-1,3-dihydrobenzo[e][1,4]diazepin-2-one 676128-38-4P,  
5-Phenyl-3-(4-trifluoromethylbenzylamino)-1,3-dihydrobenzo[e][1,4]diazepin-2-one 676128-44-2P, N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-4-methoxybenzamide 676128-51-1P,  
N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-(2-trifluoromethylphenyl)acetamide 676128-52-2P,  
N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-(3-trifluoromethylphenyl)acetamide 676128-53-3P,  
N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-(4-trifluoromethylphenyl)acetamide 676128-57-7P,  
1-(2-Chlorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676128-59-9P, 1-(4-Chlorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676128-61-3P,  
1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(p-tolyl)urea 676128-62-4P, 1-(2-Fluorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676128-63-5P,  
(S)-1-(2-Fluorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676128-64-6P,  
1-(4-Fluorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676128-66-8P, (S)-4-Methanesulfonyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-67-9P,  
5-Acetyl-2-ethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-68-0P,  
(S)-5-Acetyl-2-ethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-69-1P,  
6-Fluoro-4H-benzo[1,3]dioxin-8-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-70-4P,  
(S)-6-Fluoro-4H-benzo[1,3]dioxin-8-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-71-5P,  
(S)-2-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-4-trifluoromethylbenzamide 676128-72-6P, 2,4,5-Trifluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-73-7P,  
(S)-2,4,5-Trifluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-74-8P,  
2-Hydroxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-75-9P, (S)-2-Hydroxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-76-0P,  
1H-Indole-7-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-77-1P,  
(S)-1H-Indole-7-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-



benzo[e][1,4]diazepin-3-yl)amide 676128-78-2P,  
3-Methoxynaphthalene-2-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-79-3P,  
(S)-3-Methoxynaphthalene-2-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-80-6P,  
N-[7-Chloro-5-(2-fluorophenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-4-methoxybenzamide 676128-81-7P, 1-(2-Fluorobenzyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676128-82-8P, 1-(4-Methoxybenzyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676128-83-9P,  
1-(3-Methylbenzyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676128-84-0P, 1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(4-trifluoromethylphenyl)urea 676128-85-1P, 4-Chloro-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-86-2P,  
4-Methoxy-3-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-87-3P, 3-Methoxy-2-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-88-4P,  
2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-89-5P, 5-Chloro-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-90-8P, 5-Methoxy-2-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-91-9P,  
, 3-Methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-92-0P, 3-(2-Methoxyphenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)propionamide 676128-93-1P, 3-(3-Methoxyphenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)propionamide 676128-94-2P,  
3-(4-Methoxyphenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)propionamide 676128-95-3P, N-[5-(3-Chlorophenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-2-methoxybenzamide 676128-96-4P, N-[5-(3-Chlorophenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-4-methoxybenzamide 676128-97-5P,  
N-[5-(3-Chlorophenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-2-nitrobenzamide 676128-98-6P, N-[5-(3-Chlorophenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-4-nitrobenzamide 676128-99-7P, 4-Methoxy-N-[2-oxo-5-(4-trifluoromethylphenyl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676129-00-3P,  
2-Methoxy-N-[2-oxo-5-(3-trifluoromethylphenyl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676129-01-4P,  
4-Methoxy-N-[2-oxo-5-(3-trifluoromethylphenyl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676129-02-5P,  
2-Ethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-03-6P, 2,4-Dimethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-04-7P,  
2-Bromo-5-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-05-8P, 2-Methoxy-N-[5-(3-methoxyphenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]benzamide 676129-06-9P, N-[5-(3-Methoxyphenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-4-nitrobenzamide 676129-07-0P,  
2-Methoxy-N-(8-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-08-1P, 2-Chloro-4-methanesulfonyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-09-2P, 2-Dimethylamino-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-10-5P,  
1-(3,5-Dimethylphenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-11-6P,  
1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(4-trifluoromethoxyphenyl)urea 676129-12-7P, 1-(4-Bromo-2-trifluoromethylphenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-


benzo[e][1,4]diazepin-3-yl)urea 676129-13-8P,  
1-(4-Bromobenzyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-14-9P, 1-(2,3-Dichlorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-15-0P,  
1-(2,6-Dimethylphenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-16-1P,  
1-(2-Chloro-6-methylphenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-17-2P,  
1-(4-Nitrophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-18-3P, 1-(2-Methylsulfonylphenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-19-4P,  
1-(2,6-Dichlorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-20-7P,  
5-tert-Butyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-21-8P,  
2,5-Dimethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-22-9P, 1-(2,6-Difluorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-23-0P,  
1-(3-Fluorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-25-2P,  
1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(3-trifluoromethylphenyl)urea 676129-27-4P, 1-(3-Chlorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-29-6P, 2-Methoxy-4-methylsulfonyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-30-9P,  
4-(Methanesulfonyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-31-0P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)terephthalamic acid methyl ester 676129-32-1P, 2-Fluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-33-2P,  
2,6-Difluoro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-34-3P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-propoxybenzamide 676129-35-4P,  
2-Iodo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-36-5P, 3-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)terephthalamic acid methyl ester 676129-37-6P, 4-Amino-5-chloro-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-38-7P,  
2-Methylsulfonyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-39-8P, 2-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-5-sulfamoylbenzamide 676129-40-1P, 2-Hydroxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-phenylpropionamide 676129-41-2P,  
3-Hydroxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-phenylpropionamide 676129-42-3P, 3-(2-Fluorophenyl)-1-methyl-1-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-43-4P, 2-Methoxy-N-methyl-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676129-44-5P,  
1-tert-Butyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-45-6P, 1-Cyclohexyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-46-7P,  
1-Ethyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-47-8P, 1-Butyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676129-48-9P,  
4,5-Dimethylfuran-2-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676129-49-0P,  
Piperidine-1-carboxylic acid N-(7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676129-50-3P,  
N-[5-(3-Chlorophenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]acetamide 676129-51-4P, N-[5-(3-Chlorophenyl)-2-oxo-2,3-

dihydro-1H-benzo[e][1,4]diazepin-3-yl]isobutyramide 676129-52-5P  
 , Furan-2-carboxylic acid N-[5-(3-chlorophenyl)-2-oxo-2,3-dihydro-1H-  
 benzo[e][1,4]diazepin-3-yl]amide 676129-53-6P,  
 Thiophene-2-carboxylic acid N-[5-(3-chlorophenyl)-2-oxo-2,3-dihydro-1H-  
 benzo[e][1,4]diazepin-3-yl]amide 676129-54-7P,  
 Cyclohexanecarboxylic acid N-[5-(3-chlorophenyl)-2-oxo-2,3-dihydro-1H-  
 benzo[e][1,4]diazepin-3-yl]amide 676129-55-8P,  
 Piperidine-1-carboxylic acid N-[5-(3-chlorophenyl)-2-oxo-2,3-dihydro-1H-  
 benzo[e][1,4]diazepin-3-yl]amide 676129-56-9P,  
 N-[5-(3-Chlorophenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-  
 yl]isonicotinamide 676129-57-0P, 5-Methylfuran-2-carboxylic acid  
 N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide  
 676129-58-1P, N-[5-(3-Methoxyphenyl)-2-oxo-2,3-dihydro-1H-  
 benzo[e][1,4]diazepin-3-yl]isobutyramide 676129-59-2P,  
 Thiophene-2-carboxylic acid N-[5-(3-methoxyphenyl)-2-oxo-2,3-dihydro-1H-  
 benzo[e][1,4]diazepin-3-yl]amide 676129-60-5P,  
 Cyclohexanecarboxylic acid N-[5-(3-methoxyphenyl)-2-oxo-2,3-dihydro-1H-  
 benzo[e][1,4]diazepin-3-yl]amide 676129-61-6P,  
 Piperidine-1-carboxylic acid N-[5-(3-methoxyphenyl)-2-oxo-2,3-dihydro-1H-  
 benzo[e][1,4]diazepin-3-yl]amide 676129-62-7P,  
 Piperidine-4-carboxylic acid N-[5-(3-methoxyphenyl)-2-oxo-2,3-dihydro-1H-  
 benzo[e][1,4]diazepin-3-yl]amide 676129-63-8P,  
 Cyclohexanecarboxylic acid N-(8-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-  
 benzo[e][1,4]diazepin-3-yl)amide 676129-64-9P,  
 Thiophene-2-carboxylic acid N-(8-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-  
 benzo[e][1,4]diazepin-3-yl)amide 676129-65-0P,  
 1-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-(thiophen-2-  
 yl)urea 676129-66-1P, 1-(2-Oxo-5-phenyl-2,3-dihydro-1H-  
 benzo[e][1,4]diazepin-3-yl)-3-(thiophen-3-yl)urea 676129-67-2P,  
 Pyridine-2-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-  
 benzo[e][1,4]diazepin-3-yl)amide 676129-68-3P,  
 1H-Pyrazole-4-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-  
 benzo[e][1,4]diazepin-3-yl)amide 676129-69-4P,  
 6-Dimethylamino-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-  
 yl)nicotinamide 676129-70-7P, 2-Ethoxynaphthalene-1-carboxylic  
 acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide  
 676129-71-8P, 9-Oxo-9H-fluorene-1-carboxylic acid  
 N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide  
 676129-72-9P, 2-Oxo-2,3-dihydrobenzimidazole-1-carboxylic acid  
 N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide  
 676129-73-0P, (S)-4,5-Dibromofuran-2-carboxylic acid  
 N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide  
 676129-74-1P, (S)-Benzofuran-2-carboxylic acid  
 N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide  
 676129-75-2P, (2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-  
 3-yl)carbamic acid methyl ester 676129-76-3P,  
 (2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamic acid  
 ethyl ester 676129-77-4P, (2-Oxo-5-phenyl-2,3-dihydro-1H-  
 benzo[e][1,4]diazepin-3-yl)carbamic acid isobutyl ester  
 676129-78-5P, 2-Oxo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-  
 benzo[e][1,4]diazepin-3-yl)-2-(thiophen-2-yl)acetamide  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological  
 activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL  
 (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of aminobenzodiazepinones and pharmaceutical  
 compns. containing them for use against respiratory syncytial virus)


RN 103373-21-3 CAPLUS

CN Benzamide, 3,4-dichloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-  
 3-yl)- (9CI) (CA INDEX NAME)




RN 116842-74-1 CAPLUS

CN 2-Pyrazinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 119506-69-3 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 150964-48-0 CAPLUS


CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)



RN 168162-29-6 CAPLUS


CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-,

1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 206115-23-3 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 368870-46-6 CAPLUS

CN 2-Thiophenecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 368870-49-9 CAPLUS

CN 2-Thiophenecarboxamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 368870-50-2 CAPLUS

CN 2-Furancarboxamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-02-2 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 676128-04-4 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 676128-09-9 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-nitro- (9CI) (CA INDEX NAME)



RN 676128-15-7 CAPLUS


CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy-4-nitro- (CA INDEX NAME)



RN 676128-16-8 CAPLUS


CN Benzamide, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-methoxy-4-nitro- (CA INDEX NAME)

Absolute stereochemistry.




RN 676128-27-1 CAPLUS

CN Benzenesulfonamide, 2-bromo-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-28-2 CAPLUS

CN Benzenesulfonamide, 3-bromo-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-29-3 CAPLUS

CN Benzenesulfonamide, 4-bromo-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-30-6 CAPLUS

CN Benzenesulfonamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-fluoro- (9CI) (CA INDEX NAME)



RN 676128-36-2 CAPLUS


CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-5-phenyl-3-[[[2-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 676128-37-3 CAPLUS


CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-5-phenyl-3-[[[3-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)






RN 676128-38-4 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-5-phenyl-3-[[[4-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 676128-44-2 CAPLUS

CN Benzamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-methoxy- (9CI) (CA INDEX NAME)




RN 676128-51-1 CAPLUS

CN Benzeneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 676128-52-2 CAPLUS

CN Benzeneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 676128-53-3 CAPLUS

CN Benzeneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 676128-57-7 CAPLUS

CN Urea, N-(2-chlorophenyl)-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-59-9 CAPLUS

CN Urea, N-(4-chlorophenyl)-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-61-3 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 676128-62-4 CAPLUS


CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(2-fluorophenyl)- (CA INDEX NAME)



RN 676128-63-5 CAPLUS


CN Urea, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-N'-(2-fluorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 676128-64-6 CAPLUS


CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 676128-66-8 CAPLUS


CN Benzamide, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-methoxy-4-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 676128-67-9 CAPLUS


CN Benzamide, 5-acetyl-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-ethoxy- (9CI) (CA INDEX NAME)



RN 676128-68-0 CAPLUS


CN Benzamide, 5-acetyl-N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-ethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676128-69-1 CAPLUS


CN 4H-1,3-Benzodioxin-8-carboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-6-fluoro- (9CI) (CA INDEX NAME)



RN 676128-70-4 CAPLUS

CN 4H-1,3-Benzodioxin-8-carboxamide, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-6-fluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 676128-71-5 CAPLUS


CN Benzamide, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-methoxy-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676128-72-6 CAPLUS


CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,4,5-trifluoro- (9CI) (CA INDEX NAME)



RN 676128-73-7 CAPLUS


CN Benzamide, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2,4,5-trifluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676128-74-8 CAPLUS


CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-hydroxy- (9CI) (CA INDEX NAME)




RN 676128-75-9 CAPLUS

CN Benzamide, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 676128-76-0 CAPLUS  
CN 1H-Indole-7-carboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-77-1 CAPLUS  
CN 1H-Indole-7-carboxamide, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 676128-78-2 CAPLUS  
CN 2-Naphthalenecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 676128-79-3 CAPLUS  
CN 2-Naphthalenecarboxamide, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 676128-80-6 CAPLUS

CN Benzamide, N-[7-chloro-5-(2-fluorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 676128-81-7 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-[(2-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 676128-82-8 CAPLUS


CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 676128-83-9 CAPLUS




CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-[(3-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 676128-84-0 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 676128-85-1 CAPLUS

CN Benzamide, 4-chloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 676128-86-2 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-methoxy-3-nitro- (9CI) (CA INDEX NAME)




RN 676128-87-3 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-methoxy-2-nitro- (9CI) (CA INDEX NAME)




RN 676128-88-4 CAPLUS

CN Benzamide, 5-chloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 676128-89-5 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-fluoro-2-methoxy- (9CI) (CA INDEX NAME)




RN 676128-90-8 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-methoxy-2-nitro- (9CI) (CA INDEX NAME)




RN 676128-91-9 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-methoxy-4-nitro- (9CI) (CA INDEX NAME)




RN 676128-92-0 CAPLUS

CN Benzenepropanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 676128-93-1 CAPLUS

CN Benzenepropanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 676128-94-2 CAPLUS

CN Benzenepropanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-methoxy- (9CI) (CA INDEX NAME)




RN 676128-95-3 CAPLUS

CN Benzamide, N-[5-(3-chlorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 676128-96-4 CAPLUS

CN Benzamide, N-[5-(3-chlorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 676128-97-5 CAPLUS


CN Benzamide, N-[5-(3-chlorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]-2-nitro- (9CI) (CA INDEX NAME)




RN 676128-98-6 CAPLUS  
 CN Benzamide, N-[5-(3-chlorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]-4-nitro- (9CI) (CA INDEX NAME)




RN 676128-99-7 CAPLUS  
 CN Benzamide, N-[2,3-dihydro-2-oxo-5-[4-(trifluoromethyl)phenyl]-1H-1,4-benzodiazepin-3-yl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 676129-00-3 CAPLUS  
 CN Benzamide, N-[2,3-dihydro-2-oxo-5-[3-(trifluoromethyl)phenyl]-1H-1,4-benzodiazepin-3-yl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 676129-01-4 CAPLUS  
 CN Benzamide, N-[2,3-dihydro-2-oxo-5-[3-(trifluoromethyl)phenyl]-1H-1,4-benzodiazepin-3-yl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 676129-02-5 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-ethoxy- (9CI) (CA INDEX NAME)




RN 676129-03-6 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,4-dimethoxy- (9CI) (CA INDEX NAME)




RN 676129-04-7 CAPLUS

CN Benzamide, 2-bromo-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-methoxy- (9CI) (CA INDEX NAME)




RN 676129-05-8 CAPLUS

CN Benzamide, N-[2,3-dihydro-5-(3-methoxyphenyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 676129-06-9 CAPLUS

CN Benzamide, N-[2,3-dihydro-5-(3-methoxyphenyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]-4-nitro- (9CI) (CA INDEX NAME)




RN 676129-07-0 CAPLUS

CN Benzamide, N-(2,3-dihydro-8-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 676129-08-1 CAPLUS

CN Benzamide, 2-chloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 676129-09-2 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 676129-10-5 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 676129-11-6 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 676129-12-7 CAPLUS

CN Urea, N-[4-bromo-2-(trifluoromethyl)phenyl]-N'-(2,3-dihydro-2-oxo-5-phenyl-




1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676129-13-8 CAPLUS

CN Urea, N-[(4-bromophenyl)methyl]-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676129-14-9 CAPLUS

CN Urea, N-(2,3-dichlorophenyl)-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676129-15-0 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 676129-16-1 CAPLUS

CN Urea, N-(2-chloro-6-methylphenyl)-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676129-17-2 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 676129-18-3 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-[2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 676129-19-4 CAPLUS

CN Urea, N-(2,6-dichlorophenyl)-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676129-20-7 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-(1,1-dimethylethyl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 676129-21-8 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,5-dimethoxy- (9CI) (CA INDEX NAME)




RN 676129-22-9 CAPLUS

CN Urea, N-(2,6-difluorophenyl)-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676129-23-0 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 676129-25-2 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(3-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)




RN 676129-27-4 CAPLUS

CN Urea, N-(3-chlorophenyl)-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676129-29-6 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy-4-(methylthio)- (9CI) (CA INDEX NAME)




RN 676129-30-9 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 676129-31-0 CAPLUS

CN Benzoic acid, 4-[[2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 676129-32-1 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-fluoro- (9CI) (CA INDEX NAME)




RN 676129-33-2 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 676129-34-3 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-propoxy- (9CI) (CA INDEX NAME)




RN 676129-35-4 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-iodo- (9CI) (CA INDEX NAME)




RN 676129-36-5 CAPLUS

CN Benzoic acid, 4-[[[(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)amino]carbonyl]-3-methoxy-, methyl ester (9CI) (CA INDEX NAME)




RN 676129-37-6 CAPLUS

CN Benzamide, 4-amino-5-chloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 676129-38-7 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 676129-39-8 CAPLUS

CN Benzamide, 5-(aminosulfonyl)-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 676129-40-1 CAPLUS

CN Benzenepropanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- $\alpha$ -hydroxy- (9CI) (CA INDEX NAME)




RN 676129-41-2 CAPLUS

CN Benzenepropanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- $\beta$ -hydroxy- (9CI) (CA INDEX NAME)




RN 676129-42-3 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(2-fluorophenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 676129-43-4 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy-N-methyl-4-nitro- (9CI) (CA INDEX NAME)



RN 676129-44-5 CAPLUS


CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 676129-45-6 CAPLUS

CN Urea, N-cyclohexyl-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)







RN 676129-46-7 CAPLUS  
 CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-ethyl-  
 (9CI) (CA INDEX NAME)



RN 676129-47-8 CAPLUS  
 CN Urea, N-butyl-N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-  
 (9CI) (CA INDEX NAME)




RN 676129-48-9 CAPLUS  
 CN 2-Furancarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4,5-dimethyl- (9CI) (CA INDEX NAME)




RN 676129-49-0 CAPLUS

CN 1-Piperidinecarboxamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676129-50-3 CAPLUS

CN Acetamide, N-[5-(3-chlorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)




RN 676129-51-4 CAPLUS

CN Propanamide, N-[5-(3-chlorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 676129-52-5 CAPLUS

CN 2-Furancarboxamide, N-[5-(3-chlorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)




RN 676129-53-6 CAPLUS

CN 2-Thiophenecarboxamide, N-[5-(3-chlorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)




RN 676129-54-7 CAPLUS

CN Cyclohexanecarboxamide, N-[5-(3-chlorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)




RN 676129-55-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-(3-chlorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)




RN 676129-56-9 CAPLUS

CN 4-Pyridinecarboxamide, N-[5-(3-chlorophenyl)-2,3-dihydro-2-oxo-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)




RN 676129-57-0 CAPLUS

CN 2-Furancarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-5-methyl- (9CI) (CA INDEX NAME)




RN 676129-58-1 CAPLUS

CN Propanamide, N-[2,3-dihydro-5-(3-methoxyphenyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 676129-59-2 CAPLUS

CN 2-Thiophenecarboxamide, N-[2,3-dihydro-5-(3-methoxyphenyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)




RN 676129-60-5 CAPLUS

CN Cyclohexanecarboxamide, N-[2,3-dihydro-5-(3-methoxyphenyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)




RN 676129-61-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[2,3-dihydro-5-(3-methoxyphenyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)




RN 676129-62-7 CAPLUS

CN 4-Piperidinecarboxamide, N-[2,3-dihydro-5-(3-methoxyphenyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)




RN 676129-63-8 CAPLUS

CN Cyclohexanecarboxamide, N-(8-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676129-64-9 CAPLUS

CN 2-Thiophenecarboxamide, N-(2,3-dihydro-8-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676129-65-0 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-2-thienyl- (9CI) (CA INDEX NAME)




RN 676129-66-1 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-3-thienyl- (9CI) (CA INDEX NAME)




RN 676129-67-2 CAPLUS

CN 2-Pyridinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676129-68-3 CAPLUS

CN 1H-Pyrazole-4-carboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676129-69-4 CAPLUS

CN 3-Pyridinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-6-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 676129-70-7 CAPLUS

CN 1-Naphthalenecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-ethoxy- (9CI) (CA INDEX NAME)




RN 676129-71-8 CAPLUS

CN 9H-Fluorene-1-carboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-9-oxo- (9CI) (CA INDEX NAME)



RN 676129-72-9 CAPLUS

CN 1H-Benzimidazole-1-carboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 676129-73-0 CAPLUS

CN 2-Furancarboxamide, 4,5-dibromo-N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 676129-74-1 CAPLUS


CN 2-Benzofurancarboxamide, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 676129-75-2 CAPLUS

CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 676129-76-3 CAPLUS


CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 676129-77-4 CAPLUS  
 CN Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, 2-methylpropyl ester (9CI) (CA INDEX NAME)



RN 676129-78-5 CAPLUS  
 CN 2-Thiopheneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- $\alpha$ -oxo- (9CI) (CA INDEX NAME)




IT 4173-63-1P, N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)acetamide 70890-53-8P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)acetamide 103373-17-7P, 2-Chloro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 368870-47-7P, Furan-2-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676127-95-0P, 1,1-Diethyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676127-96-1P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)propionamide 676127-97-2P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)butyramide 676127-98-3P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)isobutyramide 676127-99-4P, 2,2-Dimethyl-N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)propionamide 676128-00-0P, Cyclopentanecarboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-01-1P, Cyclohexanecarboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-03-3P, 4-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-05-5P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-trifluoromethylbenzamide 676128-06-6P, Piperidine-1-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-07-7P, Morpholine-4-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-08-8P, 4-Nitro-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-10-2P, 4-Methylpiperazine-1-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide 676128-11-3P, N-(2-Oxo-5-phenyl-2,3-dihydro-1H-


benzo[e][1,4]diazepin-3-yl)-2-trifluoromethylbenzamide  
676128-12-4P, 4-Bromo-N-(2-oxo-5-phenyl-2,3-dihydro-1H-  
benzo[e][1,4]diazepin-3-yl)benzamide 676128-13-5P,  
2-Methyl-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-  
yl)benzamide 676128-14-6P, 2-Nitro-N-(2-oxo-5-phenyl-2,3-dihydro-  
1H-benzo[e][1,4]diazepin-3-yl)benzamide 676128-17-9P,  
Benzo[b]thiophene-3-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-  
benzo[e][1,4]diazepin-3-yl)amide 676128-18-0P,  
2,3-Dihydrobenzofuran-5-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-  
benzo[e][1,4]diazepin-3-yl)amide 676128-19-1P,  
Isoxazole-5-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-  
benzo[e][1,4]diazepin-3-yl)amide 676128-20-4P,  
Benzo[b]thiophene-2-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-  
benzo[e][1,4]diazepin-3-yl)amide 676128-21-5P,  
Thiophen-3-carboxylic acid N-(2-oxo-5-phenyl-2,3-dihydro-1H-  
benzo[e][1,4]diazepin-3-yl)amide 676128-22-6P,  
N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-  
yl)isonicotinamide 676128-23-7P, N-(2-Oxo-5-phenyl-2,3-dihydro-  
1H-benzo[e][1,4]diazepin-3-yl)nicotinamide 676128-24-8P,  
N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-  
yl)methanesulfonamide 676128-25-9P, Propane-1-sulfonic acid  
N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide  
676128-26-0P, Butane-1-sulfonic acid N-(2-oxo-5-phenyl-2,3-dihydro-  
1H-benzo[e][1,4]diazepin-3-yl)amide 676128-31-7P,  
3-(2-Nitrobenzylamino)-5-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one  
676128-32-8P, 3-(3-Nitrobenzylamino)-5-phenyl-1,3-  
dihydrobenzo[e][1,4]diazepin-2-one 676128-33-9P,  
3-(4-Nitrobenzylamino)-5-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one  
676128-34-0P, 3-(2-Methoxybenzylamino)-5-phenyl-1,3-  
dihydrobenzo[e][1,4]diazepin-2-one 676128-35-1P,  
3-(3-Methoxybenzylamino)-5-phenyl-1,3-dihydrobenzo[e][1,4]diazepin-2-one  
676128-39-5P, 3-[(Furan-2-ylmethyl)amino]-5-phenyl-1,3-  
dihydrobenzo[e][1,4]diazepin-2-one 676128-40-8P,  
N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-  
yl)isobutyramide 676128-41-9P, N-(7-Chloro-2-oxo-5-phenyl-2,3-  
dihydro-1H-benzo[e][1,4]diazepin-3-yl)methanesulfonamide  
676128-42-0P, Cyclohexanecarboxylic acid N-(7-chloro-2-oxo-5-  
phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)amide  
676128-43-1P, N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-  
benzo[e][1,4]diazepin-3-yl)-2-methoxybenzamide 676128-45-3P,  
N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2-  
nitrobenzamide 676128-46-4P, 2-(2-Methoxyphenyl)-N-(2-oxo-5-  
phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)acetamide  
676128-47-5P, 2-(3-Methoxyphenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-  
benzo[e][1,4]diazepin-3-yl)acetamide 676128-48-6P,  
2-(4-Methoxyphenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-  
3-yl)acetamide 676128-49-7P, 2-(4-Nitrophenyl)-N-(2-oxo-5-phenyl-  
2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)acetamide 676128-50-0P  
, 2-(3-Nitrophenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-  
3-yl)acetamide 676128-54-4P, 1-(2-Methoxyphenyl)-3-(2-oxo-5-  
phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea 676128-55-5P  
, 1-(2-Nitrophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-  
3-yl)urea 676128-65-7P, 4-(Methanesulfonyl)-2-methoxy-N-(2-oxo-5-  
phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide  
676129-79-6P, 6-(Morpholin-4-yl)-N-(2-oxo-5-phenyl-2,3-dihydro-1H-  
benzo[e][1,4]diazepin-3-yl)nicotinamide  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(drug candidate; preparation of aminobenzodiazepinones and pharmaceutical


comps. containing them for use against respiratory syncytial virus)  
 RN 4173-63-1 CAPLUS  
 CN Acetamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (8CI, 9CI) (CA INDEX NAME)




RN 70890-53-8 CAPLUS  
 CN Acetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI)  
 (CA INDEX NAME)



RN 103373-17-7 CAPLUS  
 CN Benzamide, 2-chloro-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 368870-47-7 CAPLUS  
 CN 2-Furancarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676127-95-0 CAPLUS

CN Urea, N'-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 676127-96-1 CAPLUS

CN Propanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676127-97-2 CAPLUS

CN Butanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676127-98-3 CAPLUS

CN Propanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methyl- (9CI) (CA INDEX NAME)




RN 676127-99-4 CAPLUS

CN Propanamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 676128-00-0 CAPLUS

CN Cyclopentanecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-01-1 CAPLUS

CN Cyclohexanecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (CA INDEX NAME)




RN 676128-03-3 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-methoxy- (9CI) (CA INDEX NAME)




RN 676128-05-5 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 676128-06-6 CAPLUS

CN 1-Piperidinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-07-7 CAPLUS

CN 4-Morpholinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-08-8 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-nitro- (9CI) (CA INDEX NAME)




RN 676128-10-2 CAPLUS

CN 1-Piperazinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-methyl- (9CI) : (CA INDEX NAME)




RN 676128-11-3 CAPLUS

CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 676128-12-4 CAPLUS

CN Benzamide, 4-bromo-N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)







RN 676128-13-5 CAPLUS  
CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methyl- (9CI) (CA INDEX NAME)




RN 676128-14-6 CAPLUS  
CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-nitro- (9CI) (CA INDEX NAME)



RN 676128-17-9 CAPLUS  
CN Benzo[b]thiophene-3-carboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-18-0 CAPLUS  
CN 5-Benzofurancarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 676128-19-1 CAPLUS

CN 5-Isoxazolecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-20-4 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-21-5 CAPLUS

CN 3-Thiophenecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-22-6 CAPLUS

CN 4-Pyridinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-23-7 CAPLUS

CN 3-Pyridinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-24-8 CAPLUS

CN Methanesulfonamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-25-9 CAPLUS

CN 1-Propanesulfonamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-26-0 CAPLUS

CN 1-Butanesulfonamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-31-7 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-3-[[ (2-nitrophenyl)methyl]amino]-5-phenyl- (9CI) (CA INDEX NAME)




RN 676128-32-8 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-3-[[ (3-nitrophenyl)methyl]amino]-5-phenyl- (9CI) (CA INDEX NAME)




RN 676128-33-9 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-3-[[ (4-nitrophenyl)methyl]amino]-5-phenyl- (9CI) (CA INDEX NAME)




RN 676128-34-0 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-3-[[ (2-methoxyphenyl)methyl]amino]-5-phenyl- (9CI) (CA INDEX NAME)




RN 676128-35-1 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-3-[[ (3-methoxyphenyl)methyl]amino]-5-phenyl- (9CI) (CA INDEX NAME)




RN 676128-39-5 CAPLUS

CN 2H-1,4-Benzodiazepin-2-one, 3-[(2-furanylmethyl)amino]-1,3-dihydro-5-phenyl- (9CI) (CA INDEX NAME)




RN 676128-40-8 CAPLUS

CN Propanamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methyl- (9CI) (CA INDEX NAME)




RN 676128-41-9 CAPLUS

CN Methanesulfonamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-42-0 CAPLUS

CN Cyclohexanecarboxamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RN 676128-43-1 CAPLUS

CN Benzamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 676128-45-3 CAPLUS

CN Benzamide, N-(7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-nitro- (9CI) (CA INDEX NAME)




RN 676128-46-4 CAPLUS

CN Benzeneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy- (9CI) (CA INDEX NAME)




RN 676128-47-5 CAPLUS

CN Benzeneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-methoxy- (9CI) (CA INDEX NAME)




RN 676128-48-6 CAPLUS

CN Benzeneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-methoxy- (9CI) (CA INDEX NAME)




RN 676128-49-7 CAPLUS

CN Benzeneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-nitro- (9CI) (CA INDEX NAME)




RN 676128-50-0 CAPLUS

CN Benzeneacetamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-3-nitro- (9CI) (CA INDEX NAME)




RN 676128-54-4 CAPLUS

CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 676128-55-5 CAPLUS


CN Urea, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(2-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 676128-65-7 CAPLUS


CN Benzamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2-methoxy-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)





RN 676129-79-6 CAPLUS

CN 3-Pyridinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-6-(4-morpholinyl)- (9CI) (CA INDEX NAME)




IT 103343-61-9P, [(1S)-1-[[[(3S)-2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamoyl]-2-phenylethyl]carbamic acid tert-butyl ester 116842-76-3P, (2S)-2-Amino-N-((3S)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-phenylpropanamide 155452-87-2P, (7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamic acid benzyl ester 676127-93-8P, (2S)-N-(2-Oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-3-phenyl-2-(3-phenylthioureido)propanamide  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of aminobenzodiazepinones and pharmaceutical compns. containing them for use against respiratory syncytial virus)

RN 103343-61-9 CAPLUS

CN Carbamic acid, [(1S)-2-[[[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 116842-76-3 CAPLUS


CN Benzenepropanamide,  $\alpha$ -amino-N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 155452-87-2 CAPLUS


CN Carbamic acid, (7-chloro-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 676127-93-8 CAPLUS

CN Benzenepropanamide, N-[(3S)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]- $\alpha$ -[[ (phenylamino)thioxomethyl]amino]-, ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT